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ABSTRACT 
STEWART MICHAEL BOND: Trajectories and Patterns of Delirium and Vulnerability in 
Older Adults with Cancer in the Hospital and at Home Near the End of Life 
(Under the direction of Virginia J. Neelon) 
 
Patients with advanced cancer often develop delirium (acute confusion), the 
prevalence rising to 90% in the final weeks of life. Age, illness severity, comorbidity, and 
preexisting cognitive impairment increase the risk of delirium, but despite its prevalence, 
little is known about delirium in older cancer patients.  
This three-phase study addresses the empirical gap in knowledge about delirium in 
older cancer patients. The first phase, a secondary analysis of data from studies of acute 
confusion in hospitalized elders, examined delirium and its etiology in 76 hospitalized older 
cancer patients, 10 of whom were near the end of life. The second phase comprised a pilot 
study of a home-based protocol to evaluate delirium in older adults with advanced cancer. 
The third phase was a descriptive, longitudinal, multiple case study of delirium and delirium 
vulnerability in seven older adults with advanced cancer near the end of life.  
The findings clarify the role of delirium in older cancer patients. Delirium occurred in 
all seven with advanced cancer (the three patients who died had reversible and terminal 
episodes of delirium; the four who lived each had one reversible episode). Delirium also was 
common in the hospitalized older cancer patients: 43 of 76 (56%) were delirious at some 
point during hospitalization; 8 of 10 (80%) who were near the end of life became delirious. 
Delirium resolved in 13 of the 43 (30%) hospitalized patients, but in 30 (70%) delirium
iv 
symptoms persisted at discharge.  
These older cancer patients were at risk for multiple etiologies of delirium: 90%, 
(including all near the end of life) had metabolic-nutritional risks, and hypoxic, orthostatic-
dehydration, and metabolic-toxic risks were common. Five of the hospitalized patients and 
one of the seven with advanced cancer had chronic cognitive impairment (all became 
delirious).  
Physical, behavioral, and physiological functioning in the older adults with advanced 
cancer declined before they became delirious. This decline in functioning may indicate 
diminishing reserve capacity, and suggests that early interventions aimed at specific etiologic 
risk factors may sustain reserve capacity and minimize delirium, thereby enhancing the 
quality of living and dying of older cancer patients, and minimizing distress for their 
caregivers.  
v 
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  CHAPTER ONE 
INTRODUCTION 
People dying from cancer experience an array of distressing symptoms that greatly 
diminish their quality of living and dying. In recent years, there have been increasing 
demands and efforts to improve cancer care and to incorporate palliative care throughout the 
disease course particularly in the advanced stages and at the end of life (IOM, 1999; IOM 
2001). Research and other quality improvement initiatives have focused on improving pain 
control and the management of symptoms such as fatigue and dyspnea. To date, however, 
little research has investigated the prevention and management of delirium, a common and 
troubling symptom in cancer patients at the end of life. There is a need to develop a better 
understanding of end-of-life delirium in cancer patients and to develop a rational, systematic, 
evidenced-based treatment approach based on this understanding. 
 
Background and Significance 
Delirium in Advanced Cancer 
Cognitive impairment is a common and feared complication of terminal illness. 
Concerns about cognitive impairment negatively affect quality of life among terminally ill 
patients (Cohen et al., 2002). Steinhauser et al. (2000) found that the number one desire, 
endorsed by 92% of terminally patients, was to remain mentally aware. Cognitive 
impairment in patients with advanced cancer often occurs in the context of delirium, a 
pathophysiologic syndrome characterized by the rapid onset of impaired cognitive function,
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altered attention, and disturbed psychomotor behavior. Delirium is the second most common 
neuropsychiatric disorder in cancer patients (Massie & Holland, 1987), occurring in 14-56% 
of hospitalized cancer patients (Flostein, Fetting, Lobo, Niaz, & Capozzoli, 1984; Levine, 
Silberfarb, & Lipowski, 1978; Tuma & DeAngelis, 2000). The incidence of delirium 
increases in this population with disease progression and approaching death. Up to 90% of 
patients with advanced cancer exhibit delirium in the final weeks of life (Bruera et al., 1992; 
Lawlor, Gagnon et al., 2000, Massie, Holland, & Glass, 1983, Minigawa, Uchitomi, 
Yamawaki, & Ishitani, 1996; Morita, Tei, Tsunoda, Inoue, & Chihara, 2001). 
Delirium in patients with advanced cancer negatively affects quality of life and care 
(Breitbart, Bruera, Chochinov, & Lynch, 1995) and forecasts shortened survival (Caraceni et 
al., 2000; Lawlor, Gagnon et al., 2000; Metitieri, Bianchetti, & Trabucchi, 2000; Morita, 
Tsunoda, Inoue, & Chihara, 1999). Delirium is distressing for cancer patients, their family 
members, and professional caregivers (Brajtman, 2003; Brajtman, Higuchi, & McPherson, 
2006; Breitbart, Gibson, & Tremblay, 2002; Gagnon et al., 2002; Hallberg, 1999; Hull, 1990; 
Morita, Hirai, Sakaguchi, Tsuneto, & Shima, 2004; Schofield, 1997). Patients experiencing 
delirium need more assistance with self-care activities and require close monitoring to 
prevent injury. Delirium impairs patient-family communication, hinders treatment decision-
making, and interferes with the recognition and management of other physical and 
psychological symptoms (Bruera, Fainsinger, Miller, & Kuehn, 1992; Coyle, Breitbart & 
Weaver, 1994; Feldt, Ryden, & Miles, 1998; Miller, Moore et al., 1996; Miller, Neelon et al., 
1996). Although many patients with advanced cancer desire to remain at home during their 
final days, delirium deters home care at the end of life (Fainsinger, Cemoissac, Cole, Mead-
Wood, & Lee, 2000) and often contributes to the decision to hospitalize elderly cancer 
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patients or place them in other institutional settings (Berkman, Stolberg, Calhoun, Parker, & 
Stearns, 1983; Cintron et al., 2003; Evans, Cutson, Steinhauser, & Tulsky, 2006). 
 
Older Cancer Patients: A Population at Risk for Delirium  
Currently, 60% of all cancers and 70% of cancer deaths occur in older adults (Yancik 
& Ries, 2000). Since older age (Andersson, Gustafson, & Hallberg, 2001; Duppils & 
Wikblad, 2000; Eden, Foreman, & Sisk, 1998; Schor et al., 1992; Williams, et al., 1985), 
advanced illness (Francis, Martin, & Kapoor, 1990; Inouye, Viscoli, Horwitz, Hurst, & 
Tinetti, 1993; Rockwood, 1989), comorbidity (Andersson et al.; Eden et al.; Pompei et al., 
1994; Rahkonen et al., 2001), and pre-existing cognitive impairment (Duppils & Wikblad; 
Eden et al.; Fisher & Flowerdew, 1995; Francis, Martin, & Kapoor; Galanakis, Bickel, 
Gradinger, von Gumppenberg, & Forstl, 2001; Inouye et al; Pompei et al; Rahkonen et al.; 
Rockwood; Schor et al.; Williams et al.) are significant risk factors for delirium, older cancer 
patients are more likely to develop delirium particularly at the end of life. However, research 
on delirium in older cancer patients is almost non-existent (Boyle, 2006). With the projected 
growth of the aging population and the associated increase in cancer in older adults (Yancik 
& Ries), cases of delirium are likely to increase, underscoring the need to better understand 
this clinical problem in older patients with advanced cancer.  
 
Delirium in the Home Setting 
Delirium in patients with advanced cancer has been studied primarily in inpatient 
hospice and palliative care settings (Bruera et al., 1992; Caraceni et al., 2000; Gagnon, 
Allard, Masse, & DeSerres, 2000; Lawlor, Gagnon et al., 2000; Morita et al., 2001; Pereira, 
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Hanson, & Bruera, 1997; Stiefel, Fainsinger, & Bruera, 1992). While the prevalence of 
confusion has been examined retrospectively in home hospice patients (Nowels, 2002), 
delirium has not been studied prospectively in patients with advanced cancer cared for at 
home.  
The early recognition and treatment of delirium in patients being cared for at home is 
critical and requires ongoing and prompt clinical assessment. Because of their ongoing 
presence and interaction with patients and their knowledge of baseline functioning, family 
caregivers may play a key role in monitoring for and detecting subtle cognitive and 
behavioral changes associated with the onset of delirium (Cassarett & Inouye, 2000; Irving, 
Fick, & Foreman, 2006). Family caregivers can notify clinicians as soon as the first signs of 
delirium occur, facilitating earlier and more rapid intervention that may prevent the 
development of more severe delirium.  
There are few studies of delirium in patients being cared for at home and on the role 
of family caregivers in the detection of delirium. Research is needed to gain a better 
understanding of delirium in cancer patients cared for at home and to examine the role of 
family caregivers in the early identification of delirium symptoms. These are important gaps 
in current palliative care research and practice knowledge.  
 
Delirium at the End of Life 
Prospective longitudinal studies of delirium in patients with advanced cancer, in 
general, have examined the prevalence and incidence of delirium; its etiology; its behavioral 
and psychomotor manifestations; and outcomes such as reversibility and survival (Bruera et 
al., 1992; Massie et al., 1983; Caraceni et al., 2000; Lawlor, Gagnon, Mancini, Pereira, & 
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Bruera, 1998; Lawlor, Gagnon et al., 2000; Morita et al., 1999; Morita et al., 2001; Power et 
al., 1993; Sarhill, Walsh, Nelson, LeGrand, & Davis, 2001; Tuma & DeAngelis, 2000; 
Zhukovsky et al., 1998). Yet, little is known about the nature of delirium and delirium 
vulnerability in older cancer patients at the end of life, and how they change over time. 
Anecdotal and other evidence suggests that delirium at the end of life is a dynamic condition 
characterized by much heterogeneity and change (Gagnon et al., 2000). The onset, 
manifestations, and course of delirium vary not only between individuals but also within an 
individual over time. Similarly, delirium vulnerability and patterns of risk also are likely to 
vary both within and between individuals over time. 
There have been no studies of the natural course and progression of delirium in older 
cancer patients receiving palliative and end-of-life care in the home setting. In addition, 
investigators have not examined the relationships between baseline vulnerability and changes 
in delirium vulnerability at the end of life and the development of delirium. Longitudinal 
studies are needed to provide basic descriptive information about delirium in this population 
specifically focusing on individual variations in delirium at the end of life, patterns of change 
in delirium vulnerability during this period, the relationship between individual vulnerability 
and the development of delirium, and factors associated with delirium reversibility. 
Knowledge of the characteristics and course of delirium at the end of life will help to 
distinguish potentially reversible delirium from other irreversible patterns of delirium and 
cognitive decline associated with advanced cancer and dying. 
The early identification of patients at risk and the identification and correction of 
underlying etiologic mechanisms are critical for preventing and managing delirium near the 
end of life. Recent studies of delirium in patients with advanced cancer show that correctable 
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etiologic factors can be identified with minimally burdensome diagnostic procedures 
(Lawlor, Gagnon et al., 2000; Morita et al., 2001). Furthermore, when etiologic factors are 
identified and treated, delirium near the end of life is reversible in up to 50% of cases (Bruera 
et al., 1992; Gagnon et al., 2000; Lawlor, Gagnon et al.; Morita et al.; Pereira et al., 1997). 
Delirium in cancer patients at the end of life too often is viewed as an inevitable, irreversible 
condition—a view which leads to symptomatic treatment with sedative medications rather 
than a search for correctable causes and attempts at reversal (Lawlor, Fainsinger, & Bruera, 
2000). Clinicians are challenged by the inability to differentiate between delirium that is 
potentially reversible and other irreversible patterns of delirium and cognitive impairment. 
Currently, there is little phenomenological or pathophysiological data to guide clinicians in 
distinguishing between them (Rockwood & Lindesay, 2002).  
This research examines delirium in older cancer patients approaching the end of life 
and begins to explore the relationships among factors influencing its development and 
reversibility. This research contributes important information to the understanding of and 
differentiation between irreversible patterns of delirium and cognitive impairment associated 
with advanced cancer and dying and pathologic patterns that are treatable and reversible. The 
ability to differentiate between these conditions will promote the use of more appropriate 
treatment strategies consistent with the goals of care and will enable clinicians to better 
educate and support patients and their family caregivers. The appropriate and effective 
management of delirium and other patterns of cognitive and functional decline at the end of 
life will enhance the quality of living and dying for older cancer patients and minimize 
distress for their caregivers. 
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Overview and Purpose of the Study 
The purpose of this study was to examine delirium in older cancer patients in order to 
develop a better understanding of the phenomenon in this population. The study involved 
three phases of investigation. In order to learn more about delirium in hospitalized older 
cancer patients and to develop a basis for studying delirium in older cancer patients at the end 
of life, the first phase consisted of secondary analyses of data from the Acute Confusion in 
Hospitalized Elders Studies (NR01339-05: Neelon & Champagne). The second phase was a 
pilot study to test the feasibility and burden associated with a protocol to study delirium in 
older cancer patients near the end of life. In the third phase, a longitudinal, multiple case 
study design was used to identify and describe the nature of delirium and to examine 
delirium vulnerability in older adults with advanced cancer near the end of life, during active 
palliative treatment and in the terminal period.
 CHAPTER TWO 
LITERATURE REVIEW 
 
 
This literature review starts with an overview of delirium, presenting a historical 
perspective and the definition and pathophysiological basis of delirium and discussing issues 
associated with its diagnosis and measurement.  The review contrasts delirium with other 
common disorders characterized by cognitive impairment in older adults—specifically 
dementia, depression, terminal decline, and terminal restlessness. Age-associated cognitive 
decline in older adults and cognitive impairment in cancer patients, in general, are discussed 
because both likely increase delirium risk in older cancer patients. The review examines the 
literature about cognitive changes at the end of life. It then focuses on delirium in the context 
of cancer in general, and in the context of advanced cancer in particular. The review 
concludes by presenting a framework for studying delirium and delirium vulnerability at the 
end of life. The specific aims and research questions for each phase of investigation are 
presented.  
 
Overview of Delirium 
History of Delirium   
Lipowski (1990) provides an extensive historical review of delirium dating back to 
the first century AD. Even so, delirium, a common neuropsychiatric disorder in older adults, 
is poorly understood.  Delirium remains underrecognized, underdiagnosed, undertreated, and
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 understudied in at risk populations (Breitbart et al., 1995). Clinical care and research on 
delirium have been impeded by the multiplicity of terms used to refer to the syndrome 
including acute confusion, acute confusional state, acute brain failure, acute brain syndrome, 
cerebral insufficiency, exogenous psychosis, ICU psychosis, metabolic encephalopathy, 
organic brain syndrome, post-pump psychosis, reversible dementia, toxic psychosis, and 
toxic delirium (Lipowski, 1990). The nursing literature typically uses the term acute 
confusion while the medical literature uses delirium. The two also are often used 
interchangeably. There is a need to establish consistency in language related to delirium.  
 
Definition of Delirium 
Delirium is a neuropsychiatric syndrome that results from disturbances in central 
nervous system functioning. Delirium encompasses a broad spectrum of psychophysiological 
and behavioral manifestations. Delirium is characterized by the rapid onset of disordered 
cognitive function (thinking, perception, and memory), a disturbance of consciousness 
resulting from reticular activating system dysfunction (arousal and attention), and altered 
psychomotor behavior (hyperactivity or hypoactivity), which are often accompanied by 
adverse physiologic manifestations and autonomic nervous system instability (Lipowski, 
1990; Neelon, 1990; Neelon & Champagne, 1992).   
Strictly speaking, delirium is a psychiatric diagnosis defined by a specific set of 
criteria put forth in the American Psychiatric Association’s Diagnostic and Statistical 
Manual of Mental Disorders (DSM). The first two DSM editions defined pathophsyiological 
disorders of the brain as organic brain disorders differentiating between acute and chronic 
disorders and between psychotic and non-psychotic disorders (Tucker, 1999). Diagnostic 
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criteria for delirium based on specific cognitive and behavioral symptoms were first included 
in DSM III (American Psychiatric Association [APA], 1980). In the initial version of DSM 
IV (APA, 1994) and in the current version, DSM IV-Text Revised (DSM IV-TR) (APA, 
2000), the specific symptoms were deleted and the focus placed on the attentional and 
cognitive deficits seen in delirium. Sleep-wake cycle disturbances and altered psychomotor 
behavior, both common in delirium, are viewed as associated features. Table 2.1 presents the 
DSM IV-TR diagnostic criteria for delirium. With the exception of the DSM IV criteria, 
which have been subjected to limited validation testing, the diagnostic criteria for delirium 
have been based on consensus of expert opinion and clinical experience without systematic 
scientific evidence (Smith, Breitbart, & Platt, 1995). 
 
 
Table 2.1. DSM IV-TR diagnostic criteria for delirium 
 
 
A. 
 
Disturbance of consciousness with a reduced ability to focus, sustain, or 
shift attention 
 
B. 
 
A change in cognition OR the development of a perceptual disturbance 
 
C. Develops over a short period or time and tends to fluctuate over the course 
of the day 
  
D. Evidence that the disturbance is caused by the direct physiological 
consequence of a medical condition OR substance intoxication OR 
substance withdrawal OR medication side effect or toxin exposure OR 
multiple etiologies 
 
 
Source. APA, 2000 
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Delirium is characterized by alterations in consciousness involving both cognition 
and arousal. Trzepacz, Meagher, & Wise (2002) place delirium on a continuum of 
consciousness between alert and awake and stupor and coma. Similarly, Plum and Posner 
(1982) define delirium as a state of acutely altered consciousness that falls between clouding 
of consciousness and obtundation, stupor, and coma. Delirium often precedes stupor and 
coma, and it also is seen in individuals emerging from stupor and coma (Plum & Posner). 
Patients experiencing delirium exhibit reduced levels of awareness, impaired attention 
spans, and fluctuating levels of alertness. They also may exhibit impaired orientation and 
memory, disorganized thinking, and distorted perceptions. The behavioral manifestations of 
delirium vary between hyperactivity, or agitation, and hypoactivity, or lethargy (Foreman, 
1993; Lipowski, 1983; Lipowski, 1990; Neelon, 1990). They are easily distracted and have 
disturbed sleep-wake cycles. The manifestations of delirium develop abruptly over hours to 
days and fluctuate diurnally, often worsening at night (Foreman; Neelon). In general, 
delirium is defined as a transient condition that is potentially reversible, particularly with the 
early recognition and treatment of its underlying causes (Lipowski, 1990; Wolanin & 
Phillips, 1981). 
Three clinical delirium subtypes have been identified: hyperactive or hyperalert, 
hypoactive or hypoalert, and mixed (Camus et al., 2000; Lipowski, 1990; Liptzin & Levkoff, 
1992; Stagno, Gibson, & Breitbart, 2004). In the literature, the subtypes have been defined 
inconsistently with some authors focusing on the psychomotor behavior component 
(Meagher, O’Hanlon, O’Mahony, Casey, & Trzepacz, 2000; O’Keefe & Lavan, 1999), others 
on the arousal component (Ross, Peyser, Shapiro, & Folstein, 1991), and others on both 
(Lipowski; Liptzin & Levkoff). Hyperactive delirium is characterized by increased 
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psychomotor activity, sympathetic nervous system overactivity, increased alertness or 
hypervigilance, psychosis, and labile mood. In contrast, hypoactive delirium is exhibited as 
decreased psychomotor activity, withdrawal, apathy, lethargy or somnolence, and inattention. 
Psychotic features—delusions and perceptual disturbances—also are common in hypoactive 
delirium (Stagno et al.). In the mixed delirium subtype, symptoms associated with 
hyperactive and hypoactive delirium alternate in the same individual. The distinction 
between subtypes is important because the subtypes may have different etiologies and 
pathophysiology (Meagher, O’Hanlon, O’Mahony, Casey, & Trzepacz, 1998; O’Keefe, 
1999; Ross et al.), may respond differently to treatment (Kobayashi, Takeuchi, Suzuki, & 
Yamaguchi, 1992; Liptzin & Levkoff), and may be associated with different outcomes 
(Liptzin & Levkoff; O’Keefe & Lavan, 1999).   
 
Pathophysiology of Delirium 
Engel and Romano (1959) characterized delirium as a “syndrome of cerebral 
insufficiency” representing a global failure of brain metabolism based on their finding of 
diffuse slowing of the electroencephalograph (EEG) in delirious patients that correlated with 
clinical severity and occurred regardless of the underlying medical condition or etiology. On 
the other hand, patients presented with appreciably different constellations of cognitive and 
behavioral symptoms. More recent reviews (Flacker & Lipsitz, 1999; Trzepacz, 1999; van 
der Mast, 1998), suggest that delirium results from dysfunction of multiple brain regions 
including cortical and subcortical areas and multiple interacting neurotransmitter systems 
rather than global metabolic failure of the brain. Electrophysiological, neuroimaging, and 
neurotransmitter studies (Gaudreau & Gagnon, 2005; Jacobson & Jerrier, 2000; Koponen, 
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1999; Reischies et al., 2005) support this new understanding of the neuropathogenesis of 
delirium. 
Varying degrees of impairment occur in multiple domains of cognitive function 
including attention, arousal, orientation, memory, thought processing, language, perception, 
visuospatial and constructional abilities, and executive functioning (Tzrepacz, Meagher, and 
Wise, 2002). Trzepacz (1994a) emphasizes the involvement of the right hemisphere and 
prefrontal cortex. Flacker & Lipsitz (1999) identify probable neurological mechanisms of 
delirium that result from the effects of multiple etiological factors and pathophysiological 
processes. For example, medications may affect cholinergic, dopaminergic, and serotonergic 
systems resulting in delirium. Other neurotransmitter systems, gamma-aminobutyric acid and 
glutamate, may also play a role in delirium. In addition, abnormal cortisol (Flacker & Lipsitz; 
van der Mast, 1998) and cytokine levels (Broadhurst & Wilson, 2001; Flacker & Lipsitz; van 
der Mast) have been identified as neurobiological factors involved in the pathogenesis of 
delirium.  
The etiology of delirium in cancer patients is multifactorial. Older cancer patients are 
at increased risk for delirium because of age-related changes in the brain and other age-
related physiological changes. Delirium in cancer patients is related to the direct and indirect 
effects of cancer (and cancer treatment) on the central nervous system (CNS) (Fann & 
Sullivan, 2003; Meyers, 2000). Delirium also may be caused by factors unrelated to the 
cancer such as prior stroke, pre-existing dementia, or other comorbid processes common in 
the elderly.  
Primary and metastatic brain tumors can compress the brain and its blood vessels, 
obstructing the flow of blood and cerebral spinal fluid, thus causing delirium and other 
14 
neurological symptoms. Encephalopthy following therapeutic radiation of the brain can occur 
within hours of the first treatment, or be delayed by weeks, months or years after treatment 
(Keime-Guibert, Napolitano, & Delattre, 1998; Moretti, Torre, Antonello, & Cazzato, 2001). 
Biotherapies such as interleukin-2 and interferon-α can produce acute confusion or other 
disorders like depression and mania (Forman, 1994; Raison, Demetrashvili, Capuron, & 
Miller, 2005). 
Metabolic encephalopathies are common in cancer patients, particularly those with 
primary or metastatic liver involvement, and those with underlying liver and renal 
dysfunction. Wernicke’s encephalopathy (thiamine deficiency) is an often overlooked but 
reversible cause of delirium in malnourished cancer patients (Onishi et al, 2004; Turner, 
Alley, & Sharpless, 2005). Hypoxia, ischemia, infection, and electrolyte abnormalities 
(Morita et al., 2001; Tuma & DeAngelis, 2000), as well as paraneoplastic syndromes, 
resulting from tumor secretion of pro-inflammatory cytokines or antineuronal autoantibodies 
or other substances, can induce delirium in cancer patients (Kung, Mueller, Geda, & Krahn, 
2002; Munshi et al., 2005; Young, 1998; Zeimer, 2000). 
Medications used to treat cancer or to ameliorate symptoms can cause delirium. 
These include anticholinergics like diphenhydramine (Tune & Egeli, 1999), 
chemotherapeutic and biological agents (Lerner, Stoudemire, & Rosenstein, 1999; Young, 
1998), opioids (Gaudreau, Gagnon, Harel, Roy, & Tremblay, 2005; Lawlor, 2002), 
corticosteroids (Gaudreau et al.; Jenkins & Bruera, 2000; Stiefel, Breitbart, & Holland, 
1989), and non-opioid psychoactive medications including benzodiazepines, hypnotics, and 
antiemetics (Guadreau et al., Lawlor, Gagnon et al., 2000). 
15 
Measurement of Delirium  
Multiple designs and methods have been used to study and measure delirium. 
Retrospective methods have used medical record reviews to identify a documented diagnosis 
of delirium or to identify delirium based on documentation of delirium symptoms or 
diagnostic criteria. However, retrospective methods are imprecise (Johnson et al., 1992) and 
have significant limitations primarily because it is well documented that delirium is 
underrecognized and underreported by physicians and nurses (Inouye, Foreman, Mion, Katz, 
& Cooney, 2001; Neelon, Champagne, McConnell et al., 1992). Additionally, the evaluation 
and documentation of cognitive function and behaviors associated with delirium in clinical 
practice are not systematic or complete (Foreman, 1993). Prospective longitudinal designs 
using valid and reliable instruments to measure delirium are crucial to study and gain a better 
understanding of the phenomenon. Because delirium is characterized by alterations in 
cognition and behavior, the bedside assessment and observation of cognitive function and 
behavior are required for proper identification and measurement. 
In addition to the gold standard – a clinical interview by a psychiatrist – more specific 
instruments and scales have been developed for screening, diagnosing, and monitoring 
delirium in research and clinical settings. These instruments have been extensively reviewed 
(Smith et al., 1995; Levkoff, Liptzin, Cleary, Reilly, & Evans, 1991; Rapp et al., 2000; 
Trzepacz, 1994b). Smith et al. (1995) separate these instruments into three main categories: 
cognitive impairment screening instruments such as the Mini-Mental Status Exam (MMSE) 
(Folstein, Folstein, & McHugh, 1975), delirium diagnostic instruments such as the Confusion 
Assessment Method (CAM) (Inouye et al., 1990), and delirium numerical rating scales such 
as the Delirium Rating Scale (DRS) (Tzrepacz, Baker, & Greenhouse, 1988), the Delirium 
16 
Rating Scale-Revised-98 (DRS-R-98) (Tzrepacz et al., 2001), the Memorial Delirium 
Assessment Scale (Breitbart et al., 1997) and the NEECHAM Confusion Scale (Neelon, 
Champagne, Carlson, & Funk, 1996). All of these instruments have established psychometric 
properties and have been used in research and in clinical practice to measure delirium and 
acute confusion.  
Neelon et al. (1996) identify the characteristics of an ideal instrument for measuring 
delirium. It should cause low respondent burden, allow for rapid bedside assessment, and 
measure all aspects of the phenomenon. Furthermore, it should allow repeated measurement 
and monitoring of delirium over time.  
The MMSE and other cognitive impairment screening instruments are measures of 
global cognitive function and are not specific for delirium because they exclude the 
evaluation of behavioral symptoms commonly seen in delirium. Therefore, some (Lawlor & 
Bruera, 2002; Inouye et al., 1990) have suggested that the use of cognitive screening 
instruments followed by a more in-depth delirium assessment using a delirium instrument is 
best.  
As previously noted, a number of methods and instruments have been used to identify 
and diagnose delirium. Observational instruments that are minimally burdensome may be the 
most useful and most practical in the palliative care setting. Patients with advanced cancer 
near the end of life may not be able to complete instruments that require active participation. 
They may have the cognitive ability but lack the motor skills required to complete the test. 
Lawlor, Nekolaichuk et al. (2000) found that 20-30% of advanced cancer patients could not 
participate in the objective assessment components on the MDAS because of fatigue, 
dyspnea, and delirium. Similarly, in a retrospective review of the MMSE, Pereira et al. 
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(1997) found a number of missing items. The items most frequently missing were those that 
required writing and drawing. 
Several observational instruments have been developed specifically to measure 
delirium in terminal cancer patients. The Bedside Confusion Scale (Stillman & Rybicki, 
2000) is a screening tool that assesses level of alertness and attention. The Agitation Distress 
Scale and the Communication Capacity Scale (Morita, Tsunoda, Inoue, Chihara, & Oka, 
2001) are observational rating scales that quantify agitation and ability to communicate in 
terminally ill patients with delirium. Although these scales were found to be reliable and 
valid in limited testing, they need further evaluation. 
 
Subsyndromal Delirium 
The development and use of the DSM criteria has increased reliability in the 
diagnosis of delirium. However, these criteria are restrictive and do not identify patients with 
emerging or partial delirium syndromes. Subsyndromal delirium, the manifestation of 
delirium symptoms without meeting diagnostic criteria for the full syndrome may be a 
common phenomenon in patients with advanced cancer at the end of life. Subsyndromal 
presentations of delirium may indicate a change in the underlying medical condition or the 
development of a new undiagnosed medical condition (Caraceni & Grassi, 2003). The 
prompt recognition and treatment of subsyndromal delirium may promote symptom 
improvement and prevent the development of more severe delirium. Delirium must be more 
broadly understood as a spectrum of nonadaptive psychophysiological responses 
encompassing a range of cognitive and behavioral abnormalities ranging from mild to severe 
(Neelon & Champagne, 1992). Subsyndromal or preclinical delirium may represent the 
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milder range of the continuum, while delirium meeting diagnostic criteria represents the 
more severe extreme (Levkoff et al., 1996). 
Lipowski (1990) describes a pre-delirious state in which patients exhibit one or more 
symptoms of delirium including difficulty with thinking and concentration, restlessness, 
anxiety, irritability, drowsiness, insomnia, hypersensitivity to environmental stimuli, 
nightmares, and transient perceptual disturbances. Similarly, Meagher & Trzepacz (1998) 
describe a prodromal phase characterized by disturbances in behavior, affect, and sleeping 
patterns. Subsyndromal manifestations of delirium have been minimally studied. Levkoff et 
al. (1992) found that a number of hospitalized medical-surgical patients may exhibit 
individual symptoms of delirium without meeting full diagnostic criteria. Patients with pre-
delirium may or may not go on to develop diagnostic delirium. Currently there is no measure 
for subsyndromal delirium. 
Delirium does, in fact, demonstrate a continuum of severity. Typically, delirium is 
often only recognized, diagnosed, and treated when severe symptoms such as disorientation, 
hallucinations, and agitation are present. While this prevents false-positives in diagnosis, it 
has significant implications—specifically the failure to recognize and diagnose, and 
therefore, the failure to treat mild delirium and hypoactive presentations of delirium. 
Symptoms of subsyndromal or mild delirium include fearful mood or anxiety, inattention, 
and distractibility; these symptoms are non-specific and may be difficult to distinguish from 
normal behavior. Mild delirium is most often missed, overlooked, or misdiagnosed, but may 
be the most treatable. Early treatment may prevent progression to moderate or severe 
delirium. Furthermore, subsyndromal delirium is not only common, but also clinically 
relevant because it increases the risk of further cognitive decline, functional dependence, and 
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increased mortality during and after hospitalization (Francis & Kapoor, 1992; Levkoff et al., 
1992) 
In clinical practice, delirium often is not recognized until a patient exhibits extreme 
cognitive and behavioral dysfunction (i.e., agitated confusion). It is likely that subsyndromal 
delirium or acute confusion can be identified before all of the diagnostic criteria for delirium 
are met. Clinicians often either fail to recognize subtle cognitive and behavioral changes 
associated with subsyndromal delirium or they see them as normal for the patient’s condition. 
Acute confusion may precede delirium as an indication that something is not right. Early and 
prompt recognition and treatment of acute confusion may prevent more severe delirium from 
developing.  
 
Differentiating Patterns of Impaired Cognitive Functioning: Confusion, Dementia, 
Depression, Terminal Decline, and Terminal Restlessness 
 
Impaired cognitive functioning refers to problems in the brain’s ability to acquire, 
process, store, and retrieve information (Lawlor, 2002). Cognitive impairment is common in 
older adults, and most likely results from structural and functional changes in the brain. 
Cognitive impairment is a defining feature in a number of psychiatric and clinical disorders 
including delirium, dementia, depression, terminal decline, and terminal restlessness. These 
syndromes are not mutually exclusive, as they frequently coexist. Since delirium is often 
misdiagnosed as dementia or depression there is a need to discuss the unique features that 
differentiate between these disorders. Additionally, dementia and depression are recognized 
risk factors for delirium. The defining features of delirium, dementia, and depression are 
presented in Table 2.2.
  
Table 2.2. Defining features of delirium, dementia, and depression 
 
 
Feature 
 
Delirium 
 
Dementia 
 
Depression 
 
Onset 
 
Acute, abrupt 
 
Slow, progressive 
 
Weeks to months 
 
Course 
 
Fluctuates, often diurnal 
 
Stable 
 
Stable or with situational fluctuation 
 
Duration 
 
Short or variable 
 
Chronic 
 
Variable 
 
Consciousness 
 
Clouded, decreased 
 
Alert 
 
Intact 
 
Orientation 
 
Often impaired particularly to 
place, time, and events 
 
Often impaired 
 
Intact 
 
Attention 
 
Reduced or vigilant 
 
Usually normal 
 
Variable 
 
Memory 
 
Impaired, variable 
 
Impaired 
 
Normal or impaired short-term 
 
Affect 
 
Mood lability 
 
Mood lability 
 
Consistent, flat, or blunted 
 
Thinking 
 
Disorganized, fragmented 
 
Abstraction and judgment impaired 
 
Intact but with hopelessness and 
helplessness  
 
Speech 
 
Incoherent, slow or rapid 
 
Word finding difficulty 
 
Normal or slowed 
 
Sleep-wake cycle 
 
Disturbed, cycle reversed 
 
Fragmented 
 
Fragmented, increased or decreased 
 
Delusions 
 
Common, often paranoid 
 
Sometimes 
 
Occasional in severe cases 
 
Hallucinations 
 
Visual and auditory common, 
tactile and olfactory possible 
 
Uncommon 
 
Rare except in severe cases 
 
Sources. Insel & Badger, 2002; Kennedy, 2003; Lipowski, 1990 
20
 21 
Confusion 
Confusion is a non-specific term often used to describe a state of cognitive 
impairment. There is much imprecision in the use of the term, clinically and in research 
reports. Clinicians often use the term “confused” indiscriminately to describe or label persons 
exhibiting cognitive impairment. Nurses often use the term confusion to describe a state of 
disorientation, while physicians emphasize memory component (Wolanin & Phillips, 1981).  
 
Dementia  
Dementia, in contrast to delirium, is characterized by a progressive, usually gradual, 
decline in global cognitive function. The prevalence of dementia increases with age. 
Dementia affects up to 10% of older adults over 65 years of age and 50% of those over the 
age of 85 (Insel & Badger, 2002; Kennedy, 2003; Ritchie & Lovestone, 2002). Patients with 
dementia exhibit profound alterations in thinking and memory such that it interferes with 
normal daily function (Insel & Badger). The ability to learn and retain new information is 
significantly impaired. Executive functioning is also impaired. Typically, attention and 
alertness remain intact in dementia until late in the disease. 
The cognitive changes associated with dementia are often accompanied by alterations 
in mood, behavior, and personality (Ritchie & Lovestone, 2002). These changes are similar 
to those that occur with delirium and depression contributing to the difficulty in 
differentiating between them. The presence of dementia is a significant risk factor for 
delirium so that clinicians should be aware of the potential for delirium superimposed on 
dementia.  
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Depression 
Rates of depression in community-dwelling older adults are low, but increase in 
hospitalized older persons, nursing home residents, and those who are chronically ill (Koenig 
& Blazer, 2003). The prevalence of depressive symptoms can average 20-30% (Insel & 
Badger, 2002). Older persons with depression experience prominent difficulties with memory 
and concentration.  Depressed persons may also exhibit apathy and irritability. Older persons 
may be more likely to experience cognitive dysfunction when depressed. Patients with 
cognitive impairment also experience depression, suggesting that depression and cognitive 
impairment likely have interactive, reciprocal influences (Goy & Ganzini, 2003). Depression 
in older adults accompanied by cognitive impairment may herald the onset of dementia 
(Kennedy, 2003).  
 
Terminal Drop and Terminal Decline  
Kleemeier (as cited in Siegler, 1975) introduced the terminal drop hypothesis when 
he reported a relationship between intellectual function and death. More specifically, 
Kleemeier (as cited in Berg, 1996) noted that individual differences in intellectual 
functioning in old age could be accounted for by a terminal drop or decline associated with 
the death of the individual rather than the chronological age of the individual. Two terms, 
terminal drop and terminal decline, have been used to describe observed decrements in 
cognitive functioning prior to death. Palmore & Cleveland (1976) differentiated between the 
two by noting that a curvilinear decline of intellectual functioning close to death is terminal 
drop, while a more gradual linear deterioration is terminal decline.  
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Terminal Restlessness 
Terminal restlessness is a common occurrence at the end of life. Terminal restlessness 
is characterized by agitation, fidgeting, involuntary muscle twitching or jerking, and moaning 
in the context of impaired consciousness (Back, 1992; Travis, Conway, Daly, & Larson, 
2001). Terminal restlessness is disturbing for family caregivers (Brajtman, 2003; Morita et 
al., 2004) and professional caregivers (Brajtman, 2006). Several authors have discussed the 
need to differentiate between delirium and the terminal state (Neelon & Champagne, 1992) 
or between reversible delirium and delirium as a terminal event (Lindesay, Rockwood, & 
MacDonald, 2002). 
 
Age-Related Cognitive Decline in Older Adults 
Age-related cognitive decline in older adults increases their baseline vulnerability for 
delirium. Therefore, this section discusses normal cognitive changes associated with aging 
and factors contributing to cognitive decline in older adults, specifically age-related central 
nervous system (CNS) changes and other physiological and health-related factors.  
 
Normal Age-Related Cognitive Changes 
Baltes (1993) describes the trajectory of cognitive functioning across the lifespan. He 
notes that cognitive mechanics, or fluid intelligence, involve the speed and accuracy of 
processing, visual and motor memory, and other aspects of working memory, and that 
cognitive pragmatics, or crystallized intelligence, include reading and writing skills, language 
comprehension, and other learned skills and procedural knowledge. Typically, decrements in 
the cognitive mechanics begin in early adulthood and continue throughout life. On the other 
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hand, the cognitive pragmatics continue to develop across the lifespan and remain relatively 
stable into old age.  
While there is an overall pattern of age-related decline, cognitive functioning in older 
adults is marked by significant individual differences. In a review of cognitive functioning in 
old age, Backman, Small, Wahlin, & Larsson (2000) demonstrate that demographic, 
cognitive, psychological, lifestyle, and biological factors influence cognitive performance in 
older adults and probably account for these individual differences in cognitive function. 
Many factors and age-related processes contribute to cognitive decline in older adults. 
 
Age-Related Central Nervous System (CNS) Changes 
Raz (2000) provides an extensive overview of neuroanatomical and 
neurophysiological changes associated with aging. Multiple global structural and 
biochemical changes have been observed in the aging brain. In the normal aging brain, the 
loss of neurons is limited to discrete areas and exhibits individual variability. More extensive 
neuronal loss occurs with age-associated neurological disorders such as Alzheimer’s disease 
and Parkinson’s disease (Timiras, 2003). While the question regarding an age-related 
reduction in the total number of neurons is widely debated, neurons undergo significant and 
pervasive structural changes, including the loss of dendrites and synapses (Raz, Timiras). 
There is a reduction in white matter resulting from changes in myelin and neuronal atrophy. 
Autopsy studies have revealed an overall decrease in brain weight and volume with aging. In 
addition, there is enlargement of the cerebral ventricles and the cerebral sulci. Functional 
neuroimaging studies have shown evidence of a reduction in cerebral blood flow and a 
reduction in glucose and oxygen metabolism (Raz). Multiple cognitive processes are affected 
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by age-related changes in neurological structures—including the hippocampus, amygdala, 
striatum, and prefrontal cortex—and changes in the levels and functioning of 
neurotransmitters (Raz, Timiras).  
 
Physiologic and Health-Related Factors Associated with Cognitive Decline in Older 
 Adults 
 
 A number of health-related factors associated with aging significantly affect 
cognitive function in older adults (Backman, Small, Whahlin, & Larsson, 2000). These 
health-related factors include systemic biological changes and factors such as nutrition, 
vitamin deficiency, hormonal changes, and medications. In addition, age-related decreases in 
organ functional capacity or reserve and the failure of regulatory mechanisms and 
homeostatic systems also cause systemic changes that impair cognitive functioning. Acute 
and chronic illnesses are increasingly common in older adults. Disease-specific factors 
associated with cardiovascular disease and hypertension (Brown, Baird, Shatz, & Bornstein, 
1996; Madsen, Nielsen, & Christiansen, 2000), diabetes (Croxon & Jagger, 1995), lung 
disease (Rourke & Adams, 1996), and cancer (Meyers, Byrne, & Komaki, 1995) contribute 
to alterations in cognitive functioning in older adults. Hamerman et al. (1999) reported that 
inflammatory processes involving cytokines are associated with many acute and chronic 
conditions in older adults. These inflammatory processes have both local and systemic 
effects that result in additional health-related morbidity and chronicity. Cytokines have been 
associated with alterations in cognitive function and the role of cytokines in delirium has 
been proposed as discussed below (Broadhurst & Wilson, 2001; Flacker & Lipsitz, 1999; van 
der Mast, 1998). 
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Cognitive Impairment in Cancer Patients 
Studies of cognitive impairment and delirium in cancer patients have included 
patients with a wide range of ages. Few studies have examined cognitive alterations or 
delirium exclusively in older adults with cancer, nor have they described particular cognitive 
alterations that occur in older cancer patients with delirium. Studies have examined the 
frequency of psychiatric disorders, neuropsychiatric symptoms, and neurocognitive 
impairments in cancer patients at different stages of illness (Derogatis, 1983; Minagawa, 
Uchitomi, Yamawaki, & Ishitani, 1996; Portenoy, Krupp, & Kanner, 1986). Some studies 
have examined symptom prevalence, including cognitive symptoms in cancer patients 
(Grond et al; 1994; Portenoy et al, 1994). Studies also have focused on cognitive impairment 
in specific patient populations, small cell lung cancer patients (Myers, Byrne, & Komaki, 
1995) and breast cancer patients (Cimprich, 1998; Schagen, 1999), and in association with 
different cancer treatments such as surgery (Cimprich) and adjuvant chemotherapy (Schagen) 
in breast cancer and cytokine therapies including interferon (Bender et al., 2000) and 
interlukin-2 (Rosenberg et al., 1989). An increasing number of studies have examined 
cognitive impairment or delirium in patients with advanced or terminal cancer (Bruera et al, 
1992; Caraceni et al., 2000; Cobb et al., 2000; Donnelly & Walsh, 1995; Gagnon, Allard, 
Masse, & DeSerres, 2000; Lawlor et al., 2000; Massie, Holland, & Glass, 1983; Minagawa et 
al.; Morita, Tei, Tsunoda, Inoue, & Chihara, 2001; Pereira, Hanson, & Bruera, 1997; Sarhill 
et al., 2001; Stiefel, Fainsinger, & Breura, 1992; Wakefield & Johnson, 2001). Findings from 
these studies have shown that delirium and cognitive impairment are common in patients 
with advanced cancer and become more prominent closer to death. 
Studies of cognitive impairment and delirium in cancer patients have used a variety of 
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methods making it difficult to summarize and compare results. However, multiple cognitive 
alterations are common in cancer patients and may be related to direct effects of the cancer, 
side effects of cancer treatment, or possibly unrelated processes. Alterations have been found 
in many domains of cognitive function including attention (Cimprich, 1998; Schagen, 1999), 
orientation and alertness (Rosenberg et al, 1989), mental flexibility and speed of information 
processing (Schagen), verbal memory (Myers et al, 1995), visual memory (Schagen), motor 
function (Myers et al; Schagen) and executive function (Myers et al.). Myers et al. found that 
similar cognitive alterations in small cell lung cancer patients were present before and after 
treatment suggesting that the disease itself may be a contributing factor. In her study 
evaluating attention in women following surgery for breast cancer, Cimprich found that older 
women had significant declines in attention regardless of the extent of surgery. Although 
only one study (Cimprich) evaluated a single aspect of cognitive function in older women, it 
is expected that cognitive alterations in older adults with cancer would be similar to cognitive 
alterations in other cancer patients but possibly even more pronounced and long-standing. 
 
Cognitive Changes at the End of Life 
Cognitive impairment is one of the most common, and most feared, complications of 
terminal illness. Studies examining symptom prevalence in patients with advanced cancer 
receiving palliative and end of life care have reported a variety of cognitive symptoms 
including confusion (Brescia et al., 1990; Coyle, Adelhart, Foley, & Portenoy, 1990; 
Klinkenberg, Willems, van der Wal, & Deeg, 2004; McCarthy, Phillips, Zhong, Drews, & 
Lynn, 2000), impaired memory and concentration (Curtis, Krech, & Walsh, 1991), agitation 
(Elshamy & Whedon, 1997), drowsiness (Fansinger et al., 1991), altered level of 
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consciousness (Fainsinger et al., Lichter & Hunt, 1990; Morita et al., 1998, Peruselli et al., 
1999), sedation (Curtis et al.), hallucinations (Fountain, 2001), and other parapsychological 
phenomena such as visions (Barbato et al., 1999). 
A pattern of diminishing level of consciousness is common in patients approaching 
the end of life. Studies of dying patients report that 50% or more were comatose or 
unconscious in the last hours of life, most of the others were drowsy, and only a small 
percentage of patients remained awake or alert (Fainsinger et al., 1991; Morita et al., 1998). 
Lichter and Hunt (1990) reported that 30% of 200 hospice patients were conscious until 
death. The timing of loss of consciousness was examined in the other patients: 38% became 
unconscious from 0-12 hours prior to death, 24% became unconscious from 12-24 hours 
prior to death, 7% became unconscious 24-48 hours prior to death, and 1% were unconscious 
48 hours or more prior to death. However, the level of consciousness is not described further. 
Interestingly, Turner et al. (1996) found that 60% of patients maintained cognitive function 
and were able to speak lucidly at a moderate to good level in the last 3 days of life according 
to physician and nurse ratings. 
Fainsinger et al. (1991) found that average visual analogue scale scores (0-100) for 
drowsiness increased from 51 + 28 on Day 6 prior to death to 85 + 45 on the date of death. 
Additionally, a large percentage of patients experienced changes in their level of 
consciousness from the day of admission to the date of death. On the day of admission, 72% 
of patients were alert, 28% drowsy, and 0% unresponsive; whereas on the date of death, 2% 
were alert, 41% drowsy, and 57% unresponsive.  
Klinkenberg et al. (2004) conducted after-death interviews with close relatives of 270 
deceased older persons from a population-based sample of older persons in the Netherlands 
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to examine symptom burden in the last week of life. The sample included 167 (62%) and 103 
women (38%) with a mean age of 80 years (range 59-91). Thirty five percent of the sample 
had cancer. The remainder had a variety of chronic disease diagnoses. At least 36% of 
patients experienced cognitive decline over the last three months of life. Patients with severe 
cognitive decline over the last three months of life were reported to have had higher levels of 
symptom burden than those with low or no decline in cognitive function. Relatives reported 
that 34% of patients were unable to make decisions in the last week of life. Relatives also 
reported that no communication was possible during the last week in 15% and that 4% of 
patients were unconscious throughout the last week. 
McCarthy, Phillips, Zhong, Drews, and Lynn (2000) conducted a retrospective 
analysis of the last 6 months of life to describe the dying experience of lung and colon cancer 
patients enrolled in the SUPPORT project. Patients experienced functional decline and 
poorly controlled pain and confusion. Severe confusion was more common in lung cancer 
patients than in colon cancer patients during the 3-6 month period prior to death, but in the 
last 3 days of life the frequency of severe confusion was similar in both groups. 
Approximately 28% of patients in both groups experienced severe confusion during this 
period.  
Brescia et al. (1990) retrospectively studied symptom prevalence in 1,103 advanced 
cancer patients admitted to a palliative care hospital. One third (33%) of the patients 
exhibited at least one episode of confusion or disorientation during the first 24 hours after 
admission. Confusion was greater in older patients; those over the age of 75 years were more 
likely to experience confusion.  
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Coyle et al. (1990) conducted a retrospective record review to identify the prevalence 
of symptoms volunteered by patients in the last 4 weeks of life. Symptoms had been elicited 
by daily telephone contacts between the team nurse and patient or family. Only the 
symptoms volunteered by patient or family informants were included. Cognitive impairment 
reported by 24% of informants was one of the most prevalent symptoms 4 weeks before 
death. One week prior to death 28% of informants reported mental haziness or confusion. 
The prevalence of sleepiness increased from 24% 4 weeks before death to 57% one week 
before death.    
Morita et al (1998) prospectively studied the process of dying in 100 terminally ill 
cancer patients. The level of consciousness of patients was measured using a categorical 
scale: awake, drowsy, very drowsy, and coma. The level of consciousness diminished over 
the last week of life. One week prior to death 56% of patients were awake, 44% drowsy, and 
0% comatose. In the last 24 hours, 26% were awake, 62% drowsy, and 12% comatose. In the 
final 6 hours of life, half of patients (50%) were comatose, 42% were drowsy, and 8% were 
awake.  
Elshamy and Whedon (1997) conducted a secondary analysis of data obtained from a 
retrospective chart review to examine the frequency of dyspnea, pain, agitation, and 
confusion in hospitalized patients during the last 48 hours of life. The sample included 
patients with cancer, cardiovascular disease, respiratory disease, and other diagnoses. They 
found that nearly half of the patients (43%) were fully oriented within 2 days of death. 
Overall, 47% of the patients experienced agitation in the last 48 hours; 52% of cancer 
patients experienced agitation. Among all patients, 32% experienced confusion; 37% of 
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cancer patients experienced confusion. The frequency of agitation and confusion was similar 
in cancer and non-cancer patients. 
In an Italian study, Peruselli et al. (1999) examined the place, circumstances, and 
quality of death in 401 patients admitted to home palliative care units. Following the 
patient’s death the palliative care team completed the Support Team Assessment Schedule 
(STAS), an instrument designed to evaluate quality of care, quality of life, and team 
effectiveness and a quality of death questionnaire. They report that 34% of the patients were 
conscious until death. However, level of consciousness is not further defined and data were 
missing for 44 patients. They also found that 25% of the patients required pharmacological 
sedation for symptom management in the last 12 hours of life  
The previously reviewed studies focused on cognitive impairment in the last weeks of 
life. Other studies have looked at symptom prevalence in cancer patients at the time of 
referral to palliative care services (Conill et al., 1997; Curtis, Krech, & Walsh, 1991; Jenkins, 
Schulz, Hanson, & Bruera, 2000). In these studies, patients were at various places in their 
disease trajectories and, in some cases, still receiving active cancer treatments.  
Conill et al. (1997) compared the frequency of symptoms at the first palliative care 
evaluation to the frequency of symptoms during the last week of life in 176 patients with 
advanced cancer. Patients’ self-reports of confusion more than doubled between the two 
assessments. At the initial assessment, 53 (30.1%) patients reported confusion compared to 
120 (68.2%) patients at the second assessment during the last week of life.  
Curtis et al. (1991) prospectively documented the presenting symptoms of 100 
advanced cancer patients upon referral to a palliative care service. The total number of 
symptoms experienced ranged from 1 to 25 with a median of 6. Cognitive symptoms, present 
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in a small number of patients, included confusion in 11%, memory problems in 10%, and 
sedation in 7%.  
Jenkins, Schulz, Hanson and Bruera (2000) retrospectively examined symptom 
profiles in cancer patients at the time of referral to a palliative care consult team in a tertiary 
hospital. Of the 95 patients, 36 were either newly diagnosed or diagnosed with a recurrence 
of a potentially cured cancer. Of the remaining 56 patients, 46 had a progressive terminal 
cancer, 5 had a potentially curable cancer, and 8 were thought to be in remission or potential 
remission. Almost half (44%) of the 91 patients assessed with the mini-mental status 
questionnaire (MMSQ) on the consult day exhibited cognitive impairment based on a score 
of less than 24/30 or less than 80% if they could only partially complete the test. An 
additional 10 of the 91 patients had evidence of delirium by DSM IV criteria despite a 
normal score on the MMSQ. Three patients who could not complete the MMSQ had 
cognitive impairment on the basis of clinical evaluation. Overall, 53 of the 95 (56%) patients 
referred for palliative care consultation had evidence of cognitive impairment. In this study, 
18 of 19 patients (95%) who died during hospitalization had cognitive impairment.  
The findings from these studies indicate that cognitive impairment frequently occurs 
in the last weeks of life as a pre-terminal event. Moreover, the findings also suggest that 
cognitive impairment in patients with advanced cancer may be a significant problem earlier 
in the illness trajectory. 
 
Delirium in Cancer Patients 
Most studies of delirium in cancer patients, in general, have focused on estimating its 
prevalence and incidence in hospitalized patients. These studies indicate that delirium is a 
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significant problem in hospitalized cancer patients but the findings are not consistent. The 
reported rates of delirium in cancer patients vary widely from 8% (Derogatis et al., 1983) to 
66% (Tuma & DeAngelis, 2000). Studies of delirium in cancer patients date back to 1978, 
utilize retrospective and prospective designs, and operationalize and measure delirium 
differently.  A variety of terms are used to refer to delirium in these studies including 
cerebral dysfunction (Massie et al., 1979), organic mental disorders (Derogatis et al.), 
organic brain syndrome (Levine et al., 1978), acute encephalopathy (Tuma & DeAngelis, 
1992), altered mental status (Tuma & DeAngelis, 2000), and cognitive impairment (Folstein 
et al., 1984). Most studies used DSM criteria to establish a diagnosis of delirium. However, 
different versions of the criteria were used including DSM II (Levine et al.); DSM III 
(Derogatis et al.); DSM III-R (Tuma & DeAngelis, 2000); and DSM IV (Fincannon, 1995). 
Studies using one version are not directly comparable to studies using another version. In 
most reports, the operationalization and application of DSM criteria are also not explicitly 
described. Folstein et al. (1984) used the MMSE to measure cognitive impairment in cancer 
patients.  
Several studies have evaluated the frequency of delirium in cancer patients referred 
for psychiatric consultation (Fincannon, 1995; Levine, Silberfarb, & Lipowski, 1978; Massie, 
Gorzynski, Mastrovito, Theis, & Holland, 1979). Studies examining psychiatric consultation 
in cancer patients indicate that a small number of referrals are made for suspected delirium 
and that delirium is often misdiagnosed as depression. Fincannon (1995) reported that only 
6% of 102 patients were referred to a psychiatric consulation liaison nurse (PCLN) for 
delirium, but in fact 14% were diagnosed by the PCLN as having delirium. Six patients 
(19%) referred for depression were diagnosed with delirium. In a retrospective review of 100 
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psychiatric referrals, Levine et al. (1978) noted that while only 21% of patients were referred 
for delirium (organic brain syndrome), 40% were diagnosed by the consulting psychiatrist as 
having delirium. Moreover, 26 patients with delirium had been misdiagnosed as having 
depression by the referring physician. These findings suggest that the actual incidence of 
delirium in cancer patients is probably underrepresented because of either failure to 
recognize symptoms or misdiagnosis.  
Tuma & Deangelis (2000) examined the clinical findings, causes, and outcomes of 
altered mental status in 140 hospitalized cancer patients referred for neurology consultation. 
Thirty-four percent of patients had altered mental status on admission and 66% developed 
altered mental status during hospitalization.  Patients exhibited a number of cognitive 
symptoms including lethargy and coma (61%), agitation (44%), disorientation (83%), and 
delusions and hallucinations (28%). A single cause of altered mental status was identified in 
33% of patients, while multiple causes were identified in 67%. Altered mental status 
improved in 67% of patients but it was a poor prognostic factor overall—25% of patients 
died within 30 days and 44% died within 6 months.     
Methodological issues and differences among studies of delirium in cancer patients 
make comparison across studies difficult. Studies have included heterogeneous samples with 
a wide age range, a variety of cancer diagnoses, and variable stages of disease. Few studies 
have examined delirium specifically in older cancer patients. In addition, few studies have 
prospectively examined delirium in the home setting. The frequency of measurement has 
varied across studies. The conceptualization and measurement of delirium also has varied 
across studies. Multiple instruments have been used to measure delirium. When diagnostic 
criteria have been used, investigators have operationalized them differently resulting in 
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imprecision and lack of standardization of measurement. Finally, delirium often has been 
diagnosed as a dichotomous outcome—present or absent—without regard to its level of 
severity.  
 
Delirium in Patients with Advanced Cancer  
 Over the past decade an increasing number of studies have examined delirium and 
cognitive impairment in patients with advanced cancer. Most of these studies included 
terminally ill cancer patients near the end of life and were conducted primarily in hospital 
and in inpatient palliative care settings. Studies can be divided into three groups: those 
examining confusion as a symptom at the end of life, those specifically addressing cognitive 
function or cognitive impairment (failure), and those examining delirium. Many different 
instruments were used to measure delirium and cognitive failure (Hjermstad, Loge, & Kaasa, 
2004). Studies have focused on estimating the frequency of delirium (prevalence and 
incidence), identifying etiological factors, and evaluating outcomes of delirium (reversibility 
and symptom improvement).  
 
Frequency of Delirium in Patients with Advanced Cancer 
 Massie et al. (1983) prospectively evaluated 19 cancer patients who were likely not to 
survive hospitalization. After an initial interview, assessments using a 58-item delirium 
rating scale were conducted three times a week. Six of the patients improved or were 
discharged. The 13 patients who died during hospitalization were monitored until death. 
Eleven of 13 patients (85%) developed delirium prior to death. The other two patients 
remained mentally clear until shortly before death. 
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 Bruera, Chadwick, Weinlick, and MacDonald (1987) completed a retrospective case 
review to evaluate the frequency of delirium and severe sedation in 30 patients with 
metastatic cancer who were hospitalized for at least one week. All patients were assessed 
daily. Delirium was diagnosed clinically if a patient exhibited a confusional state with or 
without hallucinations or hyperactivity. Severe sedation was diagnosed if a patient was 
unable to converse because of diminished level of consciousness. Twenty-three of 30 patients 
(77%) developed impaired mental status. Sixteen had delirium and the remaining 7 exhibited 
severe sedation. 
 Several studies with retrospective and prospective designs have used serial MMSE 
measurements to examine the frequency and course of cognitive impairment in patients with 
advanced cancer. Bruera, Miller et al. (1992) prospectively evaluated cognitive function in 
61 cancer patients admitted to an acute palliative care unit. In a retrospective study, Pereira et 
al. (1997) examined the frequency and clinical course of cognitive failure in 348 patients 
admitted to a palliative care unit over a 26-month period. Zhukovsky et al. (1998) found that 
21% of cancer patients exhibited cognitive impairment (MMSE < 23) at the time of referral 
to a palliative care service. 
 In a consecutive series, Minigawa et al. (1996) evaluated 93 terminally ill cancer 
patients within the first week of admission to determine the range of psychiatric diagnoses 
among them. They administered the MMSE followed by the Structured Clinical Interview 
(SCID) for the DSM-III-R. Overall, 54% of patients met DSM III-R criteria for a psychiatric 
disorder. Based on MMSE scores, 39 patients (42%) were cognitively impaired. Delirium 
was observed in 26 patients (28%), and was the most common psychiatric diagnosis. Ten 
patients (10.7%) were diagnosed with dementia. 
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 In a retrospective review of 100 consecutive patients admitted to a palliative care unit, 
Fainsinger et al. (1991) used nursing and physician notes to determine the presence or 
absence of delirium. Thirty-nine patients experienced delirium. For reasons previously 
mentioned, the use of chart documentation to identify or evaluate delirium has significant 
limitations.   
Two studies (Gagnon et al., 2000; Lawlor, Gagnon et al., 2000) used daily screening 
and ongoing symptom monitoring to detect delirium. When delirium symptoms were noted a 
more in-depth diagnostic assessment was performed.  
Gagnon et al. (2000) conducted a prospective cohort study to determine delirium 
frequency and outcome in 89 cancer patients hospitalized for terminal care. The nursing staff 
screened patients for delirium symptoms three times a day using the Confusion Rating Scale 
(CRS). If a patient screened positive, a diagnostic assessment with the Confusion Assessment 
Method (CAM) was performed within 24 hours. The prevalence of delirium on admission 
was 13.3%, and the incidence during hospitalization was 32.8%. The CRS also was used to 
monitor delirium symptoms following delirium diagnosis.    
Lawlor, Gagnon et al. (2000) studied the prevalence and incidence of delirium in 104 
of 113 patients consecutively admitted to an acute inpatient palliative care unit at a 
university-affiliated teaching hospital.  Screening with the MMSE was conducted on 
admission and twice weekly and anytime delirium was suspected. If patients were 
cognitively impaired based on the MMSE score, or if there was clinical evidence of delirium, 
then they underwent a semi-structured interview that operationalized DSM IV criteria for 
delirium. Patients meeting DSM IV criteria had an assessment of delirium severity using 
Memorial Delirium Assessment Scale (MDAS) and daily nursing assessments using the 
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Delirium Observational Checklist Scale (DOCS). Patients who remained delirious underwent 
an interview and MDAS testing every 72 hours until their delirium resolved or until their 
death. The prevalence of delirium on admission was 42%, and the incidence of delirium 
during hospitalization was 45%. Overall 71 patients experienced a total of 94 episodes of 
delirium. Terminal delirium occurred in 46 (88%) of the 52 patients who died during 
hospitalization. 
It is difficult to compare studies examining the frequency of delirium in advanced 
cancer patients because they have numerous methodological differences. Studies have used 
retrospective and prospective as well as longitudinal and cross-sectional designs. Most 
studies included small heterogeneous samples with a variety of cancer diagnoses. The 
samples have been select cohorts as well in that they were primarily patients admitted to 
inpatient palliative care units and hospitals for severe symptomatology. Based on the 
information provided in the reports, no studies evaluated patients for or excluded patients 
with prior cognitive impairment. Patients were followed for relatively short periods of time. 
Different methods were used for case identification including screening on admission and on 
an ongoing basis, and clinical evaluation by physicians and nurses. The studies also used 
different measures and methods of cognitive assessment including the MMSE, the CAM, the 
MDAS, DSM IV criteria, and chart documentation. The frequency and timing of evaluations 
and the intensity of follow-up varied from daily to two or three times a day to three times a 
week. Since delirium is transient and symptoms fluctuate, episodes may have been missed 
with longer intervals between assessments.   
 
 
 39 
Timing of Delirium Symptoms in Relation to Death 
Two studies examined the timing of delirium symptoms in relation to death. Bruera et 
al. (1987) detected symptoms of cognitive impairment an average of 9 + 6 days before death. 
In a subsequent study, Bruera et al. (1992) found that patients with advanced cancer 
developed cognitive failure an average of 16 + 6 days prior to death.  
 
Subsyndromal Delirium in Advanced Cancer Patients  
Subsyndromal delirium may be common in patients with advanced cancer near the 
end of life. A few studies have underscored the problem of delirium symptoms in patients 
with advanced cancer by differentiating between the presence of delirium symptoms and the 
full syndrome. Gagnon et al. (2000) used the CRS to screen for delirium symptoms and to 
trigger a diagnostic assessment. The prevalence and incidence of delirium symptoms was 
higher than confirmed delirium. The prevalence of delirium symptoms was 20.2% whereas 
the prevalence of confirmed delirium was 13.3%. The incidence of delirium symptoms 
during hospitalization was 52.1% while the incidence of confirmed delirium was 32.8%.   
Nowels et al. (2002) used nurses’ report to estimate the prevalence of confusion in 
terminally ill cancer and non-cancer patients enrolled in hospice.  Common manifestations of 
confusion included disorientation, impaired short-term memory, drowsiness, altered sleep-
wake cycle, and easy distractability. For confused patients, nurses were asked a series of 
questions about the patients’ cognition based on DSM IV criteria for delirium. According to 
the nurses’ responses to these questions, 14% of the confused patients were likely to have 
delirium. Chang (2002) questions whether confusion in terminally ill patients could represent 
pre-delirium that might evolve into delirium or terminal restlessness. 
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Etiology of Delirium in Patients with Advanced Cancer 
Posner (1979) posited that neurologic complications of systemic cancer including 
delirium were caused by direct effects of the cancer on the CNS or by indirect effects of the 
cancer or its treatment. Neurologic complications in cancer patients may also be unrelated to 
cancer but associated with or result from other comorbid medical conditions. The etiologic 
mechanisms associated with the development of delirium are often multifactorial involving 
multiple physical (physiologic), psychological, and socio-environmental factors. In a recent 
study, Lawlor, Gagnon et al. (2000) identified a median of 3 precipitating factors per episode 
of delirium in 71 cancer patients in an acute palliative care unit. Similarly, Morita et al. 
(2001) identified a median of 2 precipitating factors per person. In both studies the number of 
identified factors ranged from 1-6. 
The ability to identify specific etiologies of delirium in patients with advanced cancer 
has varied across studies depending on how potential etiologies were conceptualized and 
measured. In several studies, the etiologies of delirium could not be established in the 
majority of patients. Bruera et al (1987) were able to identify the cause of cognitive 
impairment in 21% of cases. In a subsequent prospective study, Bruera, Miller et al. (1992) 
could not identify a cause for cognitive impairment in 56% of cases. In a retrospective study 
of delirium requiring psychotropic drug treatment, Stiefel et al. (1992) were unable to 
identify a reason for delirium in 75% of cases.  These studies did not incorporate a 
standardized or systematic approach or criteria for identifying etiologic factors.  
Two studies using specific criteria for identifying delirium etiologies (Lawlor, 
Gagnon et al. 2000; Morita et al., 2001) identified etiologic factors in most cases. Morita et 
al. determined the cause of delirium in 93% of cases. Lawlor, Gagnon et al. identified 
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precipitating factors for the first episode of delirium in all patients (n = 71) who developed 
delirium.  
Massie et al. (1983) established the cause of delirium in 9 of 11 patients who 
developed delirium. Delirium was caused by metabolic encephalopathy related to electrolyte 
imbalance, sepsis, drugs, or organ failure and direct effects of the cancer by structural 
invasion of the brain, or both. The cause of delirium in the other two patients could not be 
determined because no laboratory studies were allowed.  
 
Delirium Subtypes in Advanced Cancer 
Delirium has been divided according to psychomotor behavior into three clinical 
subtypes: hyperactive, hypoactive, and mixed (Lipowski, 1983). Hyperactive delirium is 
characterized by increased psychomotor activity, sympathetic nervous system overactivity, 
increased alertness or hypervigilence, psychosis, and labile mood. In contrast, hypoactive 
delirium is exhibited as decreased psychomotor activity, withdrawal, apathy, lethargy or 
somnolence, and inattention. Symptoms of hyperactive and hypoactive forms of delirium 
alternate in the same individual when the mixed subtype of delirium is present 
Lawlor et al. (1998) observed the mixed subtype in 167 (48%) of 350 delirium 
episodes, the hypoactive subtype in 166 (47%), and the hyperactive subtype in 11 (3%). The 
delirium subtype was non-classifiable in 6 (2%) episodes. Lawlor et al. also examined the 
subtypes associated with terminal delirium that occurred within 72 hours of death. Sixty five 
percent of patients exhibited the hypoactive subtype and 35% exhibited the mixed subtype. In 
a study of delirium in the last week of life, Steifel et al. (1992) reported that the majority of 
patients exhibited the hyperactive or mixed subtype.  
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Reversibility of Delirium in Advanced Cancer 
 Delirium is conceptualized as a transient, potentially reversible condition caused by 
treatable underlying pathophysiologic disturbances. Lipowski (1990) identifies a number of 
factors that influence the reversibility of delirium including age; overall physical condition; 
baseline cognitive function; the appropriateness, effectiveness, and timeliness of treatment of 
underlying cause; and the management of delirium itself. The reversibility of delirium also 
depends on its underlying cause.  
The reversibility of delirium in patients with advanced cancer at the end of life creates 
significant clinical and ethical dilemmas. Lawlor and Bruera (2002) suggest that all delirium 
should be considered potentially reversible unless signs of active dying, related to advanced 
end-stage organ failure, or inconsistent with goals of care. On the other hand, particularly in 
patients with advanced cancer at the end of life, not all of the pathophysiologic and etiologic 
factors associated with delirium will be reversible. Furthermore, it may not always be 
possible to alter the patient’s baseline vulnerability or to remove or correct all precipitating 
factors. The primary treatment of delirium focuses on the identification and treatment of 
etiologic factors.  
In the context of terminal illness, delirium is often treated symptomatically. Patients 
who are pleasantly confused and who exhibit hypoactive manifestations of delirium are often 
not treated. On the other hand, patients exhibiting agitation and restlessness are often sedated. 
The rapid sedation of patients with delirium without adequate assessment and management 
inhibits patient–family communication and possibly shortens survival.  
An increasing number of studies provide empirical support for the potential 
reversibility of delirium in patients with advanced cancer even at the end of life (Lawlor, 
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Gagnon et al., 2000; Morita et al., Pereira et al., 1997) and that significant symptom 
improvement can occur in many cases even without specific intervention (Bruera, Miller et 
al., 1992; Gagnon et al., 2000).  Bruera, Miller et al. found that delirium improved in 22 
episodes (33%)—spontaneously in 10 episodes and as a result of treatment in 12 episodes. 
Similarly, Pereira et al. found that delirium improved in 29% of patients with advanced 
cancer prior to death or discharge from a palliative care unit. Gagnon et al. (2000) noted that 
delirium improved in 50% of cases. However, reversibility of repeated episodes was 
significantly less than reversibility of first episodes. Additionally, patients with delirium on 
admission were less likely to have symptom improvement. Lawlor, Gagnon et al. (2000) 
found that delirium reversal occurred in 49% of episodes in 71 patients. Treatment of 
delirium was based on clinical evaluation. Patients with signs of opioid toxcitiy had opioid 
reduction. Hypodermoclysis was used for dehydration. Oral or intravenous antibiotics were 
given for infection. Hypercalcemia was treated with bisphosphonates. The criteria used to 
determine delirium reversal or improvement are not always defined.  
Lawlor, Gagnon et al. (2000) used univariate and multivariate Cox proportional 
hazards models to examine the association between etiologic factors and delirium 
reversibility. Opioids and other psychoactive medications were independently associated 
with delirium reversal. Dehydration was also significantly associated with delirium 
reversibility at the univariate level, but its association was not independent in the multivariate 
analysis. Hypoxic encephalopathy resulting from pulmonary cancer or respiratory infection 
and metabolic factors were associated with non-reversibility of delirium in the univariate 
analysis. In the multivariate analysis, only hypoxic ecephalopathy was retained as a factor. 
Non-respiratory infection emerged as a significant independent factor associated with non-
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reversibility of delirium in the multivariate analysis. Similarly, Morita, Tei et al. (2001) 
found that recovery often occurred in delirium associated with medications and 
hypercalcemia and that recovery was unlikely in delirium caused by hepatic failure, 
dehydration, hypoxia, and disseminated intravascular coagulation. 
The identification of persons at risk for delirium will promote enhanced surveillance 
and monitoring of these persons and earlier implementation of prevention and intervention 
strategies. The prevention and management of delirium in older persons with advanced 
cancer will not only improve the quality of life for patients but may also extend their lives 
and improve the quality of dying.  
 
Conceptual Framework 
Vulnerability-challenge or stress models have been used to understand and study the 
development of delirium in hospitalized older patients. Neelon & Champagne (1992) used an 
information-processing framework, a vulnerability model that incorporated reserve capacity 
and the threshold nature of vulnerability, and an environmental press model to understand 
and study the development of acute confusion in hospitalized elders and to develop an 
intervention framework. More recently, Inouye and Charpentier (1996) proposed and 
validated a vulnerability-stress model of delirium development in hospitalized elderly that 
involves the interrelationships between predisposing factors, or vulnerability factors, and 
precipitating factors, or acute insults associated with hospitalization. These models also 
emphasize the cumulative effects and interactions of vulnerability and challenge.  
In the vulnerability-challenge model (Figure 2.1), delirium develops when an 
individual’s threshold of vulnerability is exceeded. The threshold of vulnerability is related to 
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reserve capacity, or an individual’s ability to respond to challenge. Johnson (1985) describes 
the decline in functional capacity or reserve capacity associated with aging. This decline in 
reserve capacity may occur over a number of years without lowering functional capacity 
below threshold. However, when reserve capacity is depleted or so diminished that 
homeostasis cannot be maintained, system failure occurs.   
 
 
Figure 2.1. Vulnerability-challenge model of delirium development 
 
From: “Vulnerability—a new view of schizophrenia” by J. Zubin and B. Spring, (1977), 
Journal of Abnormal Psychology, 86, p. 110. Copyright 1978 by the American Psychological 
Association. Adapted with permission. 
 
The onset of delirium occurs when reserve capacity is so diminished that 
neurophysiologic systems are no longer able to respond adaptively to challenge. Therefore, 
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reserve capacity influences the development of delirium at different levels or degrees of 
vulnerability and challenge and provides an explanation for why individuals under similar 
circumstances may or may not develop delirium. In the vulnerability-challenge model, the 
level of challenge needed to cause delirium depends upon the vulnerability threshold, or 
reserve capacity of the individual. For example, an older person with preexisting cognitive 
impairment has a lower threshold because of diminished cognitive reserves. Therefore, this 
individual is more likely to develop delirium than a cognitively intact elder when faced with 
environmental, physiological, or psychosocial stressors.  
Vulnerability-challenge models also emphasize that the risk for developing delirium 
is associated with interactions between and the cumulative effects of vulnerability and 
challenge. In two studies, Inouye et al. (1993) and Inouye and Charpentier (1996) proposed 
and validated a risk stratification model that supports the cumulative nature of delirium risk. 
The model predicted an increased likelihood of developing delirium as the number of 
predisposing and precipitating factors increased. Delirium risk was determined by adding one 
point for each predisposing or precipitating factor present. The risk groups were stratified 
into low-risk, intermediate-risk, and high-risk. No factors were present in the low risk group; 
one or two were present in the intermediate risk group; and more than three were present in 
the high-risk group. Development and validation cohorts in both studies showed a 
statistically significant and progressive increase in the delirium rate among each group from 
low-risk to high-risk. 
Neelon & Champagne (1992) identified patterns of confusion development that were 
associated with diminished reserve capacity in three areas: cognitive reserve, physiological 
reserve, and biochemical reserve. These three categories will be used to examine changes in 
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delirium vulnerability and the relationship between changes in delirium vulnerability and the 
development of delirium at the end of life. 
Reserve capacity also influences the outcome of delirium. Clearly, at some point in 
the dying trajectory, reserve capacity becomes totally depleted and challenges to 
neurophysiologic and other functional systems result in irreversible damage and complete 
system failure. At this point, treatment strategies should focus on managing the symptoms of 
delirium and comfort rather than on delirium reversal. On the other hand, if reserve capacity 
is sufficient enough, treatment strategies aimed at correcting the underlying mechanisms of 
delirium may result in delirium resolution. 
Several authors (IOM, 1997; Lunney, Lynn, and Hogan, 2002; Teno, Wietzen, 
Fennell, & Mor, 2001) have described the typical dying trajectory of cancer patients. These 
patients live relatively well with their illness for a long period before the illness becomes 
overwhelming. At that point, patients enter a terminal phase characterized by a rapid decline 
in function and death usually within 6 weeks. It is hypothesized that delirium vulnerability 
increases significantly as cognitive, physiological, and biochemical reserves diminish during 
this terminal phase. The individual is less able to respond to the multiple challenges 
associated with progression of their disease and its treatment and, therefore, the individual is 
more likely to develop delirium during this period.  
 
Specific Aims and Research Questions 
Phase I: Delirium in Hospitalized Older Cancer Patients 
The first phase involves extensive secondary analyses of data from the Acute 
Confusion in Hospitalized Elders Studies (NR01339-05: Neelon & Champagne) to examine 
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delirium in a sample of hospitalized older cancer patients. The specific aims of the analyses 
were: 1) to characterize the nature and course of delirium in hospitalized older cancer 
patients; 2) to determine etiologic patterns based on key clinical markers; 3) to compare 
characteristics and etiologic patterns in patients with delirium and those without delirium; 4) 
to examine trajectories of delirium resolution;  5) to compare characteristics and etiologic 
patterns in patients with delirium that resolved prior to discharge and those who had 
persistent delirium; and 6) to identify delirium trajectories and etiologic patterns in a subset 
of patients who were near the end of life. 
 
Phase II: Development and Pilot Testing of a Protocol to Study Delirium in Older Adults 
with Advanced Cancer 
 
The second phase involves a pilot study to assess the feasibility of and the burden 
associated with a protocol to study delirium and cognitive decline in older cancer patients 
receiving palliative and end of life care. The primary aims of the pilot study are: 1) to test the 
feasibility of the protocol, first, in a laboratory and, then, in the home setting; 2) to determine 
the level of patient and caregiver burden associated with the protocol; 3) to evaluate and 
refine instruments and data collection procedures; and 4) to identify and resolve 
methodological issues related to recruitment, consent, measurement and retention that may 
be encountered in studying delirium and cognitive decline in older adults with advanced 
cancer being cared for at home. More specifically the pilot study will address the following 
research questions: 
1. What minimally invasive instruments and methods can be used to measure cognitive, 
behavioral, functional, psychological, and physiological parameters associated with 
delirium in older patients with advanced cancer? 
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2. To what extent can family caregivers monitor for and identify signs of delirium in the 
home setting? 
3. What issues and concerns do participants and family caregivers have with regard to 
the research process?   
 
Phase III: Trajectories and Patterns of Delirium in Older Adults with Advanced Cancer Near 
the End of Life 
 
Findings from the first two phases of investigation—the secondary data analyses and 
pilot study—shaped the design of the final phase of this research. The purpose of the third 
phase of investigation was to develop a clearer understanding of the nature and course of 
delirium within the context of advancing illness and approaching death. A longitudinal, 
multiple case study approach, using quantitative and qualitative methods, was used to 
examine delirium in older cancer patients near the end of life, during active palliative 
treatment and in the terminal period. The primary aim of this phase is to identify and describe 
delirium and trajectories of delirium vulnerability. This aim was achieved by critically 
examining episodes of delirium when they occur and developing a comprehensive 
description of the characteristics and course of the delirium episodes. In addition, trajectories 
of delirium vulnerability and vulnerability factors (cognitive function, physical functioning, 
symptom prevalence and distress, depression, weight, etiologic pattern markers, and 
medication use and treatments) will be examined to evaluate how they change over time and 
in relationship to delirium episodes. A second aim is to examine similarities and differences 
in delirium in older cancer patients at the end of life and in hospitalized older cancer patients. 
A third aim is to identify issues associated with studying delirium in older cancer patients at 
the end of life. The following primary research questions will be addressed: 
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1. What is the nature and course of delirium in older adults with advanced cancer 
near the end of life? 
2. How does delirium vulnerability change over time and in relationship to the 
development of delirium in older cancer patients at the end of life? 
3. How is delirium in older cancer patients at the end of life similar to or different 
from delirium in hospitalized older cancer patients? 
4. What issues are associated with studying delirium in older cancer patients at the 
end of life?
  
CHAPTER THREE 
METHODS 
 
 This chapter provides an overview of the methods used in each of the three phases of 
investigation. The discussion of each phase presents a description of the design, the sample, 
the setting, the variables measured, and data analysis. The discussions of Phase II and Phase 
III also describe the recruitment and data collection procedures and protocols. The 
instruments used consistently throughout are described in the Variables and Instruments 
section in the discussion of Phase III unless otherwise noted.   
 
Phase I: Delirium in Hospitalized Older Cancer Patients 
 In the first phase of investigation, a series of secondary data analyses were conducted 
to examine delirium in a sample of hospitalized older cancer patients. The specific aims of 
the first analysis were: 1) to determine the prevalence and incidence of delirium in the 
sample, 2) to examine the course of delirium, 3) to identify etiologic patterns, and 4) to 
compare characteristics and etiologic patterns in patients with and without delirium. The 
specific aims of the second analysis were: 1) to examine trajectories of delirium resolution, 
and 2) to compare characteristics and etiologic patterns in patients with delirium that 
resolved prior to discharge and those who had persistent delirium. The specific aims of the 
third analysis were: 1) to describe delirium trajectories, and 2) to identify etiologic patterns in 
a subset of the patients who were near the end of life. 
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Design 
The first phase of investigation consisted of secondary analyses of data collected in 
three studies of acute confusion in hospitalized older adults (Neelon & Champagne: 
NR01339-05). The first of the three studies identified factors associated with delirium and 
patterns of delirium development in a sample of 158 hospitalized older medical patients. 
Written informed consent to participate in the study was obtained either from the patient or a 
family surrogate. The second study determined the incidence of delirium in a sample of 168 
hospitalized older medical patients. The third study tested pattern-specific interventions in 
301 patients admitted to an intervention unit and a control unit. The second and third studies 
were conducted in conjunction with a program to incorporate regular cognitive and 
functional assessments into usual nursing care. All studies were approved by the Institutional 
Review Board.  
 
Sample 
Analysis 1: Incidence and Prevalence. 
The sample for the first analysis consisted of 76 hospitalized older cancer patients, 
who were a subset of the total sample of 627 patients enrolled in the three parent studies. 
Patients were admitted to general medical units in a university-affiliated teaching hospital in 
the Southeastern US. Patients were 65 years of age or older, had cancer as a primary or 
secondary admitting diagnosis, and were able to speak English. Patients admitted with a 
primary psychiatric diagnosis and those admitted for terminal care were excluded in the 
parent studies. 
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Analysis 2: Delirium Resolution. 
The sample for the second analysis included the 43 hospitalized older cancer patients 
from the sample of  76 who had delirium at some point—at admission, during 
hospitalization, or at discharge.  
 
Analysis 3: Delirium Near the End of Life. 
The sample for the third analysis included 10 patients from the pattern-specific 
intervention study who, though not considered terminal at admission, died within 3 months 
of hospital discharge.  
 
Variables and Instruments 
Delirium 
Delirium was measured with the NEECHAM Confusion Scale (NEECHAM) 
(Neelon, Champagne, Carlson, & Funk, 1996) on admission, at least daily during 
hospitalization, and at discharge. A NEECHAM score < 24 on admission, during 
hospitalization, or at discharge indicated the presence of delirium.  
The NEECHAM was developed for the rapid and unobtrusive bedside assessment of 
cognitive function and behavioral performance in order to detect the presence of disturbed 
information processing and early signs of delirium (acute confusion), to rate the severity of 
delirium, and to monitor its response to treatment. The NEECHAM is a nine-item scale 
organized into three subscales: processing, behavior, and physiologic control. The processing 
subscale assesses attentiveness and alertness, ability to follow complex commands, and 
memory and orientation. The behavior subscale assesses sensory-motor function and speech 
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including appearance and posture control, motor activity, and verbal responsiveness and 
behavior. The physiologic control subscale evaluates physiological and autonomic stability 
and includes vital signs (temperature, heart rate, respiratory rate, and blood pressure), oxygen 
saturation and use of supplemental oxygen, and urinary incontinence. The items on the 
processing and behavior subscales are scored based on the patient’s response or behavior 
during the rater’s interaction. Scoring of the physiologic stability items is based on the 
presence or absence of abnormal physiologic measurements. Item specific scores are 
summed to determine a score for each of the three subscales. These scores are then summed 
to obtain a total NEECHAM score that ranges from 0-30. Higher scores indicate better 
cognitive and behavioral function.  
The NEECHAM has been used in research and in clinical practice to assess acute 
confusion in hospitalized elders and nursing home residents. In elderly hospitalized patients 
with acute illnesses, the alpha coefficient was 0.90, and inter-rater reliability was 0.91. 
Concurrent validity was established (Neelon et al., 1996) by correlating the NEECHAM to 
other measures of cognitive function and delirium including the MMSE (r = .87) and the sum 
of DSM-III-R positive items (APA, 1987) (r = -.91). The NEECHAM exhibited excellent 
sensitivity (0.95) and acceptable specificity (0.78) when compared with the DSM-III criteria 
for delirium, the MMSE, and nurses’ report of mental status problem (Neelon, Champagen, 
McConnell, Carlson, & Funk, 1992). 
NEECHAM scores distinguish four categories or levels of confusion (Neelon et al., 
1996). A score greater than 27 indicates normal function or low risk for confusion or 
delirium. A score between 25 and 26 or greater than 26 with the presence of one of the 
following clinical risk markers—respiratory rate > 23 breaths/minute, use of supplementary 
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oxygen, oxygen saturation < 91%, serum albumin < 3.0, or report of mental status change—
is indicative of risk for delirium. A score between 20 and 24 indicates mild or early delirium. 
These patients most likely exhibit preclinical or subsyndromal delirium, that is, they have 
one or more delirium symptoms but do not meet DSM diagnostic criteria. A NEECHAM 
score less than 20 is indicative of moderate to severe confusion or delirium. Patients with 
NEECHAM scores < 20 usually satisfy DSM III and DSM III-R criteria for delirium. Neelon 
et al. (1992) found that 78% of patients with NEECHAM score < 20 met at least 6 of 8 DSM 
III criteria. In another analysis (Neelon et al., 1996), 96% of patients with a NEECHAM 
score < 20 on admission had diagnosable delirium by DSM III-R criteria.   
 
Patient Characteristics 
 Patient characteristics including age, gender, ethnicity, severity of illness, and 
functional status were collected at the time of admission. Severity of illness was measured 
with the Acute Physiology and Chronic Health Evaluation (APACHE II) scale (Knaus et al, 
1985). Scores on the APACHE II range from 0-30. An increasing score is associated with 
greater severity of illness. Functional status was measured by the Instrumental Activities of 
Daily Living (IADL) subscale of the Older Americans Resources Scale (OARS) (Fillenbaum 
et al., 1988). IADL scores range from 0-14. A lower score indicates greater functional 
impairment. These items were asked so as to measure performance within the month prior to 
hospitalization to eliminate the impact of the acute episode. Length of stay was measured in 
days from admission to discharge. 
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Clinical Risk Markers and Etiologic Patterns 
 A number of clinical markers including laboratory tests were determined at admission 
in order to classify patients into etiologic patterns associated with the development of 
delirium. The five etiologic patterns were determined in prior analyses using likelihood ratios 
and cluster analysis, and include: metabolic-nutritional, hypoxic, metabolic-toxic, orthostatic-
dehydration, and chronic cognitive impairment (Belyea Champagne, Ng’andu, & Neelon, 
1992; Neelon, Champagne, Moore et al., 1992). Figure 3.1 shows the clinical risk markers 
associated with each pattern. In the present study, patients were classified as exhibiting the 
pattern if any one of the clinical risk markers was present except as noted for chronic 
cognitive impairment.  
 
Data Analysis 
Analysis 1: Incidence and Prevalence 
In the first analysis, descriptive statistics were used to examine patient characteristics, 
the prevalence and incidence of delirium, and etiologic patterns. The NEECHAM score on 
admission, the lowest NEECHAM score during hospitalization, and the NEECHAM score at 
discharge were used to examine the overall course of delirium during hospitalization. If a 
patient had a NEECHAM score less than 25 at any point during hospitalization, they were 
categorized as having delirium. Prevalent delirium was defined as the presence of delirium at 
the admission assessment, and incident delirium was defined as the development of delirium 
at any time during the entire hospital stay in patients who were free of delirium at the 
admission assessment. Chi-square and t-tests were used as appropriate to compare patient 
characteristics and etiologic patterns in patients with delirium and those without delirium. 
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Metabolic-Nutritional 
• BMI <20 
• Weight loss > 5 kg or 10% 
• Albumin < 3.5 g/dl 
• Lymphocyte count < 1000/cubic mm 
 
Hypoxic 
• On oxygen 
• O2 saturation < 91% 
• Hemoglobin < 9.0 g/dl 
 
Metabolic-Toxic 
• Albumin < 3.0 g/dl 
• Creatinine > 2.0 mg/dl 
• Diagnosis of liver or renal failure 
 
Orthostatic-Dehydration 
• Diagnosis of dehydration 
• Presence of orthostatic symptoms 
• Blood Urea Nitrogen/Creatinine ratio > 20 
 
Chronic Cognitive Impairment 
• Report of mental status problems and inability to take meds without assistance 
• Diagnosis of dementia 
 
 
Figure 3.1. Etiologic Patterns and Clinical Risk Markers 
 
 
Adapted with permission from: Neelon, V.J., & Champagne, M.T. Acute Confusion in 
Hospitalized Elders: Patterns-Interventions.  Funded by NIH, National Center for Nursing 
Research, 1988-1993. (NR01339-05). 
 
 
 
Analysis 2: Delirium Resolution 
In the second analysis, descriptive statistics were used to examine patient 
characteristics and delirium resolution. Delirium resolution was defined as a change in 
NEECHAM score < 24 either at admission or during hospitalization to a score > 25 at 
discharge. A change in NEECHAM score > to 3 points is considered clinically meaningful.  
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Chi square, Fisher’s exact, and t-tests were used to evaluate the differences in patient 
characteristics, etiologic patterns, and factors in patients with and without delirium 
resolution.  
 
Analysis 3: Delirium Near the End of Life 
In the third analysis, descriptive statistics were used to summarize patient 
characteristics and to determine etiologic patterns. Plots of daily NEECHAM scores from 
admission to discharge were visually examined to describe delirium trajectories.  
 
Phase II: Development and Pilot Testing of a Protocol to Study Delirium and 
Cognitive Decline in Older Adults with Advanced Cancer 
The second phase of investigation was a pilot study to assess the feasibility of and the 
burden associated with a protocol to study delirium and cognitive decline in older cancer 
patients receiving palliative and end of life care. The primary aims of the pilot study were: 1) 
to test the feasibility of the protocol, first, in a laboratory and, then, in the home setting; 2) to 
determine the level of patient and caregiver burden associated with the protocol; 3) to 
evaluate and refine instruments and data collection procedures; and 4) to identify and resolve 
methodological issues related to recruitment, consent, measurement and retention that may 
be encountered in studying delirium and cognitive decline in older adults with advanced 
cancer being cared for at home. 
 
Design 
An exploratory longitudinal design was used to evaluate minimally invasive 
instruments and methods to measure cognitive, behavioral, functional, psychological, and 
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physiological parameters associated with delirium and cognitive decline in older patients 
with advanced cancer. Participants, patients and their family caregivers, were recruited from 
the medical oncology clinics at the North Carolina (NC) Cancer Hospital at the University of 
North Carolina at Chapel Hill (UNC), from a community-based cancer support group, and 
from UNC Hospice. After providing informed consent, participants participated in 4 data 
collection sessions, a baseline assessment that was done in the Biobehavioral Laboratory 
(BBL) at the UNC School of Nursing and in-home assessments that were done weekly for 
three weeks. Each day during the study, family caregivers completed the Caregiver 
Confusion Checklist in the morning and evening. If symptoms of confusion, or delirium, 
were noted, caregivers were asked to notify the investigator who would perform an in-depth 
delirium assessment within 12 hours. Feedback regarding the data collection procedure and 
any other issues and concerns related to participation in the study and the research process 
were elicited from participants at each assessment. 
 
Sample 
Three older adults with advanced GI cancer who were at a stable state in their illness 
trajectory and their family caregivers were recruited from the medical oncology clinics at the 
NC Cancer Hospital at UNC Hospitals. All study participants were English speaking. 
Participants with advanced cancer were also 65 + years of age and undergoing palliative 
treatment. All patient participants possessed normal cognitive capacity at the time of 
enrollment as indicated by a Mini-Mental State Examination score of 24 points or greater. 
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Setting 
The study was conducted in the BBL at the UNC School of Nursing and in 
participants’ homes. Initial testing was conducted in the BBL. The BBL in the School of 
Nursing at UNC is located on the ground floor and has direct access to public transportation. 
Parking was provided in the Bell Tower Parking Lot within walking distance to the School of 
Nursing. The monitoring area in the BBL consists of two independent sleep rooms, which are 
sound proofed and equipped with florescent lighting, phosphorescent lighting, temperature 
controls, and video cameras. For this study, one of the sleep rooms was set up to simulate a 
bedroom in a home environment and was used for data collection. After receiving permission 
from the participants, the investigator’s mentor monitored the data collection sessions via 
video and provided feedback on the procedures.  
 
Recruitment 
Research participants were recruited from medical oncology clinics at the NC Cancer 
Hospital at UNC Hospitals, from a cancer patient support group in the community, and from 
UNC Hospice. 
 
Recruitment from medical oncology clinics 
Medical oncologists working with thoracic and GI oncology patients were given 
information about the study. At the start of each clinic day the principal investigator 
reviewed the list of patients to be seen in the clinic that day. According to the limited waiver 
of HIPAA requested for this study, the principal investigator reviewed potential subjects’ 
medical records as a screening method to determine eligibility. The information reviewed 
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included patient name, medical record number, patient’s birthdate and/or age; patient’s 
address; type of cancer; current treatment, and living situation. Information reviewed from 
the medical record will be used solely to identify potential subjects. None of the information 
reviewed by the principal investigator was documented in writing or communicated to any 
other persons; therefore there is a minimal risk to the privacy of the potential subjects and 
their rights and welfare will not be affected in any way by this review of their health 
information for eligibility screening. 
Potential subjects were approached personally by the principal investigator and 
informed of the study during their clinic appointment after they were placed in a private 
patient examination room. All patients who met eligibility criteria and who expressed an 
interest in knowing more about the study were provided with a recruitment flyer. Patients 
who indicated a desire to participate in the study during this meeting were asked to complete 
the information section of the recruitment flyer so that the principal investigator could 
contact them at a later date to schedule informed consent and the initial data collection 
session. All other patients who met eligibility criteria were provided with a recruitment flyer 
and self-addressed stamped envelope. They were instructed to contact the principal 
investigator at a future time if they would like to participate in the study. The methods for 
contacting the principal investigator were reviewed. The principal investigator had no other 
contact with potential subjects unless they contacted him. 
A limited waiver of HIPPA was requested to examine the patient list and medical 
records of patients in the UNC medical oncology clinic to prescreen for eligibility of 
potential subjects for the study. The specific protected health information that was reviewed 
included patient name, medical record number, patient birthdate and/or age; patient address; 
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type of cancer; current treatment, and psychosocial history to determine living situation. The 
information was used solely to identify potential subjects. None of the information was 
documented in writing or communicated to any other persons.  
 
Recruitment from community support groups  
The investigator talked with the leader of a community-based cancer support group 
for patients with advanced illness. Written information about the study was provided so that 
it could be distributed to support group members. In addition, the investigator was willing to 
attend a support group meeting to provide information about the study and to answer patient 
questions regarding study participation.  
 
Recruitment from UNC Hospice  
The investigator met with the staff of UNC Hospice to discuss the study. Hospice 
staff members were asked to identify potential patients who met the inclusion criteria and to 
provide these patients with a recruitment flyer. Patients interested in study participation were 
provided with five ways to contact the investigator: by calling the investigator’s cell phone 
number, by calling the investigator’s home phone number, by sending an email to the 
investigator, by completing the patient contact information on the flyer and sending it to the 
investigator in a self-addressed stamped envelope provided with the flyer, or by completing 
the patient contact information on the flyer and giving it to the hospice staff. The investigator 
planned to telephone persons who responded to the flyer to provide more detailed 
information about the study. For those interested in participating, the investigator would 
schedule a convenient time to meet with them and their family caregivers to obtain informed 
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consent. The meeting to obtain informed consent and baseline sociodemographic and 
cognitive data would take place in patients’ homes prior to initiating data collection. 
 
Human Subjects Considerations 
This study was approved by the Lineberger Comprehensive Cancer Center Oncology 
Protocol Review Committee and the Nursing Institutional Review Board at the University of 
North Carolina at Chapel Hill.  
 Minimally invasive instrumentation and observational techniques were used to 
decrease intrusiveness and discomfort. The investigator, a registered nurse with experience in 
cancer and palliative care nursing, performed all data collection. Participants were observed 
for signs and reports of fatigue. Participants were allowed to rest if needed during the data 
collection process. Data collection could be divided into several sessions if necessary. 
Participants and their family caregivers were allowed to refuse or to discontinue observations 
and measurements at any time if they became too burdensome.  
 The study and participation in the study were discussed in detail with prospective 
participants. Participants provided written consent to participate in the study. Confidentiality 
was maintained by assigning an identification number to each participant. All data 
instruments were coded with the participant ID number. No names appeared on data 
collection forms. The list of participants with matching identification numbers was kept in a 
locked drawer in the BBL in the School of Nursing. Additionally, all data collection forms 
were kept in a separate locked drawer in the BBL. In general, findings from this study will be 
presented in aggregate forms. Any report of finding using participant data as case exemplars 
will only use ID numbers or fictitious initials. 
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 Participants received monetary compensation for their participation in this study. 
Patients and their family caregivers were given $25 each at the completion of each data 
collection session. They each were paid a total of $100.00 if they participated in the entire 
study. 
 
Variables and Instruments 
Self-report and clinician-rated instruments were used to measure cognitive, 
behavioral, functional, psychological, and physiological parameters associated with delirium 
and cognitive decline.  
 
Cognitive Function 
Cognitive function was assessed using the Mini-Mental Status Examination (MMSE) 
(Folstein, Folstein, & McHugh, 1975) and three cognitive items on the Symptom Scale. The 
MMSE, the most widely used measure of global cognitive function, was used to screen 
participants for pre-existing cognitive impairment at baseline and as a measure of cognitive 
function at subsequent evaluations. The MMSE will be described in more detail in the 
section on Phase III. The Symptom Scale developed by the investigator is described below. 
Three items on the Symptom Scale were used to measure subject self-report of 
confusion and altered cognitive function. The Symptom Scale was developed by the 
investigator and is derived from the Memorial Symptom Assessment Scale (MSAS) 
(Portenoy et al., 1994) and the M.D. Anderson Symptom Inventory (MDASI) (Cleeland et 
al., 2000). The cognitive symptoms included on this scale are difficulty in concentrating, 
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feeling confused or mixed up, and difficulty remembering things. Responses range from 1 = 
not at all to 3 = some to 5 = very much. 
 
Level of Consciousness 
Level of consciousness was measured using the Richmond Agitation-Sedation Scale 
(RASS) (Sessler et al., 2002). The RASS will be described in detail in the section on Phase 
III.  
 
Delirium 
Delirium was assessed using the NEECHAM Confusion Scale (NEECHAM) (Neelon 
et al., 1996), the Confusion Assessment Method (CAM) (Inouye et al., 1990), and the DSM 
IV criteria for delirium (American Psychiatric Association, 1994). Additionally, the 
Caregiver Confusion Checklist (CCC) was used by caregivers to identify early signs of 
confusion and delirium and to monitor delirium symptoms over time. The DSM IV criteria 
for delirium are considered the clinical standard for the diagnosis of delirium. The presence 
or absence of DSM IV criteria was documented. The NEECHAM was described in the 
section on Phase I. The other instruments (CAM and CCC) will be described in detail in the 
variables and measurement section on Phase III. 
 
Clinical Markers and Etiologic Patterns  
Etiologic patterns and associated clinical risk markers were described in the variables 
and measurement section on Phase I.  
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Symptom Prevalence and Distress 
Symptom prevalence and distress was determined in the pilot study using a Symptom 
Scale adapted by the investigator from the Memorial Symptom Assessment Scale (MSAS) 
(Portenoy et al., 1994) and the M.D. Anderson Symptom Inventory (MDASI) (Cleeland et 
al., 2000). The Symptom Scale includes 20 physical and psychological symptoms that are 
common in patients with advanced cancer.  Examples of the items on the scale are pain, lack 
of energy, nausea, shortness of breath, constipation, lack of appetite, feeling sad, felling 
worried, and feeling upset or distressed. Using a five-point scale with numerical and verbal 
descriptors ranging from 1 (not at all) to 5 (very much), participants will rate the degree of 
bother associated with each symptom in the previous 24 hours. Total scale scores range from 
20-100. A high score indicates a high degree of symptom distress. 
 
Physical Functioning   
Physical functioning was assessed using the Older American Resources and Services 
(OARS) Activities of Daily Living Scale (Fillenbaum, 1978) and the Palliative Performance 
Scale (PPS) (Anderson, Downing, Hill, Casoroso, & Lynch, 1996). These instruments are 
described in detail in the section on Phase III.  
 
Depression 
Depression was measured using the short form of the Geriatric Depression Scale 
(GDS-15) (Sheikh & Yesavage, 1986). The GDS-15 is described more fully in the section on 
Phase III.  
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Comorbidity 
Comorbidity was measured using the Charlson Comorbidity Index (Charlson, 
Pompei, Ales, & MacKenzie, 1987). The Charlson Comorbidity Index is described in the 
section on Phase III. 
 
Sleep Quality and Quantity 
Sleep quality and quantity were measured using the Stanford Sleepiness Scale 
(Hoddes et al., 1973) and the Sleep and Rest subscale from the Sickness Impact Profile (John 
Hopkins University, 1977). These instruments are discussed in the section on Phase III. 
 
Physiological Variables 
Vital signs including heart rate, respiratory rate, temperature, blood pressure, and 
arterial oxyhemoglobin saturation were obtained by the investigator each time the 
NEECHAM was administered. Nutritional status was assessed by measuring height and 
weight and calculating body mass index. Phase angle was measured by bioelectrical 
impedance analysis.  
 
Sociodemographic Data 
Sociodemographic data were collected using a questionnaire developed by the 
investigator. Participants were asked to report their gender, age, ethnicity, years of formal 
education, employment status, treatment history (current and prior chemotherapy, radiation, 
and/or hormonal therapy), smoking and alcohol history, prior history of confusion, self-
reported health rating, and use of sensory aids (eyeglasses and hearing aids). 
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Caregiver Sociodemographic Data 
Caregivers completed a sociodemographic questionnaire developed by the 
investigator at the baseline assessment. Caregivers were asked to report their gender, age, 
ethnicity, years of formal education, marital status, employment status, relationship to the 
patient, and types of assistance provided to the patient.  
 
Medication Profile 
A medication profile developed by the investigator and include all routine and pro re 
nata (PRN) medications (prescribed and over-the-counter) being taken by the participant. 
Participants were asked to show the investigator all current medications. Medication changes 
were assessed and documented at each weekly assessment. 
 
Research Burden Assessment 
 At the conclusion of each assessment, participants, patients and family caregivers, 
were asked to provide information about the level of burden associated with research 
participation and the data collection procedures. The semi-structured interview was 
audiotaped.  
 
Data Collection Procedures 
The pilot study involved 4 data collection sessions, a baseline assessment that was 
done in the Biobehavioral Laboratory (BBL) at the UNC School of Nursing and in-home 
assessments that were done weekly for three weeks. Table 3.1 shows the data collection 
timeline for the study. 
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Family caregivers accompanied patient participants to the BBL. The investigator 
greeted participants in the parking lot and escorted them from the parking lot to the BBL. 
Written informed consent to participate in the study was completed before any measurements 
were made.  
 
Baseline Assessment 
After providing informed consent, participants underwent a baseline assessment and 
interview in the BBL. The baseline assessment included measures of cognitive function and 
delirium; determination of functional status, comorbidity, symptom prevalence and distress, 
depression, sleep quality, and medication history; collection of demographic data; and 
measurement of physiological variables using minimally-invasive instrumentation and 
procedures. The time required for data collection and any problems associated with the data 
collection protocol were documented. After the data collection was completed, an audiotaped 
interview was conducted to evaluate the level of participant burden associated with the data 
collection protocol. The caregivers provided demographic information and were trained by 
the investigator to complete the Caregiver Confusion Checklist (CCC). 
 
Weekly Assessments 
After baseline testing, participants participated in three weekly assessments and 
interviews in their homes. The weekly assessments included measures of cognitive function 
and delirium, functional status, symptom prevalence and distress, sleep quality, medication 
changes, and measurement of physiological variables. Additionally, during the three-week 
field-testing period, family caregivers completed the CCC, twice daily, in the morning and 
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evening. Caregivers were instructed to notify the investigator of a CCC score > 2, which 
indicated a probable episode of delirium. After being notified, the investigator would 
complete an in-depth delirium assessment within 12 hours. If delirium was verified, the 
caregiver would be asked about changes in medications, health status, sleep patterns, and 
symptoms or behavior or events that preceded the delirium. Feedback regarding the data 
collection procedure and any other issues and concerns related to participation in the study 
and the research process were elicited from participants and their family caregivers at each 
weekly assessment.  
 
Delirium Episode Assessment 
A delirium episode assessment was conducted by the investigator when the caregiver notified 
the investigator that the patient was exhibiting signs of delirium as evidenced by a score of 2 
or more on the Caregiver Confusion Checklist or by a NEECHAM score < 24 at the time of a 
scheduled assessment by the investigator. The delirium episode assessments included the 
completion of the MMSE and an unstructured interview with the patient for the completion 
of observational measures including the NEECHAM, CAM, DSM-IV criteria checklist, 
delirium motor patterns, the Richmond Agitation-Sedation Scale, and the Palliative 
Performance Scale. Physiologic data including vital signs, arterial oxyhemoglobin saturation, 
weight (if patient able to stand), and phase angle also were collected. In addition, the 
investigator conducted a semi-structured open-ended interview with caregivers to learn more 
about the symptoms or behaviors or events that preceded the delirium and to inquire about 
any changes in medications, patients’ health status or overall condition, physical symptoms, 
and sleep patterns.  
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Data Analysis 
 Quantitative data were analyzed using standard descriptive statistics and techniques 
for evaluating patterns, change and variability, and sequencing of events. Plots were used to 
characterize patterns and trends in the data. The feasibility and burden of the protocol was 
assessed quantitatively and qualitatively. Measures such as the length of time required to 
complete instrument, the number of rest periods needed, the number of questions about the 
instruments or the need for clarification, as well as the length of the complete evaluation 
were documented. Additionally, patient comments and feedback during the evaluation were 
documented. Patients and caregivers were interviewed at the end of each weekly assessment 
to identify components of the study that were difficult or uncomfortable. The interviews were 
audiotaped and the content of the interviews was examined to determine the level of burden 
associated with research participation and the data collection procedures.  
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Phase III: Trajectories and Patterns of Delirium and Delirium Vulnerability in Older 
Adults with Advanced Cancer  
 
Design 
A longitudinal, multiple case-study descriptive design using event analysis was used to 
examine key aspects of delirium in a small number of older cancer patients receiving 
palliative and end of life care. The longitudinal case-study design with repeated measures is 
appropriate for examining the dynamic nature of delirium at the end of life because it 
facilitates the intense study of phenomena and is particularly well-suited for studying the 
complexity and contextual nature of phenomena (Scholz & Tietje, 2002; Yin, 2003). The 
design also allowes for the evaluation of change over time and the identification of patterns 
and trends within cases and between cases. Participants were followed from enrollment into 
the study for up to six months or until the patient’s death or withdrawal from the study. At 
the end of six months, participants were given an option to end the study or continue for up 
to an additional six months. 
Event analysis involves the development of a detailed description and analysis of a 
specific event that is important to an investigation (Kayser-Jones, 2002). It is useful when the 
aim is to achieve a comprehensive description and explanation of a phenomenon in a 
complex clinical situation or setting (Happ, Swigart, Tate, & Crighton, 2004). Event analysis 
results in more than a description and explanation of the event itself but rather integrates 
multiple aspects of the event including its precursors, its consequences, relationships between 
and among key variables, and how they are related to or influence the event (Happ et al.). In 
this study, the development of delirium at the end of life was the event examined. 
Quantitative and qualitative data from a variety of sources were used to develop a 
comprehensive description of the presentation, course, characteristics, and outcomes of 
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delirium episodes in older cancer patients receiving palliative and end of life care. 
 
Sample 
A sample of 7 older adults with advanced cancer and their family caregivers were 
recruited from the medical oncology clinics at the NC Cancer Hospital at UNC Hospitals, a 
university-affiliated medical center. All study participants, cancer patients and caregivers, 
could speak, understand, and read English, and they lived within 50 miles of the university 
medical center. Participants with advanced cancer were also 65+ years of age; diagnosed 
with an advanced or recurrent non-hematologic malignancy (including but not limited to 
lung, GI tract, breast, genitourinary, head and neck, reproductive, or tumors of unknown 
primary); and undergoing palliative treatment (non-curative but may be life-prolonging) for 
either disease modification or symptom management. Caregiver participants were over 18 
years of age, lived either with the patient or nearby, had at least daily contact with the patient, 
and assisted the patient with care as needed.  
 
Setting 
 The study was conducted across care settings. Data collection took place primarily in 
the participants’ homes, but also in the hospital if participants were admitted during the 
study. The family caregiver was asked to notify the investigator if the patient was admitted to 
the hospital or to any other inpatient or institutional setting.  
 
 Recruitment 
 Participants were recruited from medical oncology clinics at the NC Cancer Hospital 
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at UNC Hospitals and UNC Hospice. Medical oncologists working with solid tumor patients 
were provided with information about the study. The list of eligibility criteria and an abstract 
of the study protocol was given to each physician. Permission to approach their patients 
regarding participation in the study was elicited (Appendix A). 
 
Recruitment from medical oncology clinics 
The following method was used to recruit study participants from the medical 
oncology clinics. At the start of each clinic day the investigator reviewed the list of patients 
to be seen in the clinic that day. According to the limited waiver of HIPAA requested for this 
study, the investigator reviewed potential subjects’ medical records as a screening method to 
determine eligibility. The information that was reviewed included the patient’s name, 
medical record number, birthdate and/or age, address, type of cancer, current treatment, and 
living situation. Information reviewed from the medical record was used solely to identify 
potential participants. The information was documented on a potential participant 
information form. The information form was kept until the investigator contacted the 
potential participant as discussed below. The information form was discarded in a shredding 
bin after the investigator contacted the potential participant. There was a minimal risk to the 
privacy of the potential participants and their rights and welfare were not affected in any way 
by the review and documentation of their health information for eligibility screening. 
Potential participants were approached personally by the investigator and informed of 
the study during their clinic appointment after they have been placed in a private patient 
examination room. All patients who met eligibility criteria and who expressed an interest in 
knowing more about the study were provided with a study brochure and recruitment flyer 
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(Appendix A). Patients indicating a desire to participate in the study during this meeting were 
asked to complete the information section of the recruitment flyer so that the investigator 
could contact them at a later date to schedule informed consent and the initial data collection 
session. All other patients who met eligibility criteria were provided with the study brochure 
and a recruitment flyer and self-addressed stamped envelope. They were instructed to contact 
the investigator at a future time if they would like to participate in the study. The methods for 
contacting the investigator were reviewed. Patients were informed that their family caregiver 
must also agree to participate in the study. The investigator did not have any other contact 
with potential participants unless they contacted him. 
 
Recruitment from UNC Hospice 
 After being informed about the study, the administration and nursing staff of UNC 
Hospice agreed to assist with participant recruitment. The hospice nurses were asked to 
identify patients who met the inclusion criteria and to provide these patients and their family 
caregivers with a study brochure. The nurses, then, would determine whether the patient and 
family caregiver would like to learn more about the study from the investigator. If a patient 
and family caregiver expressed an interest in the study, the hospice nurse would obtain 
permission to provide the patient’s name and telephone contact information to the 
investigator. If so, the investigator contacted the patient and/or family caregiver by phone to 
provide more information about the study and to elicit whether the patient and family 
caregiver would like to participate. If so, the investigator would schedule a home visit to 
obtain informed consent and to initiate data collection. The home visit would be scheduled at 
a time that was convenient for the patient and family caregiver.  
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Human Subjects Considerations 
This study was approved by the Lineberger Comprehensive Cancer Center Oncology 
Protocol Review Committee and the Nursing Institutional Review Board at the University of 
North Carolina at Chapel Hill (Appendix B). 
The sample in this study, older persons with advanced cancer nearing the end of life, 
is a vulnerable population. Although there was minimal risk associated with the study, 
measures were taken to minimize any physical or psychological discomfort that participants 
may experience. Minimally-invasive instrumentation and observational techniques were used 
to decrease intrusiveness and discomfort. Still, participation in the study and frequent 
observation including audiotaping may increase feelings of vulnerability. Attachment to 
monitoring devices may restrict movement for short periods and contribute to minimal 
physical discomfort. Some participants may experience fatigue during the evaluation and 
interview process.  
The investigator, a registered nurse with clinical experience in cancer and palliative 
care settings, performed all data collection. Participants were observed for signs and reports 
of fatigue and agitation. If fatigue or agitation occurred, participants were given the option of 
taking a rest period of 30-60 minutes or rescheduling the remaining data collection for 
another time. If possible, the data collection will be completed later the same day after a rest 
period or within the next 2 days. The subsequent data collection session will be done no less 
than 5 days and no longer than 7 days from the date of the last data collection session. 
Participants were also told that data collection could be scheduled in two sessions if desired. 
Participants and their family caregivers were allowed to refuse or to discontinue observations 
and measurements at any time if they become too burdensome.  
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If new symptoms developed or if changes in a participant’s condition were noted by 
the investigator, the participant and/or family caregiver were instructed to follow-up with 
their care provider (MD, nurse practitioner, hospice nurse, etc) in the usual manner. 
Participants received compensation for participation in the study. Patients and their 
family caregivers were each given their choice of either a gift card for gas or long-distance 
telephone calls ($25 value) or $25 in cash after the baseline visit and each month while 
enrolled in the study. If patients developed persistent cognitive impairment during the study, 
their family caregivers were allowed to select for them and to use the compensation at their 
discretion. If patients died, their family caregivers received a final compensation payment of 
choice, valued at $50. 
 
Informed Consent 
The investigator obtained informed consent from participants, patients and their 
family caregivers, upon enrollment in the study prior to the initiation of any data collection. 
During the informed consent process, prospective participants received a detailed verbal and 
written explanation describing the study, data collection procedures, potential benefits, 
potential risks, and a guarantee of confidentiality and data anonymity. Prospective 
participants were informed that their participation in the study was voluntary and that they 
could withdraw from the study at any time. They also were assured that refusal to participate 
in the study or withdrawal from the study would not affect the care or services they received 
from their medical provider. Prospective participants were given an opportunity to ask 
questions about the study. If they expressed a desire to participate in the study, patients and 
their family caregivers were asked to sign respective consent forms (Appendix C), which 
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they had read or had been read to them by the investigator. In addition, patients were asked to 
sign a HIPAA Authorization for Use of Protected Health Information (PHI) (Appendix C). 
The requested PHI included the patient’s diagnosis, diagnosis date, current and previous 
treatment plan, past medical history to determine comorbid medical conditions, diagnostic 
tests to determine extent and current status of disease, progress notes to follow the progress 
of the disease and treatment, and laboratory values to monitor etiologic pattern markers for 
the delirium pattern screen. Participants were given a copy of the consent forms and the 
investigator kept the originals in a locked file drawer in the BBL in the School of Nursing. 
 
Confidentiality 
Confidentiality was maintained by assigning an identification number to each 
participant. All data collection forms were coded with the participant identification number. 
No names appeared on data collection forms. Participant information with matching 
identification numbers was kept in a separate locked file drawer in the BBL. Additionally, all 
data collection forms, including diskettes and CDs were kept in a locked file drawer in the 
BBL. All computerized data was kept in password-protected files on the UNC School of 
Nursing network. Participants were assigned a fictitious alphabetical initial for the 
presentation of case data.  
 
Variables and Instrumentation 
A variety of data collection methods and sources of evidence were used to examine 
episodes of delirium and changes in delirium vulnerability in older cancer patients during 
active palliative treatment and during the terminal period. Self-report and clinician-rated 
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instruments were used to measure cognitive, behavioral, functional, psychological, and 
physiological parameters associated with delirium. A copy of the instruments can be found in 
Appendix D. Observational methods aided the completion of clinician-rated instruments. 
Biobehavioral instrumentation was used to measure physiological variables. Open-ended 
semi-structured interviews and unstructured informal interviews with patients and family 
caregivers were conducted to better understand the development of delirium and critical 
aspects of delirium episodes. The medical record also was used to obtain information related 
to cancer diagnosis and treatment history, comorbid medical conditions, laboratory values, 
current treatment, and disease status. Detailed field notes were written following each 
encounter.  
 
Cognitive Function 
Cognitive function was assessed using the Mini-Mental Status Examination (MMSE) 
(Folstein, Folstein, & McHugh, 1975) and items from the adapted Memorial Symptom 
Assessment Scale – Short Form (MSAS-SF) (Chang, Hwang, Feuerman, Kasimis, & Thaler, 
2000) including those added by the investigator noted below.  
 
Mini-Mental State Examination 
The MMSE, the most widely used measure of global cognitive function, was used to 
screen participants for pre-existing cognitive impairment at baseline and as a measure of 
cognitive function at subsequent evaluations. The MMSE assesses several domains of 
cognitive function including: orientation, registration, attention, calculation, recall, language, 
and visual construction. Total scores range from 0-30. The recommended criterion score of 
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24 or less was used as an indicator of cognitive impairment. The MMSE has been used to 
measure cognitive function in advanced cancer patients receiving palliative and end of life 
care (Bruera et al., 1992; Pereira et al., 1997; Zhukovsky et al., 1998). Test-retest reliabilities 
for different time periods and different patient populations range from .83-.90 (Anthony, 
LeResche, Niaz, Korff, & Folstein, 1982). Concurrent validity, obtained by correlating the 
MMSE total score with the Wechsler Adult Intelligence Scale, they report an r = .78 for 
verbal IQ and an r = .66 for performance IQ (Folstein et al., 1975). 
 
Self-Report of Cognitive Symptoms 
Two symptoms on the MSAS-SF, difficulty concentrating and feeling drowsy, and 
two symptoms added by the investigator, difficulty remembering and feeling confused, were 
used to measure participant self-report of confusion and altered cognitive function. The 
participant was asked to identify whether he/she had experienced any of the symptoms 
during the past week and if so how much it bothered him/her. Responses range from 1 = not 
at all to 3 = some to 5 = very much. Self-report of confusion or altered cognitive function 
may be indicative of prodromal delirium or diminished cognitive reserve and delirium risk. 
Bosisio et al (as cited in Caraceni and Grassi, 2003) found that although a group of patients 
reported no confusion while fulfilling diagnostic criteria for delirium, self-report of confusion 
correlated with Delirium Rating Scale and Memorial Delirium Assessment scores for 
delirium. Patients with severe symptoms were not able to answer the questionnaire. 
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Level of Consciousness 
 Richmond Agitation-Sedation Scale  
 
Level of consciousness was measured using the Richmond Agitation-Sedation Scale 
(RASS) (Sessler et al., 2002). The RASS is a 10-point scale that measures four levels of 
agitation (+1 to +4), one level that denotes a calm and alert state (0), and five levels of 
sedation (-1 to –5). The RASS is an observer-rated scale that was developed to measure 
agitation and sedation in ICU patients. It uses three clearly defined steps and has discrete 
criteria for determining levels of sedation and agitation. Excellent inter-rater reliability (r = 
0.922-0.983) (κ = 0.64-0.82) was demonstrated in a variety of ICU patients (Sessler et al., 
2002). In initial validity testing, the RASS correlated highly with other agitation-sedation 
scales including a visual analogue scale anchored by “combative” and “unresponsive” (r = 
0.84-0.98), the Ramsay sedation scale (r = -0.78) and the Sedation Agitation Scale (r = 0.78) 
(Sessler et al., 2002). In further reliability and validity testing, Ely et al. (2003) demonstrated 
excellent inter-rater reliability (weighted κ = 0.91) and construct validity using several 
methods including correlation with an attention screen examination (r = 0.78), Glasgow 
Coma Scale scores (r = 0.91), and bispectral electroencephalography (r = 0.63). Furthermore 
the RASS showed significant differences between levels of consciousness (p < .001) and 
correctly identified fluctuations within patients over time (p < .001). Criterion validity of the 
RASS was evaluated by comparing the RASS to neuropsychiatric expert ratings of patients’ 
levels of consciousness as normal, delirium, stuporous, or comatose. Data demonstrated 
significant discrimination between each level of consciousness (all p < .001). The following 
scores on the RASS corresponded with the following levels of consciousness: 0 = normal, -1 
and -2 = delirium, -3 and –4 = stuporous, and –5 = comatose.  
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Delirium 
Delirium was assessed using the NEECHAM Confusion Scale (NEECHAM) (Neelon 
et al., 1996), the Confusion Assessment Method (CAM) (Inouye et al., 1990), and the DSM 
IV-TR criteria for delirium (APA, 2000). In addition, the Caregiver Confusion Checklist was 
used by family caregivers to monitor for early signs of delirium and to monitor delirium 
symptoms over time. 
 
NEECHAM Confusion Scale 
The NEECHAM was completed at each assessment. It is described in detail in the 
section on Phase I. The total NEECHAM score was used in conjunction with the CAM to 
identify the presence of delirium and to measure delirium risk and severity. A total 
NEECHAM score > 27 indicated low risk for delirium. A score between 25 and 26 or greater 
than 26 with the presence of an identified risk marker indicated risk for delirium. A score 
between 20 and 24 with a negative CAM was indicative of subsyndromal delirium. A score 
between 20 and 24 with a positive CAM indicated mild or early delirium. A total 
NEECHAM score less than 20 with a positive CAM was indicative of severe delirium.  
The processing and behavior subscales of the NEECHAM were used as measures of 
cognitive function and reserve. The physiologic control subscale was used as a measure of 
physiologic reserve. 
 
Confusion Assessment Method 
The Confusion Assessment Method (CAM) has been widely used as a diagnostic 
measure of delirium in studies involving older adults and in clinical practice. The CAM 
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consists of nine operationalized criteria from the DSM-III-R. Delirium is scored as present or 
absent using the CAM algorithm based on four criteria: acute onset and fluctuating course, 
inattention, disorganized thinking, and altered level of consciousness. Inter-rater reliability 
using 19 paired observations ranged from 84-100% (κ = 0.56-1.0). Concurrent validity was 
established by comparison with psychiatric assessments in two samples; sensitivity ranged 
from 94-100% and specificity from 90-95%. The CAM exhibited convergent agreement with 
four other mental status indexes including the MMSE (κ = .64), story recall (κ = .59), visual 
analogue scale for confusion (κ = .82), and digit span test (κ = .66). The CAM can be 
completed in 5-10 minutes.  
 
DSM IV-TR Criteria for Delirium 
The DSM IV-TR criteria developed by the American Psychiatric Association (2000) 
are considered the clinical standard for the diagnosis of delirium. The presence or absence of 
DSM IV-TR criteria was documented on a checklist developed by the investigator. 
 
Caregiver Confusion Checklist 
The Caregiver Confusion Checklist (CCC) was completed each morning and evening 
by the family caregiver. The CCC, adapted from the Confusion Rating Scale (CRS) by 
Williams (1985), asks caregivers to record the presence or absence of behaviors indicative of 
confusion (disorientation, inappropriate behavior, inappropriate communication, 
illusions/hallucinations, and altered alertness) using a two-item response scale (0 = not 
present and 1 = present). The responses are summed to obtain a total score. A CCC score of 2 
or more indicated a positive screening and triggered a more in-depth delirium assessment by 
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the investigator. This low cut-off was used to maximize the sensitivity of the CCC as a 
screening instrument and result in an early diagnostic evaluation for delirium. Following a 
diagnostic confirmation of delirium, the CCC score was used to monitor symptom fluctuation 
over time and to determine whether symptom improvement and resolution occurs. A CCC 
score of 0 for at least 24 hours following a delirium diagnosis was used as an indicator of 
clinically significant symptom improvement.  
The CRS was originally designed for use by nurses in hospitals and has not been 
previously used by family caregivers. Gagnon et al. (2000) used the CRS to screen for 
delirium in hospitalized terminally ill cancer patients. In the present study, the CCC was used 
to identify early signs of delirium and as an indicator for a more in-depth delirium 
assessment conducted by the investigator using the NEECHAM, the CAM, and DSM 
criteria. In addition the CCC was used as an ongoing monitor of delirium symptoms since the 
investigator was unable to conduct daily assessments.  
 
Delirium Risk Markers and Etiologic Patterns 
Delirium Pattern Screen 
Delirium risk markers and etiologic patterns were determined using a Delirium 
Pattern Screen developed by Neelon et al. (1992) to identify and describe patterns of delirium 
development at the time of hospital admission and to guide interventions. The etiologic 
patterns and delirium risk markers were described in the section on Phase I. 
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Symptom Prevalence and Distress 
Memorial Symptom Assessment Scale (Short Form)  
Symptom prevalence and distress was determined using an adapted version of the 
short form of the Memorial Symptom Assessment Scale (MSAS-SF) (Chang et al., 2000). 
The MSAS-SF is a patient-rated instrument that measures the distress associated with 26 
physical symptoms and the frequency of 4 psychologic symptoms during the past week. A 
physical symptom subscale (PHYS), psychologic symptom subscale (PSYCH), and global 
distress index (GDI) can be derived from the MSAS-SF. The PHYS subscale comprises 12 
prevalent symptoms including lack of energy, pain, lack of appetite, feeling drowsy, 
constipation, dry mouth, nausea, vomiting, change in taste, weight, loss, feeling bloated, and 
dizziness. The PSYCH subscale includes 6 prevalent psychologic symptoms (worrying, 
feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and difficulty 
concentrating). The GDI subscale includes four psychologic symptoms (feeling sad, 
worrying, feeling irritable, and feeling nervous) and six physical symptoms (lack of energy, 
pain, lack of appetite, feeling drowsy, constipation, and dry mouth). 
The MSAS-SF was validated in a sample of mostly elderly male cancer patients with 
advanced disease (Chang et al., 2000). The instrument was easy to administer and took less 
than 5 minutes to complete. Chronbach alpha coefficients for the MSAS-SF and its subscales 
ranged from 0.76 to 0.87. Test-retest correlation coefficients for the MSAS-SF subscales 
ranged from 0.86-0.94 at 1 day and 0.40 to 0.84 at 1 week. Criterion validity was evaluated 
by assessing the MSAS-SF subscales scores against the subscales of the FACT-G. 
Correlation coefficients were -0.74 for the PHYS and FACT-G physical well being subscale, 
-0.68 for the PSYCH and FACT-G emotional well-being subscale, and -0.70 for the GDI and 
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FACT-G summary of quality of life subscales scores. The MSAS-SF demonstrated 
convergent validity with performance status measured by the Karnofsky Performance Status, 
inpatient status, and extent of disease. 
Five symptoms with a frequency of < 25% and that may be more often associated 
with active cancer treatment (changes in skin, mouth sores, problems with sexual interest or 
activity, hair loss, and “I don’t look like myself”) were eliminated from the adapted version 
used in this study. In addition, two cognitive symptoms (difficulty remember and feeling 
confused) were added to measure patient self-report of confusion. All symptoms in the three 
MSAS-SF subscales are included. Additionally, two spaces were added for patients to 
identify any other symptoms that they may have experienced during the past week.  
 
Physical Functioning 
Physical functioning was assessed using the Older American Resources and Services 
Activities of Daily Living Scale (OARS) (Fillenbaum, 1978) and the Palliative Performance 
Scale (PPS) (Anderson, Downing, Hill, Casoroso, & Lynch, 1996).  
 
Older American Resources and Services (OARS) Activities of Daily Living Scale  
The OARS Activities of Daily Living Scale is comprised of two subscales addressing 
physical activities of daily living (PADL) and instrumental activities of daily living (IADL). 
The 7-item PADL subscale measures functional abilities with personal self-care activities 
(eating, dressing, grooming, walking, bathing, getting in and out of bed, and continence). The 
7-item IADL subscale measures functional abilities with more complex tasks (using the 
telephone, walking long distances, taking medicine, shopping, arranging, transportation, 
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preparing a meal, and handling money). Both subscales ask subjects to grade their ability to 
independently complete each task, using response items that range from 0-2 points; a score of 
0 indicates that the subject is completely unable to complete the task, a score of 1 indicates 
inability to complete a task without help by another, and a score of 2 indicates ability to 
complete the task without help. In community-dwelling older adults, studies have reported a 
Spearman rank-order correlation of .70 with the Katz and Barthel Index (Fillenbaum & 
Smyer, 1981). The IADL subscale of the OARS was used to measure functional status in a 
sample of hospitalized older cancer patients (Bond, Neelon, & Belyea, 2002). Functional 
status was more impaired in patients with delirium compared to those without delirium.  
 
Palliative Performance Scale (PPS) 
The PPS is a clinician-rated tool that was developed to measure functional 
performance and progressive functional decline in palliative care patients. Based on the 
Karnofsky Performance Scale (KPS), physical performance is divided into 11 categories, 
measured in 10% decremental levels from fully functional and healthy (100%) to dead (0%). 
Determination of the level of performance is based on five observable parameters: ability to 
ambulate, activity level and extent of disease, ability to perform self-care activities, food and 
fluid intake, and level of consciousness. The PPS correlated with length of survival in 
patients admitted to a palliative care unit (Anderson et al., 1996). Formal reliability and 
validity testing are currently being done by the scale developers. 
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Comorbidity 
Charlson Comorbidity Index 
Comorbidity was measured using the Charlson Comorbidity Index (Charlson, 
Pompei, Ales, & MacKenzie, 1987). The Charlson measures comorbidity associated with 19 
medical conditions. Each condition is weighted 1-6 based on its relative risk of death. The 
total score on the Charlson ranges from 0-30 with a higher score indicating greater 
comorbidity. The Charlson can be adjusted for age by adding a point for each decade of age 
starting at 50 years. Interrater reliability was 0.74 by interclass coefficient in older cancer 
patients (Extermann et al., 1998). Test-retest reliability was 0.86 in the same population. The 
Charlson correlated highly with illness severity (log rank test χ2 =148) in an independent 
sample (Charlson et al., 1986). 
 
Depression 
Geriatric Depression Scale (GDS-15) 
Depression was measured using the short form of the Geriatric Depression Scale 
(GDS-15) (Sheikh & Yesavage, 1986). The GDS-15 is a self-report measure of depression 
consisting of 15 yes/no questions. The total score on the GDS-15 ranges from 0 – 15; scores 
greater than 5 indicate probable depression. Chronbach’s alpha for the GDS-15 was .81 in a 
sample of older depressed patients (Almeida & Almeida, 1999). Both long and short-forms 
of the GDS-15 were successful to differentiating depressed from non-depressed subjects with 
a high correlation (r= .84, p<.001) (Sheikh & Yesavage, 1986). The use of the cutoff point 
4/5 for the GDS-15 produced sensitivity and specificity rates of 92.7% and 65.2% in 
comparison to the ICD-10 and 97.0% and 54.8%, respectively, when compared to the DSM-
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IV diagnostic criteria for depression (Almeida & Almeida, 1999). 
 
Sleep Quality and Quantity 
Sleep quality and quantity was measured using the Stanford Sleepiness Scale (Hoddes 
et al., 1973) and the Sleep and Rest subscale from the Sickness Impact Profile (John Hopkins 
University, 1977). In addition, patients were asked to provide information about the quantity 
and quality of their sleep during the previous week. Patients were asked to rate the overall 
quality of their sleep using a 4-point scale: 1=very good, 2=fairly good, 3=fairly bad, 4=very 
bad. Patients were also asked if they experienced any disturbed dreams that seemed real or 
caused awakening and if they have awakened during the night feeling confused or 
disoriented. Patients with delirium have reported unpleasant dreams and nightmares and 
waking experiences that merged with dreams (Lipowski, 1990).  
 
Stanford Sleepiness Scale 
The Stanford Sleepiness Scale (SSS) was administered by the investigator at each 
scheduled weekly assessment. The SSS offers a series of phrases describing various states of 
arousal and sleepiness. The subject responds by selecting the set of adjectives that most 
closely corresponds to their current state of sleepiness or alertness. In studies of sleep 
deprivation (Babkoff et al., 1991) the SSS has been shown to be reliable with the Epworth 
Sleepiness Scale (r = .91) and appears to track well over a course of a day in studies of sleep 
deprivation. The SSS however, has two noteworthy limitations: (1) it is not suitable for 
persons with a limited vocabulary and persons whose primary language is not English. In 
these situations, an analog scale is recommended—one end representing extreme sleepiness 
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and the other end alertness. The subject is asked to mark the scale to describe their state at 
the time of testing. 
 
Sickness Impact Profile – Sleep and Rest Subscale  
An adapted version of the Sleep and Rest subscale (SRS) from the Sickness Impact 
Profile was administered by the investigator at each scheduled weekly assessment. The SRS 
is a 7-item choice scale that asks the subject to select those responses that “describe you 
today and are related to your state of health”. The adapted version asks the subject to provide 
a yes or no response to each statement to describe his/her sleep and rest patterns over the past 
week. Each item is weighted with scores ranging from 4.9 to 10.4 points. By totaling the 
weighted item scores, the range of possible scores on the SRS is 0-49.9 points. In a sample of 
chronically ill adults (Pollard et al., 1976), the SRS has and test-retest reliability over 1 week 
(R=.69, p<.01). In a second study of hypothyroid patients (Bergener, et al., 1981), lower 
scores on the SRS correlated with lower T4 levels over repeated measures. 
 
Physiological Variables and Instruments 
Vital signs including temperature, heart rate, respiratory rate, blood pressure, and 
oxygen saturation were obtained by the investigator each time the NEECHAM is 
administered. 
 
Vital Signs 
Heart rate was measured by auscultating the apical pulse while palpating the radial 
pulse for 1 minute. Regularity of the heartbeat was documented. Respiratory rate was 
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measured by counting the number of chest movements completed in 1 minute. Temperature, 
blood pressure, and arterial oxyhemoglobin saturation were measured using the Welch Allyn 
Vital Sign Monitor 300 Series (Welch Allyn, Beaverton, OR). Temperature was measured in 
degrees Celsius. Systolic and diastolic blood pressure was measured to the nearest 1mm HG 
in either the right or left arm of the subject. Arterial oxyhemoglobin saturation was measured 
by placing the pulse oximeter probe on the index finger. 
 
Nutritional Status (Height/Weight/Body Mass Index) 
Nutritional status was assessed by measuring height and weight and calculating body 
mass index. A stadiometer (Prospective Enterprise, Kalamazoo, MI) was used to measure 
height in inches to the nearest tenth. A digital scale (Scaletronix, Great Plains, NY) was used 
to measure body weight in pounds (lbs) to the nearest tenth. Height and weight were entered 
into the following equation to estimate the person’s body mass index: [weight in lbs/height in 
inches X height in inches] X 703.   
 
Phase Angle 
 Phase angle (PA), a measure of the electrical properties of tissues, was determined by 
bioelectric impedance analysis (BIA) using the Valhalla 1990B Bioimpedance Analyzer 
(Scientific Inc, San Diego, CA). BIA measurements include resistance in Ohms, reactance, 
and impedance. The Valhalla 1990B obtains these measures by delivering a safe low-level 
electrical alternating current of 500μA at a frequency of 50 kHz.  This signal has been shown 
to be non-detectable and electrically safe (NIH, 1996).  Reported manufacturer accuracy for 
resistance is 0.25%±1 Ohms with a detecting current range of 0-1023 Ohms.  
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PA is equal to the arc tangent of the Xc to R ratio (Xc = resistance and R = 
reactance). Toso et al. (2000) compared tissue electric properties in men with advanced lung 
cancer with healthy matched controls. The mean PA was 5.9 in healthy controls compared to 
4.7 in patients with stage IIIB cancer and 4.4 in patients with stage IV lung cancer. Among 
lung cancer patients, those with a PA less than 4.5 had a significantly shorter survival. A low 
PA has also correlated with mortality in hemodialysis patients (Chertow et al, 1997; Di Iorio 
& Bellizzi, 2000; Maggiore et al, 1997). Although the biological meaning of PA is not fully 
understood, it may be a marker of physiological and cellular integrity. 
 
Sociodemographic Data 
Sociodemographic data were collected at the baseline assessment using a 
questionnaire developed by the investigator. Participants were asked to report their gender, 
age, ethnicity, years of formal education, disease status, treatment history (surgery and/or 
current and prior chemotherapy, radiation, hormonal therapy, and/or other biological 
therapies), smoking and alcohol history, and use of sensory aids (eyeglasses and hearing 
aids). The participant’s cancer diagnosis, diagnosis date, extent of disease, and treatment 
history will also be confirmed by review of the medical record. These sociodemographic data 
were used to describe the characteristics of the participants.  
 
Caregiver Sociodemographic Data 
Caregivers completed a sociodemographic questionnaire developed by the 
investigator at the baseline assessment. Caregivers were asked to report their gender, age, 
ethnicity, years of formal education, marital status, employment status, relationship to the 
 94 
patient, and types of assistance provided to the patient.  
 
Medication Profile 
During the baseline assessment, participants were asked to show the investigator all 
of their current medications including routine and pro re nata (PRN) medications (prescribed 
and over-the-counter). The names of the medications, dosages, and reasons for taking the 
medications were documented on a medication profile developed by the investigator. 
Medication changes were documented at each weekly assessment.  
 
Delirium Episode Caregiver Interview 
When delirium symptoms were identified either by the family caregiver or the 
investigator, the investigator conducted an informal interview with the family caregiver. The 
investigator attempted to determine when the patient first exhibited changes in his cognitive 
function or behavior, the temporal nature of the symptoms (whether they developed rapidly 
or gradually), the pattern of the symptoms (whether they have been fluctuating or consistent), 
the current state of symptoms (whether the patient is exhibiting the symptoms now), whether 
the patient’s condition had changed in any other way (whether the patient has been 
experiencing any new physical symptoms or whether the patient has had a change in any 
ongoing symptoms), what medications the patient had taken in the past 24 hours and whether 
any new medications had been started or whether there had been any medications changes, 
and the caregiver’s perception of what may have contributed to the change in the patient’s 
condition.  
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Data Collection Procedures and Protocols 
Because participants were enrolled in the study for different lengths of time, the data 
collection period for each participant varied. Data were collected from the time of enrollment 
in the study for up to 6 months or until the participant’s death. At the end of 6 months, 
participants were given the option to discontinue the study or to continue in the study for up 
to another 6 months. Data were collected at the baseline assessment, at scheduled weekly 
assessments, at delirium episode assessments, and at delirium episode follow-up assessments. 
Table 3.2 shows the data collection timeline for the study. 
 
Baseline Assessment 
After providing informed consent, participants underwent a baseline evaluation and 
interview. The baseline evaluation included collection of demographic data; measures of 
cognitive function and delirium; determination of functional status, comorbidity, symptom 
prevalence and distress, depression, sleep quality and quantity, and medication history; and 
measurement of physiological variables.  
 
Scheduled Weekly Assessments 
 After baseline testing, participants underwent weekly evaluations in their homes. The 
weekly evaluations include measures of cognitive function and delirium, physical 
functioning, symptom prevalence and distress, depression, sleep quality and quantity, 
medication changes, and measurement of physiological variables. 
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Daily Monitor for Delirium Symptoms 
During the baseline assessment, family caregivers were provided with information 
about delirium and were instructed on completion of the Caregiver Confusion Checklist 
(CCC). Following this instruction, family caregivers were asked to complete the CCC twice 
daily in the morning and evening. Caregivers were instructed to contact the investigator, if 
the CCC score was > 2, indicating the presence of two or more signs of delirium. When 
contacted the investigator completed an in-home delirium episode assessment at the earliest 
possible convenience—within 1 to 2 hours.   
 
Delirium Episode Assessments 
A delirium episode assessment was conducted by the investigator when the caregiver 
notified the investigator that the patient was exhibiting signs of delirium as evidenced by a 
score of 2 or more on the Caregiver Confusion Checklist or by a NEECHAM score < 24 at 
the time of a scheduled assessment by the investigator. The delirium episode assessments 
included the completion of the MMSE and an unstructured interview with the patient for the 
completion of observational measures including the NEECHAM, CAM, DSM-IV criteria 
checklist, delirium behavior checklist, delirium motor patterns, the Richmond Agitation-
Sedation Scale, and the Palliative Performance Scale. Physiologic data including vital signs, 
arterial oxyhemoglobin saturation, weight (if patient is able to stand), and phase angle also 
were collected. In addition, the investigator conducted an informal interview with caregivers 
to learn more about the symptoms or behaviors or events that preceded the delirium and to 
inquire about any changes in medications, patients’ health status or overall condition, 
physical symptoms, or sleep patterns. 
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Table 3.2. Phase III Data Collection Timeline 
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 Delirium Episode Follow-Up Assessments  
When possible, a delirium follow-up assessment was conducted on the day after a 
delirium episode assessment. The delirium episode follow-up assessment included the 
completion of the MMSE and an unstructured interview with the patient for the completion 
of observational measures including the NEECHAM, CAM, DSM-IV criteria checklist, 
delirium behavior checklist, delirium motor patterns, the Richmond Agitation-Sedation 
Scale, and the Palliative Performance Scale. Physiologic data also were collected. In 
addition, an informal interview was conducted with caregivers to determine the current status 
of delirium symptoms and the patient’s overall condition, other symptoms, medication 
changes, and whether there has been any contact with the patient’s primary provider. Family 
caregivers and patients, if able, and the investigator agreed upon the frequency and timing of 
further follow-up assessments. The following guidelines were used: 
1) If the patient did not score positive for delirium by either the NEECHAM (score < 
24), or the CAM at a delirium episode assessment or at a delirium episode follow-
up assessment, then the next assessment was done at the time of the next 
scheduled weekly assessment. 
2) If the patient remained positive for delirium (NEECHAM score < 24 and CAM +) 
at the delirium episode follow-up assessment and the scheduled weekly 
assessment was within 3 days of the follow-up assessment, then the next 
assessment was done at the time of the next scheduled weekly assessment. 
3) If the patient remained positive for delirium (NEECHAM score < 24 and CAM +) 
at the delirium episode follow-up assessment and the scheduled weekly 
assessment was more than 3 days from the follow-up assessment, then the 
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investigator made additional visits as agreed upon by the family caregiver and the 
investigator.  
 
Data Analysis 
The primary aim of this phase of investigation was to describe the nature of delirium 
and delirium vulnerability in older adults with advanced cancer near the end of life. Data 
analysis used standard descriptive statistics and graphic techniques for evaluating patterns, 
change and variability, and sequencing of events.  
Data analysis involved several different levels. First, analysis focused specifically on 
examining and describing episodes of delirium. Second, analysis focused on understanding 
delirium and delirium vulnerability factors among individuals and subgroups of individuals. 
Individual case studies were developed for each participant using the format in Figure 3.2. 
 Key variables were plotted over time for each participant to characterize individual 
patterns and trends in the data. The variable score or value was plotted on the y-axis and the 
number of days from enrollment to death or from enrollment to the end of the study in 
reverse chronological order was plotted on the x-axis. In addition, key events—treatments, 
hospitalizations, medications, falls, disease progression, and hospice referrals—occurring 
during the study were documented on the x-axis. The graphed data were visually inspected to 
examine and describe patterns of change over time and in relation to the development of 
delirium. Data also were displayed in tables and matrices for examination of individual cases 
and comparison across cases. Individual data were examined to understand and describe 
patterns and trends within subjects. Then, data were examined to identify similarities and 
differences between subjects.  
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The first research question addressed the nature and course of delirium in older 
cancer patients at the end of life. In order to answer this research question, key variables and 
data associated with delirium episodes—total NEECHAM score, NEECHAM subscale and 
item scores, cognitive functioning, level of consciousness, delirium behaviors, delirium 
motor patterns, physiological variables, and narrative data—were examined and used to 
develop a comprehensive description of delirium episodes. Delirium episodes in participants 
who died were examined for similarities and differences. Similarly, delirium episodes in 
participants who lived were examined for similarities and differences. Finally, reversible 
delirium episodes in participants who died were compared to reversible delirium episodes in 
participants who lived.  
The second research question related to changes in delirium vulnerability at the end 
of life and the development of delirium. Measured variables—cognitive functioning, physical 
functioning, depression, symptom prevalence and distress, physiological functioning, 
etiologic pattern markers, and medication use and other treatment-related factors—were 
examined as unique markers of diminished reserves and increased vulnerability to the 
development of delirium. These variables were examined at baseline to classify participant’s 
risk at entry into the study. Plots of the variables, as well as narrative data, were examined to 
evaluate how these markers and factors changed over time and in relation to the development 
of delirium.   
The third research question asked, “How is delirium in older cancer patients at the 
end of life similar to or different from delirium in hospitalized older cancer patients?” In 
order to answer the third research question, findings related to delirium and etiologic pattern 
markers in the older cancer patients at the end of life in Phase III will be compared to 
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findings related to delirium and etiologic pattern markers in the hospitalized older cancer 
patients in Phase I. 
The fourth research question addressed issues associated with conducting this 
research in older cancer patients near the end of life. The discussion is based primarily on the 
investigator’s observations and reflections, and focuses on three areas in particular: 1) the 
changing nature of palliative treatment for older cancer patients, 2) methodological issues 
related to recruitment and measurement, and 3) the role of family caregivers in monitoring 
for delirium. 
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Figure 3.2. Case study format
  
CHAPTER FOUR 
RESULTS 
This chapter presents findings from the three phases of this research. The first phase 
consisted of secondary analyses of data from the Acute Confusion in Hospitalized Elders 
Studies to examine delirium in a sample of hospitalized older cancer patients and a subset of 
the patients who were near the end of life. The second phase was a pilot study investigating 
the feasibility and burden associated with a protocol for studying delirium in older adults 
with advanced cancer cared for at home. The findings from the third phase provide an in-
depth examination of delirium and delirium vulnerability in a sample of older adults with 
advanced cancer receiving palliative and end-of-life care primarily at home, as well as a 
comparison of delirium and delirium vulnerability in this sample and the sample of 
hospitalized older cancer patients and a discussion of key issues encountered in conducting 
this research.    
  
Phase I: Delirium in a Sample of Hospitalized Older Cancer Patients 
Analysis 1: The Nature and Course of Delirium 
 The first analysis examined the nature and course of delirium in a sample of 76 
hospitalized older cancer patients. The goals of this analysis were to: 1) determine the 
prevalence and incidence of delirium in the sample; 2) examine the course of delirium from 
admission to discharge; 3) identify etiologic patterns; and 4) compare characteristics and 
etiologic patterns in the patients with delirium and in those without delirium. 
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Table 4.1. Characteristics of Hospitalized Older Cancer Patients (N=76) 
 
Variable 
  
n 
 
% 
 
 
Gender 
    
  
Male 
 41 53.9  
  
Female 
 35 46.1  
 
Ethnicity 
    
  
Caucasian 
 41 53.9  
  
African-American 
 32 42.1  
  
Other 
    3    4.0  
 
Cancer Diagnosis 
    
  
Multiple Myeloma 
 13 17.1  
  
Lung 
 11 14.5  
  
Prostate 
 11 14.5  
  
Breast 
    8 10.5  
  
Lymphoma 
    6   7.9  
  
Other (12) 
 27 35.5  
 
Variable 
  
Mean 
 
SD 
 
Range 
 
Age (years) 
  
74.4 
 
7.29 
 
65-96 
 
Education (years) 
  
  9.9 
 
4.69 
 
  0-20 
 
APACHE II 
  
14.9 
 
4.88 
 
  6-30 
 
IADLs 
  
  8.5 
 
4.65 
 
  0-14 
 
Length of Stay (days) 
  
  9.8 
 
8.67 
 
  2-43 
 
From: “Delirium in Hospitalized Older Patients with Cancer,” by S.M. Bond, V.J. Neelon, and M.J. 
Belyea, (2006), Oncology Nursing Forum, p 1078. . Copyright 2006 by the Oncology Nursing 
Society. Adapted with Permission.  
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Patient Characteristics 
 Table 4.1 summarizes the characteristics of the sample of hospitalized older cancer 
patients. The mean age was 74.4 years. Patients were evenly divided by gender and ethnicity; 
53.9% were men and 46.1% were non-white. The majority of non-white patients were 
African-American (91.4%). A total of 17 cancer diagnoses were represented in the sample 
with the top five being: multiple myeloma (17.1%), lung cancer (14.5%), prostate cancer 
(14.5%), breast cancer (10.5%), and lymphoma (7.9%). The mean educational level was 9.9 
years (SD 4.69; range 0-20). The mean APACHE II score (14.9) indicated moderate illness 
severity. Similarly, the patients had a moderate level of functional impairment as indicated 
by a mean IADL score of 8.5. The average length of hospital stay was 9.8 days.  
 
Aim 1: Prevalence and Incidence of Delirium in the Hospitalized Older Cancer Patients 
Delirium was present at the time of admission in 29 patients, for a prevalence rate of 
38.1%. Fourteen of the 47 patients with no delirium at the time of admission developed 
delirium at some point during hospitalization, for an incidence rate of 29.8%. The cumulative 
rate of delirium during the entire hospitalization period was 56.6%, which is defined as the 
sum of the prevalent and incident cases. 
 
Aim 2: Course of Delirium in the Hospitalized Older Cancer Patients 
 Table 4.2 shows delirium at admission by NEECHAM category. Of the 29 patients 
with delirium on admission, 21 (72.4%) had mild delirium (NEECHAM score 20-24) and 8 
(27.6%) had severe delirium (NEECHAM score < 20). Twenty-nine patients (38.2%) were at 
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risk for delirium (NEECHAM score 25-26 or > 26 with risk marker) on admission and 18 
(23.7%) exhibited no delirium or minimal risk with a NEECHAM Score > 27. 
 
Table 4.2. Frequency of delirium at admission by NEECHAM category (N=76) 
 
  
Number and percentage of patients in 
each category at admission 
 
NEECHAM Category  
 
n 
 
% 
 
Severe Delirium 
 
8 
 
10.5 
 
Mild Delirium 
 
21 
 
27.6 
 
At Risk 
 
29 
 
38.2 
 
Low Risk 
 
 
18 
 
23.7 
 
From: “Delirium in Hospitalized Older Patients with Cancer,” by S.M. Bond, V.J. Neelon, 
and M.J. Belyea, (2006), Oncology Nursing Forum, p. 1078. Copyright 2006 by the 
Oncology Nursing Society. Adapted with Permission. 
 
Figure 4.1 depicts the course of delirium during hospitalization as represented by 
changes in mean NEECHAM scores for patients in each NEECHAM category on admission. 
The mean NEECHAM scores for each category worsened during hospitalization but 
improved at discharge. In other words, in patients with delirium, delirium worsened during 
hospitalization but improved prior to discharge. Even in patients with no delirium at 
admission, mean NEECHAM scores dropped during hospitalization.  
NEECHAM scores were relatively unstable in patients admitted with mild delirium 
and in those at risk for delirium. During hospitalization, 15 of the 21 patients admitted with 
mild delirium exhibited a clinically significant change of > 3 points in their NEECHAM 
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scores that resulted in a change in delirium category (worsened in 8 and improved in 7). Two 
additional patients had a 1-or 2-point change in NEECHAM score that resulted in a change in 
delirium category (worsened in one and improved in one). Eleven of the 29 at-risk patients 
(38%) developed delirium during hospitalization; 5 developed mild delirium and 6 severe. 
Three patients who were at risk based on NEECHAM score improved moving into the low-
risk category. 
 
 
Figure 4.1. Mean NEECHAM scores across hospitalization by NEECHAM category (SD) 
 
 
From: “Delirium in Hospitalized Older Patients with Cancer,” by S.M. Bond, V.J. Neelon, 
and M.J. Belyea, (2006), Oncology Nursing Forum, p. 1079. Copyright 2006 by the 
Oncology Nursing Society. Adapted with Permission. 
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Table 4.3 shows the frequency of delirium at discharge. Delirium was present in 30 
(39.5%) patients; 18 (60%) had mild and 12 (40%) had severe delirium. Twenty-one of 29 
patients (72.4%) who had delirium on admission had delirium at discharge. Delirium 
resolved prior to discharge in 13 of 43 patients (30.2%). 
 
Table 4.3. Frequency of delirium at discharge by NEECHAM category 
  
Number and percentage of patients in 
each category at discharge 
 
NEECHAM Category  
 
n 
 
% 
 
Severe Delirium 
 
12 
 
15.8 
 
Mild Delirium 
 
18 
 
23.7 
 
No Delirium* 
 
46 
 
60.5 
* Includes At Risk and Low Risk Categories 
 
Aim 3: Etiologic Patterns in the Hospitalized Older Cancer Patients 
Patients were classified into the five etiologic patterns based on the presence of 
clinical risk markers at admission. Most patients exhibited multiple etiologic patterns (M 2.3; 
SD 1.07; range 0-5). The most common pattern in hospitalized older cancer patients was 
metabolic-nutritional (90.8%) followed by hypoxic (61.8%), metabolic-toxic (39.5%), 
orthostatic-dehydration (35.5%), and chronic cognitive impairment (6.6%).  
Five of the hospitalized older cancer patients (6.6%) exhibited markers of chronic 
cognitive impairment. At admission among these patients, one was at risk for delirium, one 
had mild delirium, and three had severe delirium. At some point during hospitalization, all of 
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the patients with chronic cognitive impairment had severe delirium. In addition, at discharge, 
they all had persistent delirium. Importantly, however, in 3 of the 5 patients, delirium had 
improved from severe to mild.    
 
Aim 4: Characteristics and Etiologic Patterns in Patients With and Without Delirium 
 Patient characteristics and etiologic patterns in patients who had no delirium were 
compared with the patient characteristics and etiologic patterns in those who had at least one 
episode of delirium either on admission, during hospitalization, or at discharge. Table 4.4 
presents the characteristics of patients with and without delirium. Patients with delirium were 
more severely ill (mean APACHE II score 15.9 vs 13.5; p = 0.032) and had a greater level of 
functional impairment (mean IADL score 6.8 vs 10.7; p < 0.001). Patients with delirium also 
exhibited risk markers in more etiologic patterns (mean 2.6 vs 2.1; p = 0.045). Although not 
statistically significant, patients with delirium tended to have a longer length of 
hospitalization (mean 11.5 vs 7.7 days; p = 0.056).  
 
Table 4.4. Characteristics of Patients With and Without Delirium 
 
  
Patients with Delirium  
(n = 43) 
 
Patients without Delirium  
(n = 33) 
 
Significance 
Level† 
 
Variable 
 
n 
  
 % 
 
n 
  
 % 
 
Gender 
 
     
 Male 23 53.5 18 54.6 0.927 
 Female 20 46.5 15 45.4  
Ethnicity      
 White 20 46.5 21 63.6 0.138 
 Non-White 23 53.5 12 36.4  
† Chi square 
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Table 4.4. Characteristics of Patients With and Without Delirium (continued) 
 
 
 
Variable 
 
 
Mean 
 
 
SD 
 
 
Mean 
 
 
SD 
 
Significance 
Level†† 
 
Age 
 
74.6 
 
7.71 
 
74.1 
 
6.82 
 
0.790 
 
Education 
 
9.9 
 
5.02 
 
10.1 
 
4.35 
 
0.864 
 
APACHE 
 
16.0 
 
5.25 
 
13.5 
 
4.02 
 
0.032 
 
IADLs 
 
6.8 
 
4.75 
 
10.7 
 
3.47 
 
0.000 
 
Length of Stay 
 
11.5 
 
9.66 
 
7.7 
 
6.70 
 
0.056 
 
Etiologic 
Patterns 
 
 
2.6 
 
1.05 
 
2.1 
 
1.06 
 
0.045 
 
†† T-test 
 
 
 
From: “Delirium in Hospitalized Older Patients with Cancer,” by S.M. Bond, V.J. Neelon, 
and M.J. Belyea, (2006), Oncology Nursing Forum, p. 1080. Copyright 2006 by the 
Oncology Nursing Society. Adapted with Permission. 
 
 
 
 
Table 4.5 compares the etiologic patterns in patients with and without delirium. 
Patients with hypoxic pattern markers were more likely to have delirium (χ2 = 4.410; p = 
0.036). As previously noted, all of the patients with chronic cognitive impairment (n = 5) had 
delirium at some point during hospitalization.  
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Table 4.5 Etiologic Patterns in Patients With and Without Delirium 
 
  
Patients with Delirium  
(n = 43) 
 
Patients without Delirium 
(n=33) 
 
Significance 
Level† 
 
Etiologic Pattern 
 
n 
 
  % 
 
n 
 
  % 
 
 
Metabolic-Nutritional 
 
 
41 
 
95.3 
 
28 
 
84.8 
 
0.117 
Hypoxic 
 
31 72.1 16 48.5 0.036 
Metabolic-Toxic 
 
18 41.9 12 36.4 0.627 
Orthostatic-Dehydration 
 
15 34.9 12 36.4 0.894 
Chronic Cognitive 
Impairment 
 
5 11.6   0   0.0  
 
†Chi-square 
From: “Delirium in Hospitalized Older Patients with Cancer,” by S.M. Bond, V.J. Neelon, 
and M.J. Belyea, (2006), Oncology Nursing Forum, p. 1079. Copyright 2006 by the 
Oncology Nursing Society. Adapted with Permission. 
 
 
Analysis 2: Delirium Resolution 
 The purpose of the second analysis was to examine delirium resolution in the 43 
hospitalized older cancer patients who had delirium at some point during hospitalization. The 
specific aims were: 1) to identify trajectories of change in delirium between hospitalization 
and discharge, and 2) to compare characteristics and etiologic patterns in patients with 
delirium that resolved by discharge and those with delirium at discharge. 
 
Patient Characteristics 
The characteristics of the 43 hospitalized older cancer patients with delirium are 
presented in Table 4.6. The patients were relatively young with a mean age of 74.6 years. 
Patients were almost evenly divided by gender and ethnicity. Multiple hematologic and solid 
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organ malignancies were represented in the sample including multiple myeloma (n=8), 
leukemia (n=3), lymphoma (n=1), lung (n=9), breast (n=8), prostate (n=4), colon (n=2), liver 
(n=2), and other (n=6). The mean APACHE II score (16.0) indicated moderate to high illness 
severity. The patients had a moderate level of functional impairment as indicated by mean 
IADL score of 6.8. Patients exhibited multiple etiologic patterns with a mean of 2.6. The 
average length of hospital stay was 11.5 days. 
 
Aim 1: Trajectories of Change in Delirium  
Forty-one patients (95%) had delirium at some point during hospitalization prior to 
discharge; 18 (44%) had mild delirium and 23 (56%) had severe delirium. Thirteen patients 
(30%) had no delirium at discharge. Delirium was present in 30 patients (70%); 18 had mild 
delirium and 12 had severe delirium. 
 
Table 4.6. Characteristics of hospitalized older cancer patients with delirium (N = 43) 
     
Variable  n %  
 
Gender 
 
    
 Male  23 53.5  
 Female  20 46.5  
Ethnicity     
 Caucasian  20 46.5  
 Non-Caucasian  23 53.5  
Cancer Type     
 Hematologic  12 27.9  
 Solid Tumor  31 72.1 
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Table 4.6. Characteristics of hospitalized older cancer patients with delirium (continued) 
      
Variable  Mean SD Range 
     
Age (years)  74.6 7.71 65-96 
Education (years)  9.9 5.02 0-20 
APACHE II  16.0 5.25 9-30 
IADLs  6.8 4.75 0-14 
Length of Stay (days)  11.5 9.66 2-43 
Etiologic Patterns  2.6 1.05 1-5 
 
 
At discharge, delirium persisted in 28 of the 41 patients who had delirium during 
hospitalization; 16 (57%) had mild delirium and 12 (43%) had severe delirium. In addition, 
two patients without delirium during hospitalization had mild delirium at discharge. Figure 
4.2, Figure 4.3, and Figure 4.4 demonstrate the trajectories of change in delirium between the 
period during hospitalization and discharge.  
Figure 4.2 shows the change trajectory for the two patients with no delirium during 
hospitalization, but who had mild delirium (NEECHAM score 20-24) at discharge. One of 
the patients had a 3-point drop in NEECHAM score from 27 during hospitalization to 24 at 
discharge. The other had a 2-point drop in NEECHAM score from 26 to 24. A change in 
NEECHAM score > 3 points is considered clinically significant.  
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Figure 4.2. Change trajectory for patients with no delirium during hospitalization but with 
delirium at discharge 
 
 
Figure 4.3 shows the change trajectories for patients with mild delirium during 
hospitalization (n = 18). At discharge, delirium had resolved in 12 patients (66%). The mean 
change in NEECHAM score among the patients with mild delirium that resolved was 5.1 
points (SD 2.47; range 2 – 10). All but one of the patients had a change in NEECHAM score 
> 3 points. Six patients (33%) had persistent mild delirium. No patients with mild delirium 
during hospitalization had more severe delirium at discharge.  
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Figure 4.3. Change trajectories for patients with mild delirium during hospitalization 
 
 
Figure 4.4 shows the change trajectories for patients with severe delirium 
(NEECHAM score <20) during hospitalization (n = 23). At discharge, delirium had resolved 
in one patient with severe delirium. This patient’s lowest NEECHAM score during 
hospitalization was 7, and at discharge it was 27. More than half (n = 12; 52%) had persistent 
severe delirium. Delirium improved from severe to mild in 10 patients (43%). The mean 
change in NEECHAM score for those that improved was 6.1 points (SD 4.38; range 1 – 17). 
All but one of the patients had a change in NEECHAM score > 3 points.  
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Figure 4.4. Change trajectories for patients with severe delirium during hospitalization 
 
 
Aim 2: Characteristics in Patients With and Without Delirium Resolution 
 Table 4.7 presents characteristics in patients with and without delirium resolution. 
Patients with delirium resolution were less functionally impaired (mean IADLs 10.3 versus 
5.3) and exhibited fewer etiologic risk patterns (mean frequency 1.9 versus 2.8) (Table 4.7). 
Patients with delirium resolution also had a shorter length of hospital stay (mean LOS 7.3 
versus 13.3). There were no differences among patients with delirium resolution and those 
without resolution with regard to gender, ethnicity, cancer type, delirium onset, or specific 
etiologic patterns except for chronic cognitive impairment. All patients with chronic 
cognitive impairment had delirium during hospitalization that persisted at discharge. Patients 
with mild delirium were more likely to have resolution than those with severe delirium 
(Fisher’s Exact; p < 0.0001). 
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Table 4.7. Characteristics of Patients With and Without Delirium Resolution 
 
 
 Variable 
 
Delirium Resolution 
(n = 13) 
 
No Resolution 
(n = 30) 
 
  
  
Mean 
 
 
SD 
 
Mean 
 
SD 
 
t Value 
 
Significance 
Level 
 
Age 
 
 
73.0 
 
7.87 
 
75.3 
 
7.67 
 
0.89 
 
0.358 
APACHE 
 
16.4 6.09 15.8 4.94 -0.31 0.764 
IADLs 
 
10.3 3.42 5.3 4.48 -3.97 0.000 
Length of 
Stay 
 
7.3 2.32 13.3 11.03 2.83 0.008 
Etiologic 
Patterns 
 
1.9 0.86 2.8 1.01 2.81 0.008 
 
 
Analysis 3: Delirium in Hospitalized Older Cancer Patients Near the End of Life 
Delirium trajectories and etiologic patterns were examined in 10 of the hospitalized 
older cancer patients in the Patterns and Interventions Study who died within 3 months of 
discharge. Table 4.8 summarizes their patient characteristics. Six were men and 7 were 
African-American. They represented a variety of cancer diagnoses. Their ages ranged from 
65-90 years (mean = 76). The patients had moderate to high illness severity (mean APACHE 
score = 16) and moderate functional impairment (mean PADL = 10.1; IADL = 8.3). The 
patients exhibited multiple etiologic patterns. Their average length of hospital stay was 12.2 
days. While the patients were not considered terminal at admission, their deaths occurred 2 to 
70 days after hospital discharge; 5 patients died within 10 days of discharge.  
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Table 4.8. Characteristics of patients near the end of life (N = 10) 
     
Variable  n %  
     
Gender     
 Male  6 60  
 Female  4 40  
      
Ethnicity     
 Caucasian  3 30  
 African-American  7 70  
      
Cancer Diagnosis     
 Lung  3 30  
 Prostate  2 20  
 Multiple Myeloma  2 20  
 Breast  1 10  
 Colon  1 10  
 Gall Bladder  1 10  
      
      
Variable  Mean SD Range 
     
Age (years)  75.9 9.72 65-90 
APACHE II  16.0 3.65 12-24 
IADLs  8.3 4.11 3-14 
Etiologic Patterns  3.2 1.03 2-5 
Length of Stay (days)  12.2 8.31 5-30 
Time to Death (days)  20.1 21.82 2-70 
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Aim 1: Delirium Trajectories in Patients Near the End of Life 
Eight of the 10 patients experienced delirium during their hospitalization 
(NEECHAM < 24). The severity and course of delirium varied except in one patient who had 
persistent severe delirium (NEECHAM < 20). Six of the 8 with delirium had intermittent 
periods without symptoms. All patients with delirium during hospitalization had delirium 
symptoms at discharge. Based on NEECHAM scores, four delirium trajectories were 
identified among the older cancer patients near the end of life: no delirium, fluctuating 
delirium, progressive delirium, and persistent severe delirium.  
Figure 4.5 shows the NEECHAM score trajectories for the two patients who had no 
delirium during hospitalization. One patient remained at low risk for delirium during a 5-day 
hospitalization. This patient was 65 years old, had multiple myeloma, and died 70 days post-
discharge. The other patient fluctuated between being at low risk and at risk for delirium over 
a 21-day hospital stay. This patient was 66 years old, had breast cancer, and died 21 days 
following discharge. Her NEECHAM scores were consistently lower toward the end of her 
hospitalization.  
Figure 4.6 shows the NEECHAM score trajectories of the six patients with 
fluctuating delirium. Throughout their hospitalization, their NEECHAM scores tended to 
vary widely. Five of the patients had severe delirium at some point; the other fluctuated 
between mild delirium and no delirium. All but one of the patients had periods without 
delirium symptoms (NEECHAM score > 25). At discharge, all of the patients with 
fluctuating delirium during hospitalization were delirious; 4 had mild delirium and 2 had 
severe delirium 
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Figure 4.5.  NEECHAM score trajectories in patients with no delirium (n = 2)     
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Figure 4.6. NEECHAM score trajectories in patients with fluctuating delirium (n = 6)  
 
 Figure 4.7 represents the NEECHAM score trajectory for the patient who had 
progressive delirium. Although this patient’s NEECHAM scores fluctuated during 
hospitalization, overall, they declined. The patient, a 90-year old, African-American female 
with colon cancer, was free of delirium at admission and until hospital day 9 when she 
developed mild delirium (NEECHAM score = 21). Her NEECHAM scores improved over 
the next 3 days. When she was assessed on day 12 and day 13, she was without delirium 
symptoms (NEECHAM score = 26). On day 14, she, again, developed mild delirium 
(NEECHAM score = 21). After that point, she fluctuated between severe and mild delirium 
until her discharge on day 30. She died 7 days later.       
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Figure 4.7. NEECHAM score trajectory in patient with progressive delirium (n = 1) 
 
 Figure 4.8 presents the NEECHAM score trajectory for one patient who had 
persistent severe delirium from admission to discharge. This patient, a 79-year old, African-
American male with cancer of the gallbladder, had severe delirium (NEECHAM score = 16) 
at admission. Overall, his delirium worsened during his 5-day hospitalization. His 
NEECHAM scores obtained on hospital day 3 (NEECHAM score = 8) and on hospital day 5 
(NEECHAM score = 12), indicated persistent severe delirium. He died at home with hospice 
care, 2 days after discharge.  
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Figure 4.8. NEECHAM score trajectory in patient with persistent severe delirium (n = 1) 
 
 
Aim 2: Etiologic Patterns in Patients Near the End of Life 
Etiologic patterns were determined by the presence of clinical risk markers at 
admission. Patients had clinical risk markers for multiple etiologic patterns (Table 4.8). All 
patients, whether delirious or not, had metabolic-nutritional pattern markers. Seven of the 8 
delirious patients had hypoxic markers; 6 had orthostatic-dehydration markers; 4 had 
metabolic-toxic markers; and 2 patients had markers for chronic cognitive impairment.  
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Phase II: Development and Pilot Testing of a Protocol to Study Delirium  
in Older Adults with Advanced Cancer 
  
 The second phase of the research was a pilot study to assess a protocol to study 
delirium in older adults with advanced cancer receiving palliative cancer treatment and end 
of life care primarily at home. The specific aims were: 1) to test the feasibility of the 
protocol, first, in a laboratory and, then, in the home setting; 2) to determine the level of 
patient and caregiver burden associated with the protocol; 3) to evaluate and refine 
instruments and data collection procedures; and 4) to identify and resolve methodological 
issues related to recruitment, consent, measurement, and retention. 
  
Participant Characteristics 
Three older persons with advanced cancer and their family caregivers were enrolled 
in the study. Participant #1 was an 87 year-old Caucasian male with metastatic gastric cancer. 
His cancer was diagnosed in December 2003, and he underwent surgical resection in January 
2004. During the study, he was receiving palliative treatment with oral chemotherapy. 
Participant #2 was a 68 year-old Caucasian male with metastatic gastric cancer that was 
diagnosed in March 2004. He was receiving infusional chemotherapy throughout the study, 
except during Week 3, when he had a break between cycles. Participant #3 was a 69 year-old 
Caucasian female with metastatic colon cancer involving the liver. She had been diagnosed 
in June 2003. She had been receiving palliative chemotherapy throughout the past year after 
undergoing an initial surgical resection. All of the participants were being cared for by their 
spouses.  
Family caregivers completed the Caregiver Confusion Checklist twice a day. During 
the study, all of the participants exhibited possible symptoms of confusion or altered 
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cognition. The following symptoms were documented on the CCC by their caregivers: being 
tired, difficulty sleeping, feeling irritable, slowed response, frustration, being withdrawn, 
feeling drowsy, decreased concentration, fatigue, slowed movements, apathy, being 
impatient, and foggy. Only one participant (#3) had a suspected episode of delirium 
following an anaphylactic reaction to Erbitux, a monoclonal antibody that had been added to 
her regimen when she experienced disease progression. The investigator was not contacted 
during this episode. Based on information obtained in an interview with the participant’s 
husband following the episode, the participant’s NEECHAM Confusion Scale score was 
estimated to be 16. The participant’s caregiver reported observing the following symptoms 
during the episode: slowed response, slowed movements, simple speech, slurred speech, 
drowsy, and slowed thinking. 
 
Feasibility and Burden Associated with the Protocol 
 Data collection sessions were scheduled at a time that was convenient for patients and 
their caregivers. Patients and caregivers reported minimal burden associated with the 
protocol. The initial data collection session was conducted in the Biobehavioral Laboratory 
in the UNC School of Nursing. During the initial session, the investigator provided informed 
consent, evaluated cognitive function, obtained sociodemographic data, and completed the 
protocol for routine data collection. The initial data collection sessions lasted from 1.5 to 
1.75 hours. The informed consent process and the collection of sociodemographic data took 
approximately 20 minutes each. Weekly in-home data collection sessions lasted 1.5 hours on 
average. The time for completion of questionnaires ranged from 15 to 45 minutes (mean = 22 
minutes). Collection of physiological data including equipment set up and clean-up took 20 
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to 60 minutes (mean = 35 minutes). Interviews with patients and caregivers evaluating 
research burden lasted from 10 minutes to 45 minutes. 
Both patients and caregivers reported minimal burden associated the study protocol 
and data collection procedures. None of the patients acknowledged physical discomfort with 
any of the procedures. There were few requests for clarification of questions or instruments. 
None of the patients asked to take a break during any of the data collection sessions. 
Additionally, none exhibited signs of fatigue. One patient took more time than the others to 
complete the questionnaires. He pondered over many of the questions and reported 
frustration when completing of the Geriatric Depression Scale. All patients felt that they 
could tolerate the procedure at times when they were feeling less well. Each also indicated 
that it would not be too burdensome to continue in the study for a longer period of time. One 
patient, however, stated that weekly data collection session might be confining. 
Caregivers reported that they were able to complete the CCC without difficulty. One 
caregiver reported that it would have been helpful to have more information about the signs 
and symptoms of confusion or delirium. Caregivers often entered comments or descriptors 
when patients exhibited signs of confusion. Two patients had a CCC score of 2, but their 
caregivers did not contact the investigator. In each case, the investigator was scheduled to 
make a visit for data collection on the following day. The investigator did not determine why 
the caregivers did not contact him. The caregiver for Patient #3 did not contact the 
investigator when she was hospitalized following the reaction to Erbitux. He did not 
complete the CCC during that time even though the patient exhibited signs of confusion. He 
stated that he was not sure what he should do. Based on these findings several changes were 
implemented in the follow-up study. Caregivers were provided with more information about 
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delirium and delirium symptoms. Instructions for contacting the investigator were moved to 
the bottom of the CCC just below the total score. Finally, caregivers were instructed to 
complete the CCC twice each day in all care settings and to notify the investigator if the 
patient is admitted to the hospital or changes care settings. 
 
Recruitment Issues 
 Several recruiting issues arose during the pilot study. Initially, recruitment was to be 
done by physicians and nursing staff in the medical oncology clinics. After talking with the 
staff, it was obvious that the investigator should be more involved in the recruiting process. 
Therefore, the recruiting strategy was revised and submitted to the IRB for approval. The 
revised strategy included a limited waiver of HIPAA allowing the investigator to use the 
medical record to identify prospective participants. Following IRB approval, the investigator 
attended targeted medical oncology clinics to identify and provide prospective participants 
with information about the study. Three of 7 patients who were approached agreed to 
participate in the study. One patient refused during the clinic contact. Three other patients 
were given a recruitment flyer but did not follow-up with the investigator.  
Soon after initiating the pilot study, the investigator determined that hospice patients 
also should be recruited to participate in the study. An IRB addendum was submitted and 
approved. The hospice recruitment strategy relied on the hospice staff to identify and 
approach prospective participants. The investigator met with the hospice team to discuss the 
study and to provide them with recruitment flyers for prospective participants. One hospice 
patient who was given a recruitment flyer followed up with the investigator to express an 
interest in participating. An initial visit was scheduled, but the patient’s condition declined 
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rapidly and his caregiver cancelled the visit. Hospice team members consulted the 
investigator about three other patients who did not meet inclusion criteria. No hospice 
patients were enrolled in the study. 
 
Summary 
 The pilot study was done to evaluate the feasibility and burden associated with a 
protocol to study delirium and cognitive decline in older adults with advanced cancer cared 
for at home and to identify methodological issues related to conducting this research. 
Findings from this study were used to design and conduct the third phase of this research—a 
longitudinal, multiple case study of delirium in older adults with advanced cancer.  
  
Phase III: Trajectories and Patterns of Delirium and Delirium Vulnerability in 
 Older Adults with Advanced Cancer Near the End of Life 
  
 This study was conducted to examine delirium in older adults with advanced cancer 
near the end of life. The primary aim was to identify and to describe the nature of delirium 
and trajectories of delirium vulnerability in this population. After providing a description of 
the entire sample, the research questions will be answered. In the end, there were two groups 
of participants, those who died during the study and those who lived. Data from all 
participants will be used to answer the research questions. Following a general discussion, 
selected data from individual cases will be used to illustrate, in more detail, the nature of 
delirium and trajectories of delirium vulnerability. An exemplar case study is presented in 
Appendix E.  
 
 
 129 
Participant Characteristics 
 The sample consisted of 7 older adults, 6 men and 1 woman, with advanced cancer 
recruited from the outpatient oncology clinics at a university-affiliated cancer center. Table 
4.9 provides detailed characteristics of the individual participants. Their ages ranged from 
66-87 years (M 75.6; SD 8.54). Most were married (n = 5), one was widowed, and the other 
was separated. Two of the men were African-American. The participants had varying levels 
of education—ranging from 6 years of school to having a graduate degree. 
  Two of the men had non-small cell lung cancer, two had prostate cancer, one had 
esophageal cancer, and the other had liver cancer. The woman had colon cancer. All but two 
of the participants had been diagnosed with cancer for more than one year prior to enrollment 
in the study and had undergone multiple treatments. The two who were recently diagnosed 
(Mr. B and Mr. F) underwent surgical resections after neoadjuvant treatment.   
 Table 4.10 summarizes the baseline characteristics of the sample. Overall, the 
participants had normal baseline cognitive functioning. Although the baseline MMSE scores 
varied, the mean MMSE was 25, and the median was 27. One participant (Mr. F) had an 
extremely low baseline MMSE (15/30). However, his baseline NEECHAM score was 28, 
indicative of normal information processing and behavioral functioning. His low baseline 
MMSE most likely reflected his 8th grade educational level, a low literacy level, and the rural 
cultural environment in which he lived.    
 The mean baseline NEECHAM score was 26.7. All of the participants exhibited some 
deficit in motor functioning, either tremor or slowing. Few showed difficulties with 
information processing or cognitive functioning, except that some (n = 3) had a slowed 
response to or completion of command, which may have been influenced by their slowed 
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motor functioning. Most (n = 6) had alterations in physiological control, particularly with 
regard to vital function stability or vital signs. In addition, one participant (Mr. G) was on 
continuous oxygen, and another (Mr. D) had a long-term indwelling foley catheter.   
The level of baseline physical functioning varied among participants. Few exhibited 
deficits in PADLs, but all needed some assistance with IADLs—particularly needing help 
with shopping, preparing meals, and with doing housework and yard work.  Some also 
needed assistance with transportation or managing money. Only one participant needed 
assistance with taking medications. Baseline scores on the PPS demonstrated a moderate 
level of functional impairment. While the participants were independent in providing self-
care, most had a reduced ability to ambulate, were unable to do normal work, and had either 
normal or reduced food intake.   
 Although symptom prevalence varied at baseline, on average, the participants 
reported a high number of symptoms (M 11.4; SD 4.96). Most likely, the prevalent symptoms 
were related to the cancer, its treatment, other symptom management, or some combination 
of each. The most frequently reported physical symptoms were lack of energy (n = 7), cough 
(n = 5), lack of appetite (n = 5), change in the way food tastes (n = 5), diarrhea (n = 4), 
itching (n = 4), pain (n = 3), difficulty sleeping (n = 3), and weight loss (n = 3). Two 
participants reported nausea, shortness of breath, and swelling in arms or legs. The most 
frequent psychological symptom was feeling irritable (n = 5), followed by feeling nervous (n 
= 3), and worrying (n = 2) and feeling sad (n = 2). The most common cognitive symptom 
was feeling drowsy (n = 5), followed by difficulty remembering (n = 3), difficulty 
concentrating (n = 2), and feeling confused (n = 1). 
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 Baseline symptom distress also varied among the participants. Global symptom 
distress scores ranged between 0.16 and 2.06 (M 1.16; SD 0.61). All participants reported a 
certain level of physical symptom distress (M 0.96; SD 0.58; Range 0.13-1.67), but not 
psychological symptom distress (M 0.76; SD 0.57; Range 0-1.83) or cognitive symptom 
distress (M 0.64; SD 0.61; Range 0-1.65). Mr. F reported no psychological symptom distress 
at baseline. Mr. B and Mr. F reported no cognitive symptom distress. 
At baseline, the mean GDS score was 4.6 (SD 2.1; Range 2-7). Three participants 
(Mr. B, Mrs. C, and Mr. E) had baseline GDS scores > 5, indicating probable depression. 
Only one participant (Mr. A) reported a history of depression, and he was on antidepressant 
medications at the time of enrollment. His baseline GDS score was 4.  
The five men who were married lived with their wives and, in some cases, other 
family members. All but one were cared for primarily by their wives. Prior to his illness, Mr. 
F was the primary caregiver for his wife who had mild dementia. When he became ill, his 
daughter and two sons assisted in caring for him and his wife. Mrs. C, a widow, lived alone 
until 2 weeks before her death. Her daughter and granddaughter-in-law who lived nearby 
were her primary caregivers. Initially, Mr. G’s neighbor assisted with his care, but as he 
needed more assistance, other family members and friends became involved and provided 
around-the-clock care in his home.     
  
Table 4.9. Characteristics of individual participants 
 
Case Age Gender Ethnicity Marital Status Primary Caregiver Educational 
Level 
Employment 
Status 
 
Mr. A 
 
66 
 
 
Male 
 
Caucasian 
 
Married 
 
Wife 
 
Graduate 
Degree 
 
 
Retired 
 
Mr. B 
 
87 
 
 
Male 
 
Caucasian 
 
Married 
 
Wife 
 
College 
Degree 
 
 
Retired 
 
Mrs. C 
 
81 
 
Female 
 
Caucasian 
 
Widowed 
 
Daughter & 
Granddaughter-in-law 
 
 
11th Grade 
 
Retired 
 
Mr. D 
 
71 
 
 
Male 
 
AA 
 
Married 
 
Wife 
 
6th Grade 
 
Retired 
 
Mr. E 
 
84 
 
 
Male 
 
Caucasian 
 
Married 
 
Wife 
 
Graduate 
Degree 
 
 
Retired 
 
Mr. F 
 
74 
 
 
Male 
 
 
Caucasian 
 
 
Married 
 
Daughter & Sons 
 
8th Grade 
 
Retired 
 
Mr. G 
 
 
66 
 
Male 
 
AA 
 
Separated 
 
Friends & Family 
 
6th Grade 
 
Retired 
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Table 4.9. Characteristics of individual participants (continued). 
Case Cancer 
Diagnosis 
Date of 
Diagnosis 
(Date Enrolled in 
Study) 
Cancer Treatment 
During Study 
Prior Cancer  
Treatment 
Charlson 
Comorbidity 
Index 
Comorbid Medical 
Conditions 
Mr. A Non-small cell 
lung cancer 
 
Initial 03/96 
Recurrence 02/04 
(04/20/05 
Iressa 
Sutent 
R lung resection; Cisplatin and 
navelbine; Radiation therapy to 
chest and brain; Pemetrexed 
 
1 Hypertension; Depression 
with anxiety; Degenerative 
joint disease  
Mr. B Hepatocellular 
carcinoma 
04/07/05 
 
(05/23/05) 
Surgical resection Chemo embolization with 
Mitomycin and Doxorubicin 
 
1 COPD; Degenerative joint 
disease; Hypertension; 
Glaucoma 
 
Mrs. C Colon cancer 
 
02/03 
 
(05/25/05) 
Irinotecan  and 
Cetuximab; 
Globimmune vaccine 
trial 
Surgical resection; 
5-FU/Leucovorin; 
Xeloda; Oxaliplatin; 
Avastin 
 
2 Hypertension; Atrial 
fibrillation; Aortic stenosis, 
Mitral regurgitation; Chronic 
heart failure 
Mr. D Prostate cancer 
 
10/95 
 
(06/23/05) 
Taxotere 
 
Casodex and Proscar; 
Orchiectomy; 
Taxotere, carboplatin, and 
estramustine; 
Taxotere and estramustine; 
Taxotere 
1 Gout; Chronic renal 
insufficiency; Long-term 
indwelling foley catheter 
Mr. E Prostate cancer 
 
01/99 
 
(07/14/05) 
Secondary hormone 
therapy with 
Ketoconazole and 
Hydrocortisone; 
Zometa 
 
Lupron; 
Orchiectomy 
2 Coronay artery disease;  3- 
vessel CABG; Orthostatic 
hypotension; Neurogenic 
bladder; Renal insufficiency 
Mr. F Esophageal 
cancer 
 
06/27/05 
 
(09/08/05) 
Cisplatin and 
Irinotecan; 
Concurrent radiation 
therapy (45 Gy); 
Surgical resection 
None 1 Hypertension; 
Gastroesophageal reflux 
disease 
Mr. G Non-small cell 
lung cancer 
 
06/16/04 
 
(09/26/05) 
None Gemcitabine and Taxol; 
Pemetrexed; Iressa; 
Carboplatin/Abraxane 
Radiation therapy 
3 COPD; Hypertension; 
Coronary artery disease; 
Degenerative joint disease; 
Chronic low back pain; 
Anemia  
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Table 4.9. Characteristics of individual participants (continued). 
Case Tobacco 
Use 
Alcohol 
Use 
Visual Deficit 
Correction 
(Self-Reported) 
Hearing Deficit 
Correction 
(Self-Reported) 
History of 
Confusion Prior to 
Cancer Diagnosis 
History of 
Confusion Since 
Cancer Diagnosis  
Self Report of 
Health at 
Enrollment 
 
Mr. A 
 
No 
 
Past 
 
Yes  
Glasses 
 
 
Yes – some words 
None 
 
Yes 
 
Yes 
 
Fair 
 
Mr. B 
 
Past 
 
No 
 
 
Yes 
Glasses 
 
 
No 
 
No 
 
No 
 
Fair 
 
Mrs. C 
 
Past 
 
No 
 
 
Yes 
Glasses 
 
 
No 
 
No 
 
No 
 
Fair 
 
Mr. D 
 
Chewing 
Tobacco 
 
 
Past 
Heavy 
Use 
 
 
Yes 
Glasses for 
reading 
 
No 
 
No 
 
No 
 
Excellent 
 
Mr. E 
 
No 
 
No 
 
 
Yes 
Glasses 
 
Yes 
Hearing aids 
 
 
No 
 
Yes 
 
Good 
 
Mr. F 
 
No 
 
No 
 
 
No 
 
No 
 
No 
 
 
Yes 
 
Good 
 
Mr. G 
 
Past 
 
Past 
Heavy  
Use 
 
 
No 
 
No 
 
No 
 
Yes 
 
Poor 
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Table 4.10. Baseline characteristics of older adults with advanced cancer (N = 7) 
 
     
Variable  n   
     
Gender     
 Male  6   
 Female  1   
      
Ethnicity     
 Caucasian  5   
 African-American  2   
      
Cancer Diagnosis     
 Lung  2   
 Prostate  2   
 Liver  1   
 Esophagus  1   
 Colon  1   
      
Variable  Mean SD Range 
     
Age  (years) 75.6 8.54 66-87 
MMSE  (0-30) 25.0 5.48 15-30 
NEECHAM (0-30) 26.7 2.06 23-29 
IADLs (0-14) 11.0 1.53 9-13 
PADLs (0-14) 13.7 0.49 13-14 
PPS  (0-100) 68.6 6.90 60-80 
GDS-15 (0-15) 4.57 2.07 2-7 
Total # of Symptoms  (0-31) 11.4 4.96 4-18 
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Table 4.11 provides information about time in study, the frequency and types of 
visits, and disposition at the end of the study. Participants were enrolled in the study for 
periods of time ranging from 93 days to 330 days. Three participants died during the study 
after being followed for 93 days (Mrs. C), 109 days (Mr. G), and 296 days (Mr. D). During 
the study, two participants, Mr. B who had liver cancer and Mr. F who had locally advanced 
esophageal cancer opted for surgical treatments that rendered them “cancer-free”. Mr. B and 
Mr. F were enrolled in the study for 162 and 161 days, respectively. Another participant (Mr. 
E) was enrolled for 160 days. Although he showed evidence of disease progression with 
increasing PSA at that time, he and his wife decided not to continue in the study because they 
were in the process of selling their home and moving into a retirement community. The final 
participant (Mr. A) was enrolled for 330 days. During the study, he participated in a clinical 
trial that slowed the progression of his lung cancer and resulted in improved function.  
Over the course of the study, a total of 220 assessments were conducted. The total 
number of assessments per participant varied depending upon the length of enrollment in the 
study, and the number of delirium and delirium follow-up assessments conducted. Most of 
the initial delirium assessments were conducted at scheduled weekly assessments—that is, 
participants were found to be positive for delirium at the time of scheduled weekly 
assessments. Even though caregivers were monitoring participants daily for signs of delirium 
using the Caregiver Confusion Checklist (CCC) and had been instructed to contact the 
investigator for a CCC score > 2, they rarely called to report an increase in CCC score or any 
other change in the participants’ conditions.  Mr. G’s caregivers called twice to report a 
change in his condition that included signs of delirium—the calls were not triggered by the 
CCC score.  
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Table 4.11. Time in study, number of assessments by type, and disposition by participant 
 
 
Case 
 
Time in 
Study 
(Days) 
 
Total # of 
Assessments 
 
Scheduled 
Weekly 
Assessments 
 
Delirium  
Assessments 
Triggered by 
Caregiver 
Call 
 
 
Delirium 
Follow-Up 
Assessments 
 
Disposition 
 
Mr. A 
 
330 
 
49 
 
47 
 
0 
 
2 
 
Continued  
Treatment 
 
 
Mr. B 
 
162 
 
23 
 
21 
 
0 
 
 
2 
 
Observation 
 
 
Mrs. C 
 
93 
 
19 
 
12 
 
0 
 
7 
 
Died 
 
 
Mr. D 
 
296 
 
52 
 
42 
 
0 
 
10 
 
Died 
 
 
Mr. E 
 
160 
 
22 
 
 
21 
 
0 
 
1 
 
Observation 
 
 
Mr. F 
 
161 
 
25 
 
23 
 
0 
 
2 
 
Observation 
 
 
Mr. G 
 
 
109 
 
30 
 
16 
 
2 
 
12 
 
Died 
 
Total 
 
 
220 
 
182 
 
2 
 
36 
 
 
 
Research Question1: What is the nature and course of delirium in older adults with advanced 
cancer near the end of life? 
 
 The nature and course of delirium was determined by examining the total 
NEECHAM score trajectories to identify when delirium occurred. The total NEECHAM 
score and total NEECHAM score trajectory were used to evaluate severity and duration of 
delirium. The NEECHAM subscale trajectories and other data were used to identify and 
describe the cognitive, behavioral, and physiological characteristics of delirium episodes. 
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First, delirium was examined in each of the participants who died. Second, across case 
comparisons of delirium trajectories and delirium episodes among the participants who died 
were made. Third, delirium was examined in the participants who were alive at the end of the 
study. Finally, reversible episodes of delirium in participants who died were compared to the 
delirium episodes in participants who lived.   
    
Delirium Episodes in Participants Who Died 
Mrs. C 
Figure 4.9 shows the trajectory of Mrs. C’s total NEECHAM scores during the study 
with the delirium episodes marked. Mrs. C had two delirium episodes determined by positive 
delirium assessments – NEECHAM score < 24 and positive CAM.  
Mrs. C’s first delirium episode occurred 30 days before her death. She scored 
positively for delirium at the time of the scheduled weekly assessment. During her first 
episode, the total NEECHAM score was 21. Mrs. C had only one positive delirium 
assessment with this episode. She did not score positive for delirium at the follow-up 
assessment the next day or during assessments over the next three weeks. During this period, 
her NEECHAM scores were 23 and 24 and the CAM was not positive; she may have been 
exhibiting subsyndromal delirium or fluctuating delirium.  
Mrs. C’s second positive delirium assessment was on Day 9 before her death. Her 
total NEECHAM score was 16 and the CAM was positive. Her NEECHAM scores on Day 7 
(10) and on Day 6 (7) demonstrated increasingly severe delirium. From Day 5 until her 
death, Mrs. C was stuporous and essentially unresponsive. During this period, her 
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NEECHAM scores were 1 and 0. She exhibited moderate to deep levels of sedation before 
becoming unarousable 2 days before her death. The CAM could not be scored. 
  
 
 
Figure 4.9. Mrs. C’s NEECHAM score trajectory with delirium episodes 
 
 
Figure 4.10 shows the trajectory of Mrs. C’s NEECHAM subscale scores. At the time 
of her first delirium episode, she showed deficits in each of the subscales. Her Level 1: 
Processing subscale scores were stable prior to the first delirium episode, but dropped during 
the episode. During the two weeks before the delirium episode, Mrs. C experienced declines 
in her NEECHAM Level 2: Behavior and NEECHAM Level 3: Physiological Control 
subscale scores. She exhibited changes in her postural control and appearance, slowed motor 
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movements, and more limited speech. During the week prior to the first delirium episode, her 
granddaughter-in-law documented that Mrs. C had been staying in bed more, sleeping a lot, 
and talking less. She “only talks when you talk to her.”     
 
 
Figure 4.10. Trajectories of Mrs. C’s NEECHAM subscale scores 
 
 
On Day 16, one week prior to her second delirium episode, Mrs. C’s NEECHAM 
Level 1: Processing subscale score dropped. Her Level 2 and Level 3 subscale scores were 
slightly improved. All three subscale scores had declined sharply at the positive delirium 
assessment on Day 9. At that time, Mrs. C was bedbound and her level of alertness was more 
diminished. When awake, she tended to stare rather than focus on people at her bedside. She 
demonstrated little movement of her extremities, but she would drink from a straw placed 
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near her mouth. Prior to the second delirium episode, she was started on oxygen. She also 
had intermittent urinary incontinence that became progressively worse. 
Mrs. C’s first delirium episode was characterized by a decrease in her level of 
alertness and attention, as well as by slowed motor and verbal behavior. At the time of the 
positive delirium assessment, she exhibited the following hypoactive delirium behaviors on 
the Delirium Behavior Checklist: diminished alertness, lethargy, slow speech, slow 
movements, unawareness, and apathy. No hyperactive behaviors were noted. Mrs. C’s score 
on the sedation subscale of the Richmond Agitation-Sedation Scale (RASS) was -1 (drowsy) 
and her score on the motor retardation item from the Delirium Rating Scale (DRS-R 98) was 
1, indicating a mild reduction in frequency of movement. 
Mrs. C’s second delirium episode that preceded her death was characterized primarily 
by hypoactive delirium behaviors. However, on two days, Day 7 and Day 6, she had 
intermittent periods of restlessness with hallucinations. Otherwise, on these days and on other 
days, Mrs. C exhibited a decrease in her level of alertness and responsiveness and slowed 
motor behavior. When Mrs. C exhibited restlessness, her family administered diazepam 2.5 
mg. During this episode, Mrs. C became progressively more sedated until she became 
unresponsive two days before her death. Her RASS sedation subscale scores ranged from -1 
(drowsy) to -5 (unarousable).     
At the time of her first positive delirium assessment on Day 30, Mrs. C’s NEECHAM 
Level 3 subscale score was 3, indicating deficits in physiological control. She specifically 
exhibited alterations in her vital function and urinary continence. Figure 4.11 presents Mrs. 
C’s vital function parameters throughout the study. During her first delirium episode, her 
blood pressure was elevated. It was 167/94 compared to her average during prior 
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assessments, 135/73. Mrs. C always had an irregular heart rhythm due to atrial fibrillation, 
but overall her heart rate was controlled with digoxin. At the time of the first positive 
delirium assessment her heart rate was elevated at 84 beats per minute compared to her 
average of 65 beats per minute at prior assessments. Mrs. C’s temperature also was elevated 
at 37.6 degrees Celsius. Her respiratory rate, while elevated at 24 breaths per minute, was 
similar to her usual respiratory rate which had ranged between 20 and 28 breaths per minute.  
 
 
Figure 4.11. Trajectory of Mrs. C’s vital function parameters 
 
Mrs. C also exhibited altered physiologic control during her second delirium episode 
prior to her death. Most notably, her heart rate was increased. On the morning of the second 
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positive delirium assessment, Mrs. C experienced chest pain and shortness of breath. She was 
started on supplemental oxygen. At the time of the assessment, later in the afternoon, Mrs. 
C’s oxygen saturation was 97% on oxygen at 2 liters per minute. Her respiratory rate was 
decreased at 16 breaths per minute. After that point, she exhibited greater physiological 
instability—hypotension, tachycardia, hyperthermia, and demand for increased oxygen—
until her death. During the same time, she had increasingly severe delirium before becoming 
unresponsive prior to her death. 
 
Mr. G  
Figure 4.12 shows the trajectory of Mr. G’s NEECHAM scores with positive delirium 
assessments noted. Even though Mr. G had two NEECHAM scores > 27 early in the study, 
he was at risk for delirium because of his need for oxygen supplementation. Mr. G had 5 
delirium episodes. The first occurred on Day 85 before his death, the second on Day 74, the 
third on Day 35, the fourth on Day 26, and the fifth on Day 12, respectively. Mr. G’s first 
four delirium episodes resolved. After each of the episodes, his NEECHAM score was > 24 
for at least one assessment. His fifth episode persisted until his death.   
 Each of Mr. G’s first 3 delirium episodes consisted of a single positive assessment. 
His NEECHAM scores during these episodes indicated the presence of mild delirium. His 
total NEECHAM score was 20 at the first positive assessment, and his NEECHAM score 
was 21 at the second and third positive delirium assessments. He was not positive for 
delirium at follow-up assessments conducted one to three days after the initial positive 
assessments. Mr. G’s fourth delirium episode consisted of 3 consecutive positive assessments 
over 4 days. His total NEECHAM score fluctuated between 19 and 22. Mr. G’s fifth delirium 
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episode began with a positive delirium assessment on Day 12. At the assessment on Day 12, 
his total NEECHAM score was 22 and the CAM was positive. Although his NEECHAM 
scores fluctuated, Mr. G remained positive for delirium until his death. On Day 11 at the 
follow-up assessment, his NEECHAM score was 24. His NEECHAM score was 21 on Day 9 
but dropped sharply to 10 on Day 5. Mr. G’s NEECHAM score was 19 on Day 4. Although 
his level of alertness and attention fluctuated during the assessment on Day 4, Mr. G. was 
more alert primarily because prior to the assessment, the hospice nurse had given him an 
enema and had attempted to manually disimpact him. After this assessment, his NEECHAM 
score began to drop again. On Day 2, his NEECHAM score was 11, and on the day before 
his death it dropped to 7.  
 
 
Figure 4.12. Mr. G’s NEECHAM score trajectory with delirium episodes 
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 As Mr. G approached the end of his life, the time between delirium episodes 
decreased and the delirium episodes became progressively longer. Although his NEECHAM 
scores fluctuated during the later episodes, the scores were lower demonstrating more severe 
delirium. 
 Figure 4.13 shows the trajectory of Mr. G’s NEECHAM subscale scores. Prior to his 
first delirium episode, Mr. G had deficits in all of the subscales. The subscale scores dropped 
further during his first delirium episode. Between the first and second delirium episodes, his 
Level 1: Information Processing and Level 2: Behavior scores improved but his Level 3: 
Physiologic Control subscale score remained decreased. At the time of the second delirium 
episode, his Level 3 score was improved. All of the subscale scores tended to stabilize 
between the second and third delirium episodes. Four days prior to his third delirium episode, 
the Level 3 subscale score dropped. During that assessment, his Level 1 subscale score 
remained stable and his Level 2 subscale score was improved. Mr. G’s Level 1 and Level 2 
subscale scores fluctuated with delirium episodes. He exhibited more significant fluctuations 
during his final episode. 
During the four delirium episodes that resolved, Mr. G exhibited only hypoactive 
delirium behaviors.  He had a decrease in his level of alertness and attention, as well as 
slowed motor and verbal behavior. Mr. G’s scores on the sedation subscale of the RASS 
ranged between -1 (drowsy) and -2 (light sedation). His scores on the motor retardation item 
from the DRS-R 98 ranged between 1 and 2, indicating a mild to moderate reduction in 
frequency, spontaneity, or speed of movement. Mr. G’s final delirium episode was 
characterized primarily by hypoactive delirium behaviors. Two days before his death, 
however, he began to exhibit intermittent restlessness. On the day before he died, the periods 
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of restlessness were more frequent, and he exhibited more motor agitation. At times he would 
attempt to sit up in bed. He also would take his oxygen off and resist his caregivers’ attempts 
to provide care and assistance.  
 
 
Figure 4.13. Trajectories of Mr. G’s NEECHAM subscale scores 
 
 Figure 4.14 presents Mr. G’s vital function parameters throughout the study. His vital 
signs often fluctuated with his delirium episodes. At the time of his first positive assessment 
on Day 85, his heart rate was increased at 118 and his blood pressure was decreased at 
112/67. Prior to the episode, his average heart rate and blood pressure were 90 and 135/80, 
respectively. His temperature and respiratory rate were also increased. His temperature was 
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37.7 0C, and his respirations were at 24 breaths per minute. His oxygen saturation was 
decreased at 93%.  
 
Figure 4.14. Trajectories of Mr. G’s vital function parameters 
 
At his second positive delirium assessment (Day 74) , overall, Mr. G’s vital signs 
were stable, except that his temperature was slightly elevated at 37.2 0C. Prior to his third 
episode, his respiratory rate was decreased. From the time of his third delirium episode (Day 
35) until his death, Mr. G showed increasing variability in his vital functioning. His heart 
rate, respiratory rate, and temperature fluctuated. During the last week before his death, and 
on the day before death, Mr. G’s vital functioning was increasingly unstable.    
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 Mr. D 
Figure 4.15 shows the trajectory of Mr. D’s total NEECHAM scores with the 
delirium episode noted. Mr. D had one documented episode that coincided with a 
hospitalization for urosepsis—44 days before his death. During the delirium episode, Mr. D 
had four positive delirium assessments over four consecutive days. His total NEECHAM 
score at the first positive delirium assessment on Day 44 was 20. His NEECHAM score 
dropped to 12 at the second assessment on Day 43, but then increased to 20 on Day 42. Prior 
to his discharge on Day 41, his NEECHAM score was 23. The CAM remained positive. At a 
follow-up assessment in his home on Day 38, Mr. D’s NEECHAM score was 24. The CAM 
was negative.  
 
 
Figure 4.15. Mr. D’s NEECHAM score trajectory with delirium episode  
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Mr. D’s last assessment of the study was conducted on Tuesday, April 11, 3 days 
before his death. On the morning of Friday, April 14, Mrs. D called to report that Mr. D had 
died. His death was precipitated by an acute event that caused severe metabolic acidosis and 
organ failure. At a follow-up visit with Mrs. D after his death, she reported that Mr. D 
exhibited hyperactive delirium behaviors—agitation and restlessness—prior to being 
intubated the night before he died. According to his medical record, he was obtunded and had 
altered mental status upon arrival in the Emergency Room. His mental status fluctuated with 
treatment prior to being intubated. Mr. D died in the ICU the next morning after the removal 
of life support.   
Figure 4.16 shows the trajectories of Mr. D’s NEECHAM subscale scores. Overall, 
his Level 1: Processing scores improved over the first 60 days in the study, and remained 
high except during the delirium episode when he showed a sharp drop in his Level 1 scores. 
Mr. D’s Level 2: Behavior scores dropped after his first hospitalization for urosepsis, and 
throughout the rest of the study remained consistently lower. During his delirium episode his 
Level 2 score dropped more, but improved. Mr. D’s Level 3: Physiologic Control subscale 
scores show that he had baseline deficits in his physiological functioning. While he always 
maintained his oxygen stability, Mr. D had variability in his vital functioning which 
worsened after his initial hospitalization (See also Figure 4.17). In addition, he had a chronic 
in-dwelling foley catheter due to obstruction from his prostate cancer. During his delirium 
episode, his Level 3 subscale score improved more rapidly than his Level 1 and Level 2 
scores, an indication that information processing and behavior improve after achieving 
physiologic stability. Similar trends were also seen in Mr. G’s case.   
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Figure 4.16. Trajectories of Mr. D’s NEECHAM subscale scores 
   
Although hyperactive delirium behaviors predominated, Mr. D’s delirium episode 
was classified as of the mixed subtype because he exhibited both hypoactive and hyperactive 
behaviors. During the first positive delirium assessment on Day 44, Mr. D’s mood and 
behaviors were labile. In addition to being quiet with slowed movements at times, he also 
became impatient and irritable. The content of his speech was rambling, and occasionally, he 
laughed inappropriately. When Mr. D was seen in the hospital on Day 43, his hyperactive 
behaviors were increased. At that assessment, he exhibited the following hyperactive 
behaviors: hypervigilance, distractability, restlessness, fast and loud speech, easy startling, 
and tangentiality. Intermittently, he also exhibited hypoactive delirium behaviors including 
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unawareness and slowed movements. On Day 42, the same behaviors were present but less 
pronounced. Mr. D also was joking and laughing when interacting with the hospital staff. On 
Day 41, Mr. D was preparing to be discharged. Most of the behaviors were resolved, but he 
demonstrated impatience and he talked persistently about his wife coming to pick him up. He 
also remained easily distracted by people and sounds in the hallway. Overall, his movements 
were slowed. Mr. D was unable to complete the sentence and drawing on the MMSE because 
he had significantly limited motion of his right arm and hand which he attributed to arthritis 
and gout.  
Figure 4.17 shows the trajectories of Mr. D’s vital function parameters. He shows 
variability in vital function throughout the study, but it is much more unstable after his 
hospitalization for urosepsis. His blood pressure and heart rate fluctuated widely. He also 
developed an occasional irregular heart rhythm. His temperature was more stable except 
during the episodes of urosepsis. 
At the scheduled weekly assessment on Day 45, Mr. D exhibited significant 
physiological instability. His blood pressure was 71/43 and his heart rate was 104 and 
irregular. His temperature was slightly elevated at 37.2 0C. Although strongly encouraged to 
seek medical evaluation that evening, Mr. D and his wife chose not to do so. On the 
following day, Mr. D was positive for delirium. He remained physiologically unstable. His 
blood pressure was 77/39, and his heart rate remained irregular and increased at 114 beats per 
minute. His respiratory rate was 24 breaths per minute, and his temperature was 37.4 0C. 
Following this assessment, Mr. D was taken to the emergency room and admitted to the 
hospital. His vital functioning stabilized over the next three days, and his delirium resolved.  
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Figure 4.17. Trajectories of Mr. D’s vital function parameters 
 
Summary of Delirium Episodes in Participants Who Died 
Mrs. C and Mr. G had two or more episodes of delirium. Both had episodes that 
either reversed or improved prior to an irreversible episode that preceded their deaths. In 
each case, the episodes that reversed were shorter and less severe. Mr. G had four episodes 
that reversed or improved. As he approached the end of his life, the time between delirium 
episodes decreased and the delirium episodes became progressively longer. Although his 
NEECHAM scores fluctuated during the later episodes, the scores were lower demonstrating 
more severe delirium. All of the episodes prior to the terminal episode were characterized by 
hypoactive delirium behaviors, by decreased alertness and attentiveness, and by altered 
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physiological functioning. In both cases, the terminal delirium episodes were longer and the 
delirium was progressively more severe. During their terminal episodes, hypoactive delirium 
behaviors were predominant. However, Mrs. C and Mr. G exhibited intermittent periods of 
hyperactive behavior specifically restlessness during their terminal episodes.  
Mr. D’s dying trajectory and delirium episodes were different from Mrs. C’s and Mr. 
G’s. He had one documented delirium episode 44 days before his death that coincided with 
urosepsis and subsequent hospitalization. Mr. D’s death was precipitated by an acute event 
that caused severe metabolic acidosis and organ failure. His wife reported that he exhibited 
hyperactive delirium behaviors—agitation and restlessness—prior to being intubated the 
night before he died. According to his medical record, he was obtunded and had an altered 
mental status upon arrival in the Emergency Room. His mental status fluctuated with 
treatments prior to being intubated.   
Delirium episodes in patients who died were characterized by significant 
physiological instability. Physiological parameters tended to stabilize prior to or with 
resolution of delirium episodes. During the persistent episodes that preceded death, as in Mrs. 
C’s and Mr. G’s cases, the physiological parameters demonstrated variability with increasing 
instability in the days prior to death.    
 
Delirium Episodes in Participants Who Lived 
The four patients who were alive at the end of the study included: Mr. A, Mr. B, Mr. 
E, and Mr. F. Each had one delirium episode. Their delirium episodes occurred in the context 
of treatment, except in Mr. E’s case. His episode was observed the morning after he returned 
from an out-of-state trip that included visiting family and attending his sister’s funeral.  Mr. 
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A’s episode occurred following his 3rd 28-day cycle of Sutent, an investigational agent, at a 
dose of 75 mg per day. During this treatment period, he had experienced significant fatigue 
and intermittent nausea and vomiting. Mr. B and Mr. F each had a delirium episode 
postoperatively. Mr. B’s delirium episode was documented 6 days following his hepatic lobe 
resection, and Mr. F’s, 3 days after his esophagogastrectomy.    
The delirium episodes in the participants who lived were short in duration. Mr. A’s 
delirium episode consisted of 2 consecutive positive assessments, while the other 
participants’ episodes consisted of 1 positive assessment. In each episode, the severity of 
delirium was mild. NEECHAM scores at the time of positive delirium assessments ranged 
between 20 and 24.   
Each of the delirium episodes in the participants who lived were classified as 
hypoactive. All of the participants exhibited a decrease in their levels of alertness and 
attention. They also demonstrated the following hypoactive behaviors: sparse or slowed 
speech, lethargy, and slowed movements. In addition, staring was observed in three 
participants (Mr. A, Mr. B, and Mr. E), and apathy in two (Mr. A and Mr. E).  
 
Comparison of Delirium Episodes that Reversed in Participants Who Died to Delirium 
Episodes in Those Who Lived 
 
The reversible delirium episodes in participants who died were similar to the delirium 
episodes in those who lived. The delirium episodes were short in duration. All but one were 
characterized by hypoactive delirium behaviors. Mr. D’s episode coinciding with his 
urosepsis and hospitalization was mixed but hyperactive delirium behaviors were 
predominant. The severity of delirium was mild in all episodes in participants who lived. 
Similarly, the severity of delirium was mild in all but two of the reversible episodes in 
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participants who died. Mr. G’s first three delirium episodes were mild in severity. His fourth 
episode that preceded his final episode was more severe. His lowest NEECHAM score 
during this episode was 19. Mr. D’s delirium also was severe. His lowest NEECHAM score 
was 12.  
 
Research Question 2: How does delirium vulnerability change over time and in relationship 
to the development of delirium in older cancer patients at the end of life? 
 
 The literature on delirium in the elderly and in cancer patients, previously reviewed, 
reports a number of risk factors for delirium including: impaired cognitive functioning; 
limited physical functioning; depression; physical symptoms such as pain; medications; 
nutritional and metabolic abnormalities, dehydration, and hypoxia. These risk factors, or 
vulnerability factors, were examined in the older adults with advanced cancer in order to 
determine how the factors change over time during palliative treatment and at the end of life, 
and in relationship to the development of delirium.   
 
Cognitive Functioning 
 Table 4.12 summarizes the participants’ MMSE scores. Baseline MMSE scores 
tended to vary among the participants. Discrepancies in their MMSE scores may be partially 
attributed to different levels of education and literacy, ethnicity, and other lifestyle and 
environmental factors. In most participants, MMSE scores fluctuated slightly from 
assessment to assessment. When measured during episodes of delirium, MMSE scores were 
decreased.  
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Table 4.12. Summary of participants’ MMSE scores 
 
Participant 
 
Number of 
Assessments 
 
Mean 
 
SD 
 
Range 
 
 
Mr. A 
 
49 
 
29.4 
 
0.82 
 
27 – 30 
 
Mr. B 
 
20 
 
27.9 
 
1.57 
 
23 – 30 
 
Mrs. C 
 
- 
 
- 
 
- 
 
- 
 
Mr. D 
 
50 
 
21.9 
 
2.33 
 
14 – 25 
 
Mr. E 
 
22 
 
28.0 
 
1.51 
 
25 – 30 
 
Mr. F 
 
21 
 
18.3 
 
1.87 
 
15 – 22 
 
Mr. G 
 
25 
 
21.9 
 
3.19 
 
14 – 28 
 
 
 
 
Figure 4.18 shows the trajectory or Mr. A’s MMSE scores. Interestingly, he scored 
30/30 on the MMSE during his first positive delirium assessment. During this assessment, 
however, he required more direction than usual to remain focused, and it also took him 
longer to respond to questions and to complete the instruments. Two days later, he remained 
positive for delirium; his MMSE score was 27—one of his lowest. He was unable to 
determine the correct date and he was unable to recall two of the three objects that had been 
presented. 
. 
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Figure 4.18. Trajectory of Mr. A’s MMSE scores 
 
No specific pattern of decline in MMSE scores was noted prior to delirium episodes 
except in Mr. G’s case (Figure 4.19). Overall, his MMSE scores declined over the study as he 
experienced disease progression and episodic delirium, and as his death approached.  Mr. F’s 
MMSE scores increased slightly throughout the study. It is likely that he became more 
familiar with the instrument and more comfortable with questioning over time.  Mrs. C’s 
MMSE trajectory could not be evaluated because she only completed the MMSE completely 
during three of her first six assessments. Her percentage of correct responses on the MMSE 
ranged from 0.86 to 1.00.  
 
 158 
 
Figure 4.19. Trajectory of Mr. G’s MMSE scores 
 
The frequency and distress associated with cognitive symptoms varied among the 
participants. Five reported frequent cognitive symptoms: > 2 symptoms at 60% or more 
assessments. In contrast, two participants, Mr. A and Mr. F, reported cognitive symptoms at 
< 33% of assessments. The most frequently reported cognitive symptom was difficulty 
remembering (n = 103), followed by difficulty concentrating (n = 99), feeling drowsy (n = 
81), and feeling confused (n = 64). Among participants, mean cognitive symptom distress 
scores ranged from 0.15 to 2.40. The participants reporting more frequent cognitive 
symptoms and higher cognitive symptom distress tended to be older (Mr. B, Mr. E, Mrs. C), 
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were closer to death (Mrs. C, Mr. G, Mr. D), and/or had baseline cognitive impairment (Mr. 
E). 
 
Physical Functioning 
 Overall, particularly among patients who died, physical functioning declined over the 
course of the study and prior to delirium episodes. After periods of initial stability, Mrs. C 
and Mr. G experienced drops in their IADL and PADL scores one to two weeks before their 
first delirium episodes. Mrs. C’s scores continued to drop during the period between her first 
and second delirium episodes. Mr. G’s scores showed some variability but, overall, dropped 
over the study and prior to subsequent delirium episodes. At enrollment, Mr. D’s PADL 
score was 14, indicating that he was independent in all PADLs. His PADL score remained at 
14 until his first hospitalization for urosepsis. His initial IADL scores were variable, but then 
stabilized for a period before his first hospitalization. After the hospitalization, Mr. D’s IADL 
and PADL scores fluctuated. His IADL score never returned to its baseline level. He was 
independent in his PADLs for a short period after the hospitalization but throughout the 
remainder of the study he exhibited variability in his ability to perform PADLs.   
Figure 4.20 shows the trajectory of Mrs. C’s OARS scores. In Mrs. C’s case, her 
PADL score dropped two weeks before her first episode primarily because the frequency of 
her incontinence increased. After that 2-point drop, her PADL score was stable until the 
delirium episode. Mrs. C’s IADL score dropped steeply over the two weeks prior to her first 
delirium episode. In Mr. G’s case, both his PADL and IADL scores dropped during the week 
prior to his first delirium episode. His IADL score dropped more sharply than his PADL 
score.  
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Figure 4.20. Trajectory of Mrs. C’s OARS scores 
 
Mrs. C’s IADL and PADL scores continued to drop during the 21-day period between 
her first delirium episode and her second episode preceding her death. Her IADL score 
dropped steadily during this period, while her PADL score plateaued at 7 for two 
assessments a week apart. At the time of her second delirium episode, Mrs. C was completely 
bedbound and dependent in all activities of daily living. 
 Figure 4.21 shows the trajectory of Mr. G’s OARS scores. Mr. G’s IADL score 
dropped sharply during the week prior to his first delirium episode. His PADL score also 
dropped. During that week, Mr. G had increased shortness of breath and required increased 
amounts of oxygen supplementation to maintain his oxygen saturation in the low to mid 90’s. 
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He was not able to go out as he normally did, and he required increased assistance from his 
family and hospice caregivers.  
 
 
Figure 4.21. Trajectory of Mr. G’s OARS scores 
 
 After a slight increase, Mr. G’s PADL scores dropped slowly but steadily over the 
remainder study until his death. On Day 46, his PADL score dropped to 5 from 10 at the 
previous assessment, a week earlier. At the assessment on Day 46, Mr. G also reported an 
increase in symptoms and symptom distress, and he had a significant increase in his GDS 
score—from 3 to 11. A week later on Day 39, his IADL and PADL scores rebounded 
slightly, but then began to drop steadily until his death.  
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 Figure 4.22 shows the trajectory of Mr. D’s OARS scores. At the beginning of the 
study, Mr. D performed his PADLs independently. He initially exhibited variability in his 
ability to complete IADLs, but after the first 60 days, he achieved stability at an improved 
level of functioning. After being hospitalized with urosepsis between Day 151 and Day 146, 
both his PADL and IADL scores, dropped markedly.  
 After the hospitalization, Mr. D’s IADL scores never returned to baseline. His PADL 
score returned to baseline for a short period, but then fluctuated before stabilizing at a lower 
level. After the hospitalization, Mr. D stopped driving. In fact, he rarely went out of the 
house except for clinic appointments. Mr. D spent most of his time either sitting or lying on 
the sofa or in bed. Mr. D’s OARS scores did not show any other significant decline prior to 
his delirium episode. Following the episode, his IADL score was more decreased. At the 
assessment prior to his death, Mr. D’s PADL score was more decreased.  
 
Figure 4.22. Trajectory of Mr. D’s OARS scores 
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Figure 4.23 shows the trajectory of Mr. A’s OARS scores. In general, his PADL 
scores were stable throughout the study. Most of the time, he was completely independent in 
performing his PADLs.  He did experience slight intermittent declines in his PADL scores 
while being treated with Sutent. In contrast, after a period of initial stability and minimal 
deficit, his IADL score dropped markedly during the first three cycles of Sutent and prior to 
his delirium episode. His IADL scores exhibited variability over the remainder of the study 
but had improved by the end of the study after the Sutent dose was decreased.  
 
 
Figure 4.23. Trajectory of Mr. A’s OARS scores 
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 Overall, physical functioning declined prior to delirium episodes. Mr. B and Mr. F 
had delirium while hospitalized during their postoperative periods. As would be expected, 
during their perioperative periods, their IADL and PADL scores declined (See Figure , p. and 
Figure , p). While physical functioning was not measured during hospitalizations, both 
exhibited limited functioning when they developed delirium postoperatively. Their PADL 
and IADL scores returned to baseline as they recovered. The trajectories of Mr. E’s IADL 
and PADL scores were relatively stable throughout the study (See Figure, p. ). His IADL 
score was decreased 2 points from his baseline at the assessment on week prior to his positive 
delirium assessment. His PADL score was unchanged.  
 
Depression 
 The 15-item Geriatric Depression Scale (GDS-15) was used to identify depression. A 
score > 5 is indicative of probable depression. Table 4.13 summarizes the participant’s GDS 
scores. Overall, depression scores varied both within and between individuals. All but one of 
the participants (Mr. F) had intermittent GDS scores indicative of depression. Only one 
participant (Mr. A) had a prior history of depression that was currently being treated with 
antidepressant medications.  
Depression scores did not show any particular pattern in relation to the development 
of delirium. Four patterns were identified after examining the GDS score trajectories in 
relation to other variables: 1) GDS scores < 5 (no depression); 2) most GDS scores > 5 
(probable depression); 3) most GDS scores < 5 but with intermittent spikes, and 4) 
progressive increase in GDS scores.  
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Table 4.13. Summary of participants’ GDS scores 
 
Participant 
 
Number of 
Assessments 
 
 
Mean 
 
SD 
 
Range 
 
 
Mr. A 
 
46 
 
2.0 
 
2.48 
 
0 – 13 
 
Mr. B 
 
18 
 
6.2 
 
1.46 
 
4 – 10 
 
Mrs. C 
 
4 
 
6.0 
 
0.82 
 
5 – 7 
 
Mr. D 
 
43 
 
3.3 
 
0.97 
 
1 – 6 
 
Mr. E 
 
20 
 
5.8 
 
1.39 
 
4 – 10 
 
Mr. F 
 
20 
 
0.9 
 
0.64 
 
0 – 2 
 
Mr. G 
 
13 
 
6.2 
 
3.17 
 
0 – 11 
 
 
 
Table 4.14. Percentage of GDS scores < 5 and > 5 by participant 
 
Participant 
 
Number of 
Assessments 
  
Frequency with GDS 
score < 5 
 
Frequency with 
GDS score > 5 
 
    
n  
 
% 
 
n 
 
% 
 
 
Mr. A 
 
46 
  
43 
 
93.5 
 
3 
 
6.5 
 
Mr. B 
 
18 
  
7 
 
38.9 
 
11 
 
61.1 
 
Mrs. C 
 
4 
  
1 
 
25.0 
 
3 
 
75.0 
 
Mr. D 
 
43 
  
42 
 
97.7 
 
1 
 
2.3 
 
Mr. E 
 
20 
  
7 
 
35.0 
 
13 
 
65.0 
 
Mr. F 
 
20 
  
20 
 
100 
 
0 
 
0 
 
Mr. G 
 
13 
  
7 
 
53.8 
 
6 
 
46.2 
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Figure 4.24 shows the trajectory of Mr. F’s GDS scores. He did not show evidence of 
depression. His GDS scores were consistently low. His highest GDS score was 2. Even 
though he had been recently diagnosed and was undergoing intensive treatment, it is likely 
that Mr. F’s overall attitude and outlook on life played a role in his low GDS scores.  
 
Figure 4.24. Trajectory of Mr. F’s GDS scores 
 
Mr. B, Mrs. C, and Mr. E had consistently higher GDS scores—with most > 5.  These 
participants may have been experiencing depression related to their overall conditions or 
situations—recent cancer diagnosis, disease progression, or impaired function. For example, 
Figure 4.25 shows the trajectory of Mr. B’s GDS scores. He had been recently diagnosed 
with liver cancer and had undergone chemo-embolization of the tumor, which left him 
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extremely fatigued and with decreased appetite. He often talked about the negative changes 
in his overall health and function following this treatment. He did not want to undergo a 
second chemo-emobolization, the usual treatment course, but instead sought surgical 
resection—even though he was a high-risk surgical candidate. Both Mr. B and Mr. E 
exhibited some fluctuation in their GDS scores. Intermittent spikes appeared to be associated 
with increased symptom distress, and in Mr. E’s case, learning of disease progression and 
preparing for the sale of his house and move.   
 
 
Figure 4.25. Trajectory of Mr. B’s GDS scores 
 
The trajectory of Mr. A’s GDS scores (Figure 4.26) provides an example of the third 
pattern. Most of his GDS scores were < 5 but he had intermittent or occasional spikes in his 
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scores. At the assessment on Day 112, Mr. A’s GDS score following Cycle #4 of Sutent was 
13. His MMSE score was 28 and his total NEECHAM score was 27. He reported an increase 
in his total number of symptoms and an increase in his global, psychological, and physical 
symptom distress (Figure 4.27). He also reported a decline in his physical functioning, 
particularly in performing IADLs (Figure 4.28).  
 
 
 
Figure 4.26. Trajectory of Mr. A’s GDS scores 
 169 
 
Figure 4.27. Trajectory of Mr. A’s symptom distress scores 
 
Figure 4.28. Trajectory of Mr. A’s OARS scores 
 170 
 As an example of the fourth pattern, overall, Mr. G’s GDS score trajectory (Figure 
4.29) shows a progressive increase throughout the study as his condition declines and as he 
approaches death. When Mr. G enrolled in the study, he was living independently and, as 
part of his usual daily routine, he drove in to town—approximately 25 miles each way—to 
visit with family and friends. His GDS scores were low. As his condition declined, his scores 
began to fluctuate, dramatically at times, depending on his functional ability and symptom 
distress. Near the end of life as his cognitive and physical functioning declined more steadily, 
his GDS scores remained consistently higher, indicating depression. Although not nearly as 
dramatic, Mr. D’s GDS score trajectory demonstrated a similar pattern.  
 
 
 
Figure 4.29. Trajectory of Mr. G’s GDS scores 
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Figure 4.30. Trajectory of Mr. G’s symptom distress scores  
 
Figure 4.31. Trajectory of Mr. G’s OARS scores 
 172 
Symptom Prevalence and Distress 
 An adapted version of the Memorial Symptom Assessment Scale – Short Form 
(MSAS-SF) was used to measure symptom prevalence and distress. The average total 
number of symptoms reported by participants at each assessment ranged between 3.7 and 
22.8. All but one participant (Mr. F) reported, on average, 6 or more symptoms at each 
assessment. Overall, lack of energy was the most common and most distressing physical 
symptom. Taste changes and lack of appetite, also common, compound nutritional risk.  
Throughout the study, in the patients who died, symptoms and symptom distress 
increased. Mrs. C showed a pattern of increasing symptoms and symptom distress before she 
requested to stop completing the instruments. It is likely that this contributed to her request to 
stop. While Mr. G’s symptom distress fluctuated, it was consistently high. His symptom 
distress increased prior to his first delirium episode, and peaked at the last assessment on Day 
12. Mr. D’s symptom distress increased after his first hospitalization for urosepsis. Notably, 
at most assessments, his cognitive symptom distress was higher than his physical or 
psychological symptom distress.  
Mr. A’s symptom distress tended to fluctuate with his treatment. He reported 
increased cognitive distress during the first 50 days of the study while taking Iressa. He 
reported minimal cognitive symptom distress after that time. After starting the Sutent, his 
global, physical, and psychological symptom distress fluctuated with his treatment cycles. He 
reported increased distress at the end of each cycle until the dose was reduced. Among the 
other participants who lived, symptom distress across the study was relatively stable. Overall, 
Mr. B and Mr. F had lower levels of distress. On the other hand, Mr. E’s symptom distress 
was high throughout the study. At most assessments, his cognitive symptom distress was 
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higher than his global distress, physical distress, or psychological distress. Mr. E had pre-
existing cognitive impairment and significant symptoms associated with his comorbid 
medical conditions—orthostatic hypotension and neurogenic bladder.   
 
Etiologic Patterns and Risk Markers 
 At baseline, the participants who died exhibited risk markers for multiple etiologic 
patterns. All three had metabolic-nutritional pattern markers. In addition, Mrs. C had 
orthostatic pattern markers; Mr. G had hypoxic markers, and Mr. D had hypoxic and 
metabolic-toxic pattern markers. Prior to their first delirium episodes, Mrs. C also had a 
marker for the metabolic-toxic pattern and Mr. D exhibited a marker for the orthostatic 
pattern. They also had additional markers for their previously exhibited patterns.  
 
Table 4.15. Etiologic patterns at baseline by participant 
Participant Metabolic- 
Nutritional 
Hypoxic Metabolic-
Toxic 
Orthostatic-
Dehydration 
Chronic 
Cognitive 
Impairment 
 
Mr. A 
 
X 
   
X 
 
 
Mr. B 
 
X 
    
 
Mrs. C 
 
X 
   
X 
 
 
Mr. D 
 
X 
 
X 
 
X 
  
 
Mr. E 
 
X 
  
X 
 
X 
 
X 
 
Mr. F 
 
 
   
X 
 
 
Mr. G 
 
 
X 
 
X 
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Table 4.16. Etiologic patterns prior to first delirium episode by participant 
Participant Metabolic- 
Nutritional 
Hypoxic Metabolic-
Toxic 
Orthostatic-
Dehydration 
Chronic 
Cognitive 
Impairment 
 
Mr. A 
 
* 
   
* 
 
 
Mr. B 
 
* 
 
X 
 
X 
 
X 
 
 
Mrs. C 
 
* 
  
X 
 
* 
 
 
Mr. D 
 
* 
 
* 
 
* 
 
X 
 
 
Mr. E 
 
* 
  
* 
 
* 
 
* 
 
Mr. F 
 
X 
 
X 
  
* 
 
 
Mr. G 
 
 
* 
 
* 
  
X 
 
* Pattern markers present at baseline 
 
  
 Metabolic-Nutritional Pattern 
 At baseline, all of the participants who died (Mrs. C, Mr. G, and Mr. D), and three 
who lived (Mr. A, Mr. B, and Mr. E) had metabolic-nutritional pattern markers. Mr. A, Mr. 
B, Mrs. C, Mr. D, and Mr. G had experienced significant weight loss. Most exhibited other 
markers including an albumin level < 3.5 g/dl and a lymphocyte count < 1000/cu mm. Mr. 
E’s only marker was a low serum albumin level.   
Mrs. C reported that prior to her cancer diagnosis her weight averaged around 164 
pounds. Prior to her initial abdominal surgery in January 2003, her documented weight was 
136 pounds. Figure 4.32 shows the trajectory of Mrs. C’s weight during the study. At the 
time of enrollment in the study in May 2005, Mrs. C weighed 104.5 pounds. Her body mass 
index was 19.0. During the study, Mrs. C’s weight increased, reflecting generalized fluid 
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retention and, most notably, progressive abdominal ascites. Her last on Day 16 was 111.4 
pounds. Mrs. C’s baseline lymphocyte count was low, and it remained low throughout the 
study. Her baseline albumin level was 3.5 g/dl, but prior to her first delirium episode, it had 
dropped to a low of 2.7 g/dl.   
 
Figure 4.32. Trajectory of Mrs. C’s weight 
 
Prior to his cancer diagnosis in May 2004, Mr. G weighed 261 pounds. Figure 4.33 
shows the trajectory of Mr. G’s weight during the study. Upon enrollment in the study in 
September, 2005, he weighed 234 pounds. Mr. G’s weight declined progressively during the 
study. His last weight 11 days before his death was 196.2 pounds. Mr. G’s lymphocyte count 
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was decreased upon enrollment and throughout the study. He did not have a recent albumin 
level documented in his medical record.   
 
Figure 4.33. Trajectory of Mr. G’s weight 
 
Over the 6-month period between January 2005 and June 2005, prior to enrollment in 
the study, Mr. D had a 17 pound weight loss. Figure 4.34 shows the trajectory of Mr. D’s 
weight during the study. Although Mr. D’s weight fluctuated during the study, the overall 
trend showed a decline—particularly after his first hospitalization. During the study, Mr. D’s 
serum albumin level fluctuated, ranging between 1.8 and 3.5 g/dl. Prior to his delirium 
episode, his albumin level was 2.8 g/dl—an indicator of metabolic-nutritional and metabolic-
toxic risk.  
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Figure 4.34. Trajectory of Mr. D’s weight 
 
Among the patients who lived, Mr. A and Mr. B exhibited metabolic-nutritional risk 
markers at baseline and prior to their delirium episodes. Over the six months prior to 
enrolling in the study, Mr. A lost 13.2 pounds. Figure 4.35 shows the trajectory of Mr. A’s 
weight. During the study, his weight fluctuated significantly with fluid retention caused by 
his treatment. He tended to retain fluid during the two weeks between cycles of Sutent. 
Despite the fluid retention, over the course of the study, Mr. A lost approximately 13 pounds. 
His weight at enrollment was 145.9 pounds, and his last weight was 132.8 pounds. 
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Figure 4.35. Trajectory of Mr. A’s weight 
 
 
During the 6 months prior to enrolling in the study, Mr. B lost 18.5 pounds. His 
weight during the study prior to his surgery fluctuated between 166 and 170 pounds. His 
lowest weight, 163 pounds, was documented at the first home visit after his surgery. His last 
weight was 171 pounds. He often exhibited pedal edema that was worse postoperatively. 
Therefore, his weights reflect fluid retention most likely related to his low albumin level  
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Hypoxic Pattern 
At baseline, two participants, Mr. G and Mr. D, exhibited hypoxic pattern markers. 
Mr. G had a long standing history of COPD requiring supplemental oxygen. At the time of 
enrollment in the study, Mr. G intermittently wore oxygen at 3 liters/minute. He also had a 
documented history of anemia due to thalissemia; his baseline hemoglobin was . A week 
prior to his first delirium episode, Mr. G was admitted to the ER for shortness of breath. 
Subsequently, his oxygen supplementation was increased to 5 liters/minute. It was thought 
that hypoxia contributed to Mr. G’s first delirium episode. At the time of his first positive 
delirium assessment, his oxygen saturation on supplemental oxygen at 5 liters/minute was 
93%. His oxygen supplementation was increased to 6 liters/minute. At the follow-up 
assessment the next day, Mr. G’s oxygen saturation while receiving oxygen at 6 liters/minute 
was 97%.  
Mr. D’s hypoxic risk was related to his low hemoglobin level—thought to be due to 
bone marrow suppression caused by long-term chemotherapy. His baseline hemoglobin level 
was 8.8 gm/dl. During the study, Mr. D experienced instability in his hemoglobin level. In 
January, 2006, Mr. D had increasing shortness of breath. He was hospitalized and transfused 
with 4 units of packed red blood cells after his hemoglobin was determined to be 5.2 g/dl.  
When Mr. D was hospitalized with urosepsis in March 2006, he was positive for delirium 
and his hemoglobin had dropped to 5.3 g/dl. He did not show any evidence of bleeding. It 
was thought that Mr. D’s anemia was due to bone marrow failure caused by long-term 
chemotherapy administration. Mr. D was transfused again during this hospitalization. His 
hemoglobin level prior to discharge was 7.3 g/dl. A month later, when hospitalized again, the 
night before his death, Mr. D’s hemoglobin was 4.9 g/dl. 
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Other participants had hypoxic pattern markers at the time of their positive delirium 
assessments. At the time of her second delirium episode, Mrs. C exhibited a hypoxic pattern 
marker—the need for supplemental oxygen. Postoperatively and at the time of his positive 
delirium assessment, Mr. F, also was receiving supplemental oxygen.  
 
Metabolic-Toxic Pattern 
Risk markers for the metabolic-toxic pattern were common among participants at 
baseline and at the time of delirium episodes. Although no participant had a baseline 
diagnosis of liver or renal failure, some exhibited impaired liver or renal function. For 
example, while receiving the higher dose of Sutent and prior to his positive delirium 
assessment, Mr. A’s bilirubin level was increased at 1.6. Following his hepatic resection and 
prior to his positive delirium assessment, Mr. B’s bilirubin level also was increased at 1.4. 
Mr. D had chronic renal insufficiency. His baseline creatinine level was 1.5 mg/dl. Each time 
he was hospitalized for urosepsis and dehydration, Mr. D exhibited worsened renal function. 
At the first hospitalization, his creatinine level was 4.5 mg/dl. At the second hospitalization 
when he was positive for delirium, his creatinine level was 2.6 mg/dl. During each 
hospitalization, his creatinine level returned to baseline with rehydration. Mr. E also had 
chronic renal insufficiency. Throughout the study, his creatinine level ranged between 1.4 
and 1.6 mg/dl. Many of the participants also had low serum albumin levels during the study.    
 
Orthostatic-Dehydration Pattern 
Orthostatic-dehydration pattern markers also were common. Upon enrollment, four of 
the older adults with advanced cancer had markers for the orthostatic-dehydration pattern; 3 
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had a BUN/Cr ratio > 20 (Mr. A, Mrs. C, and Mr. F) and the other had orthostatic symptoms 
(Mr. E). Prior to developing delirium, all of the participants had markers for the orthostatic-
dehydration pattern. Among those without markers at enrollment, Mr. B had BUN/Cr ratio > 
20 prior to his delirium episode; Mr. G had orthostatic symptoms; and Mr. D had dehydration 
and hypovolemia with vital function instability. Mrs. C had additional pattern markers prior 
to her first delirium episode. Her physician thought that she was dehydrated, and she 
intermittently exhibited orthostatic symptoms.  
  
 Chronic Cognitive Impairment Pattern 
Mr. E was the only participant who had pattern markers for chronic cognitive 
impairment. Mr. E and his wife, as well as his medical record, noted that he had intermittent 
mental status problems—episodes of confusion. He also needed assistance with taking 
medications and with completing other IADLs. Although he also had baseline risk markers 
for other patterns (metabolic-nutritional and orthostatic), Mr. E’s delirium episode fit with 
what is commonly seen in older adults with chronic cognitive impairment or low cognitive 
reserves. His delirium occurred in the morning after he had returned late the previous night 
from an out-of-state trip to attend his sister’s funeral and to visit with family.    
 
Medications and Treatment 
At baseline, most participants were on multiple medications for the management of 
chronic illnesses, their cancer, and cancer symptom management. All of the participants 
except Mr. E were taking their medications independently. Therefore, it was difficult to 
determine specific dosages of medications taken and whether participants were taking their 
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medications correctly. In some cases, it is likely that medications and side effects played a 
role in the development of delirium. 
Diagnosed with advanced colon cancer in 2003, Mrs. C had received at least three 
lines of treatment prior to enrollment in the study. At the time of enrollment she was 
receiving Irinotecan and Cetuximab. After three cycles of Irinotecan and one cycle of 
Cetuximab, Mrs. C’s disease progressed. She was enrolled in a clinical trial investigating the 
effectiveness of a vaccine for tumors with Ras mutation. The trial involved five weekly 
vaccine injections administered in the General Clinical Research Center (GCRC) at UNC. 
During the course of the vaccine trial, Mrs. C began to exhibit changes in her physical 
functioning and behavior. She also began to experience increased abdominal and back pain. 
Up to this point, Mrs. C reported acceptable pain control with Advil and Tylenol. She started 
on Percocet during the third week of the vaccine trial. Mrs. C noted that one Percocet tablet 
made her too sleepy. She often took one-half of a tablet during the day, but took a whole 
tablet at night before going to bed. Mrs. C received the final vaccine and had a CT scan to 
evaluate the status of her disease on Day 32. On the following day (Day 31), Mrs. C’s 
caregiver noted that she was nauseated and that she ate and drank minimal amounts. Mrs. C 
took compazine to control the nausea. The next day (Day 30), at the scheduled weekly 
assessment, Mrs. C was positive for delirium. It is likely that the combination of the above 
factors contributed to the development of delirium.  
Prior to Mr. G’s first delirium episode, he was self-administering multiple pain 
medications including topical fentanyl, percocet, and concentrated morphine solution. After 
that episode, the hospice nurse changed his regimen to long-acting morphine and immediate 
release morphine tablets for breakthrough pain. After the episode, Mr. G’s family and friends 
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began to stay with him 24 hours a day. His caregivers administered his scheduled 
medications including the long-acting morphine, but he still self-administered the morphine 
for breakthrough pain. For a period, although his level of pain fluctuated, overall, his pain 
control was improved.   
At the time of his scheduled weekly visit on Day 74, Mr. G was positive for 
delirium—his second epsiode. He had been to an appointment at the cancer clinic that 
morning. The clinic note for that visit indicated that Mr. G was somnolent. His caregiver 
reported that she discovered that he had taken extra doses of pain medication prior to going 
to the clinic appointment.  
After Mr.A experienced disease progression, he was enrolled in clinical trial 
investigating the effectiveness of Sutent, an antiangiogensis agent, against non-small cell 
lung cancer. During the trial particularly while receiving a higher dose of the drug, he 
experienced   – physiologic instability (hypertension), increased fatigue, intermittent nausea 
and vomiting, weight gain – fluid retention between cycles, variable shortness of breath 
(increased with fluid retention), hypothyroid, and persistent cough. Mr. A’s delirium episode 
occurred after his 3rd 28-day cycle of Sutent. His overall function and symptom distress 
improved over time as the Sutent dose was decreased.  
As previously noted, Mr. B and Mr. F had an episode of delirium while hospitalized 
following their surgical procedures. Both were receiving pain medications at the time. During 
the week prior to his positive delirium assessment, Mr. B had an episode of tachycardia that 
required readmission to the ICU.  
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Research Question 3: How is delirium in older adults with advanced cancer near the end of 
life similar to or different from delirium in hospitalized older cancer patients? 
 
 Similarities were found between delirium in the older adults with advanced cancer 
near the end of life and delirium in the hospitalized older cancer patients. First, delirium was 
common in both groups. Fifty-six percent of the hospitalized patients and all (n = 7) of the 
patients with advanced cancer experienced at least one episode of either mild or severe 
delirium, or both. Mild delirium was more likely to resolve. Persistent delirium was common 
in the hospitalized older cancer patients and in the older adults with advanced cancer who 
died. Eight of the 10 hospitalized patients who died had persistent delirium at hospital 
discharge; one who died two days after discharge had persistent severe delirium. Likewise, 
two of the older adults with advanced cancer who died had persistent severe delirium in the 
last two weeks prior to death.  
The older adults with advanced cancer near the end of life and the hospitalized older 
cancer patients exhibited markers for multiple etiologic patterns. Most of the patients in each 
group had metabolic-nutritional markers. Hypoxic, metabolic-toxic, and orthostatic-
dehydration pattern markers were also common. In the hospitalized older cancer patients, 
pattern markers were assessed at the time of hospital admission. In the older adults with 
advanced cancer, pattern markers were determined at the time of enrollment into the study, 
and were examined over time. The type and number of pattern markers increased prior to 
delirium episodes in these patients.  
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Research Question 4: What issues are associated with studying delirium in older adults with 
advanced cancer? 
 
 Multiple issues were identified in conducting this research. The three specific issues 
that will be discussed are: 1) the changing nature of palliative cancer treatment in older 
adults; 2) methodological issues related to recruiting and measurement, and 3) the role of 
family caregivers in monitoring for delirium.   
 
Changing Nature of Palliative Cancer Treatment in Older Adults 
One of the most striking observations in conducting this research related to the nature 
of palliative cancer treatment among the older adults. It was either prolonged or intensive, or 
both. Five of the seven older adults with advanced cancer had been diagnosed for over a year 
prior to enrollment in the study. Each of them had received multiple courses of treatment, 
and in effect almost continuous treatment, from the point of diagnosis or recurrence to 
enrollment in the study.  
Palliative cancer treatments among the older adults also were intensive. Mr. B, an 87-
year old gentleman with moderate COPD, initially had chemoablation for a hepatic tumor. 
Although he was a high-risk surgical candidate, after a two-month recovery period, he had a 
hepatic lobectomy for definitive treatment. Mr. F, a 74-year old gentleman, underwent triple 
modality therapy, combined chemotherapy and radiation followed by surgical resection, as 
part of a clinical trial for esophageal cancer. His treatment was also definitive. Mrs. C, Mr. A, 
and Mr. G participated in clinical trials after multiple courses of treatment. Mr. D had been 
on and off chemotherapy for approximately 10 years. During the last four months of his life, 
it appeared as though he had bone marrow failure associated with long-term chemotherapy 
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administration. Even with intermittent transfusions, he was unable to maintain a normal 
hemoglobin level. Mr. E had been on hormone ablation therapy for 5 years. 
The prolonged and intensive nature of palliative cancer treatment raises important 
questions about the impact of treatment in older adults. Over time, how does long-term 
cancer treatment in older adults, affect their physiological and functional reserves? How do 
changes in physiological and functional reserves affect treatment response and outcomes? 
What are the primary markers of decline in reserves? What interventions would help to 
prevent or slow the loss of reserves?  
 
Issues Related to Recruitment and Measurement 
In preparing to conduct the pilot study, the investigator found that he or a member of 
his research team needed to be involved in recruiting participants. However, it was helpful to 
have a supportive introduction by a care team member – physician, nurse coordinator, or 
clinical research nurse.  Six of the seven participants in this study were recruited after a brief 
introduction of the study and investigator by the care provider. In this study, if prospective 
participants did not either agree or refuse to participate at the initial introduction of the study, 
then the investigator requested permission to contact them within two weeks of the initial 
introduction to see whether or not they would like to participate in the study.   
In this study, recruitment was affected by limited human and financial resources. 
After enrolling a group of participants into the study, the investigator could not be both in the 
clinic recruiting more participants and in the field collecting data.  
The timing of recruitment was also challenging. The investigator did not approach 
patients during “crisis” periods—at the time of a new diagnosis, just getting established with 
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new treatment team, making decisions about treatment, and when learning about disease 
progression. Because of this, some prospective participants may have been missed. Initially, 
functional status was going to be used as an indicator for eligibility—Eastern Cooperative 
Oncology Group (ECOG) performance status > 2. However, few patients with a performance 
status at this level are seen regularly in the oncology clinic. Also based on the findings of this 
study, functional status may not be a good marker. When functional status begins to drop, 
life-expectancy may be too short for longitudinal follow-up. If the change in function is 
associated with a transition into the terminal phase, the patient and family also may feel too 
overwhelmed to participate in research. There were challenges with recruiting hospice 
patients.  No hospice patients were enrolled into either the pilot study or the follow-up study. 
Potential issues with hospice patient recruitment will be discussed in Chapter 5. 
 
Role of Family Caregivers in Monitoring for Delirium 
The prevalence of delirium in the home setting is not known, but based on clinical 
literature and experience it is likely a common problem. Since daily in-home delirium 
assessments by the investigator were not feasible, identified family caregivers were asked to 
monitor patients for signs of delirium and, depending on whether or not they lived with the 
patient, to complete the Caregiver Confusion Checklist (CCC) once or twice a day. Family 
caregivers were instructed to contact the investigator if two or more signs of delirium were 
noted. When notified, the investigator would conduct a more in-depth delirium assessment.  
Caregivers demonstrated variability in completing the CCC. Some caregivers 
documented comments about treatment, activities, behavior, and other things. However, the 
caregiver comments were not always consistent with ratings on the CCC or with the 
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investigator’s observations. For example, at times when Mrs. C’s CCC score was noted as 0, 
her caregiver documented “didn’t talk to (sic) much. Mostly quiet!” On other days, she noted 
that Mrs. C “stayed in the bed off and on – sleepy,” but this was not reflected in the CCC 
score. On the day before Mr. A was positive for delirium at the scheduled weekly 
assessment, Mrs. A documented notes about changes in his behavior and thinking—“slept 
most of day” and “responses to questions are a little slow but always appropriate”—but she 
scored the CCC as 0.  Another caregiver, Mrs. E identified and documented alterations in Mr. 
E’s cognitive and behavioral functioning on the CCC and in her comments but did not 
contact the investigator because she did not want to call attention to Mr. E’s impaired 
functioning. Mr. E was aware of his difficulties and early in the study, he told Mrs. E that he 
did not want her to note any problems on the CCC. He also expressed disappointment when 
he performed poorly on the MMSE.  
Some caregivers did not complete the CCC on a regular basis. There were blank 
pages. As in the pilot study, when patients were hospitalized, not all caregivers completed the 
CCC’s consistently. The investigator also occasionally noted caregivers completing several 
pages at the time of the weekly assessment.
  
CHAPTER FIVE 
DISCUSSION 
 This chapter discusses the findings from this research. First, the discussion focuses on 
the findings related to delirium in the sample of hospitalized older cancer patients and in the 
older adults with advanced cancer near the end of life. Second, it discusses delirium 
vulnerability factors including clinical risk markers and etiologic patterns. Finally, it 
addresses methodological issues associated with studying delirium in older adults with 
advanced cancer in the outpatient or home setting. Limitations of the study and implications 
for future research and practice are integrated into the discussion.  
 
The Nature and Course of Delirium 
Delirium was common in the hospitalized older cancer patients and in the older 
cancer patients with advanced disease cared for at home. The prevalence and incidence of 
delirium in the sample of hospitalized patients were 38% and 30%, respectively. The 
cumulative rate of delirium was 56%. In another sample of mostly older cancer patients 
(median age 73 years), Tuma & DeAngelis (2000) found that 34% had confusion at 
admission, and another 66% developed confusion during hospitalization. In contrast, 
Ljubisavljevic and Kelly (2003) found a lower incidence of delirium (18%), but their patients 
were younger (mean age 53.4 years). 
Studies of delirium in patients with advanced cancer have found that up to 90% 
develop delirium in the weeks preceding death (Bruera, Miller et al., 1992; Lawlor, Gagnon
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 et al., 2000, Massie et al., 1983, Minigawa et al., 1996; Morita et al., 2001). Findings from 
the secondary analysis and the case studies also show that delirium is common in older 
cancer patients at the end of life.  Eight of the ten hospitalized older cancer patients near the 
end of life had delirium. In most of the patients, delirium tended to fluctuate. All of the 
patients with delirium during hospitalization had delirium at discharge.  All of the older 
adults with advanced cancer who died had at least one episode of delirium.   
 
Delirium Severity  
 The findings suggest that older cancer patients experience different levels of delirium 
severity. In the hospitalized older cancer patients, 41 patients had delirium during 
hospitalization prior to discharge; 18 had mild delirium and 23 had severe delirium. At 
discharge, delirium was resolved in 13 patients, but persisted in 28—mild in 16 and severe in 
12. Two additional patients who had no delirium during hospitalization had mild delirium at 
discharge.  
All of the older adults with advanced cancer experienced delirium episodes that 
resolved or reversed. Reversible episodes tended to be mild and short in duration. In most 
cases, delirium seemingly resolved on its own without specific delirium-focused 
interventions. In two patients who died, delirium that preceded death was persistent and more 
severe.  
 
Subsyndromal Delirium 
Subsyndromal delirium is common in hospitalized older patients (Cole, McCusker, 
Dendukuri, & Han, 2003; Levkoff et al., 1996). In the hospitalized older cancer patients, 21 
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patients had mild delirium (NEECHAM score 20-24) at admission. It is likely that some of 
these patients had subsyndromal delirium. Subsyndromal delirium also was noted in the older 
adults with advanced cancer. They intermittently exhibited delirium symptoms and their 
NEECHAM scores fell between 20 and 24, but the CAM was not positive.  
Two studies of delirium in patients with advanced cancer at the end of life suggest 
that subsyndromal delirium is common. In a sample of hospice inpatients with cancer, 
Gagnon et al. (2000) found that the prevalence and incidence of delirium symptoms was 
higher than confirmed delirium. The prevalence of delirium symptoms was 20.2% whereas 
the prevalence of confirmed delirium was 13.3%. The incidence of delirium symptoms 
during hospitalization was 52.1%, while the incidence of confirmed delirium was 32.8%. In 
the current study, all of the older adults with advanced cancer had at least one positive 
delirium assessment (NEECHAM score 20-24 and positive CAM). In addition, six of the 
seven had at least one assessment indicative of subsyndromal delirium (NEECHAM score 
20-24 and negative CAM). It is likely that the incidence of subsyndromal delirium in these 
patients is underestimated due to the frequency of assessments.   
In this study, changes in behavioral performance among the older adults with 
advanced cancer often preceded changes in cognitive functioning and delirium. Typically, in 
monitoring patients for delirium, the emphasis is place on impaired cognitive functioning 
(attention, orientation, perception, and memory). However, while altered cognitive 
functioning is a primary component of delirium, it may not always be the primary 
manifestation. In the current study, cognitive function was often maintained except during 
delirium episodes and in some cases, even during delirium episodes, some aspects of 
cognitive functioning—orientation and memory—were minimally affected. Jenkins et al. 
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(2000) defined cognitive impairment on the basis of a MMSQ score less than 24/30 or less 
than 80% if the patient could complete only part of the test. Ten of 91 patients (11%) were 
found to have evidence of delirium by DSM IV criteria, despite a MMSQ score in the normal 
range. Behavioral changes may be primary marker of decline and risk, or an early marker of 
impending delirium. 
Sorensen Duppils and Wikkblad (2004) found that most patients demonstrate a 
pattern of behavioral changes and early symptoms of approaching delirium. They monitored 
103 hip surgery patients for behavioral changes prior to delirium. Of the patients who met 
DSM criteria, 62% exhibited behavioral changes before delirium onset. The most common 
behavioral changes included anxiety, disorientation, decreased psychomotor activity, 
memory impairment, increased psychomotor activity, frequent calls for attention, irritation, 
incoherent speech and reduced level of consciousness. Behavioral changes presented in some 
patients up to 48 hours before delirium onset, but changes were most evident and more 
numerous within six hours of onset.  
In another study by Levkoff et al. (1994), 69% of hospitalized older patients with 
incident delirium had prodromal symptoms prior to developing DSM-III-defined delirium. 
The length of the prodromal period ranged from 1 to 19 days (M 2.7; SD 3.3). Of importance, 
they also found that the presence of certain delirium symptoms—disorientation or fluctuating 
behavior, or both—significantly increased the likelihood of developing delirium.  
 
Delirium Subtypes 
Delirium in the older adults with advanced cancer was most often hypoactive. It was 
characterized by diminished levels of alertness and attention, and by slowed motor and verbal 
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behavior. Otherwise it was of the mixed subtype and included both hypoactive and 
hyperactive features. Mr. D’s delirium episode was predominantly hyperactive. Mrs. C and 
Mr. G’s terminal delirium episodes were classified as mixed but, in both cases, hypoactive 
features were predominant. Delirium subtypes were not evaluated in the sample of 
hospitalized older cancer patients. 
In a study examining delirium subtypes in patients with advanced cancer (Lawlor et 
al., 1998), the hypoactive and mixed delirium subtypes were most common. The hypoactive 
subtype was most common in terminal delirium episodes occurring within 72 hours of death. 
In contrast, Steifel et al (1992) reported that the majority of patients in the last week of life 
had either hyperactive or mixed delirium. However, they used clinical records to identify 
delirium, and hypoactive delirium presentations may not have been recognized and 
documented.   
The predominance of hypoactive delirium among the older adults with advanced 
cancer is important. Nurses have not been quick to identify delirious patients, particularly 
those with mild delirium or hypoactive presentations (Inouye, Foreman, Mion, Katz, & 
Cooney, 2001; Neelon, Champagne, McConnell et al., 1992). There is a widely held belief 
that hypoactive delirium is not as distressing for patients and their caregivers. To the 
contrary, in a study by Breitbart et al. (2002), although more caregivers (88%) reported 
distress associated with hyperactive delirium, 66% of caregivers of patients with hypoactive 
delirium reported severe distress. Among patients with delirium recall, hypoactive delirium 
was just as distressing as hyperactive delirium. In a study by Morita et al. (2004), 34% of 
caregivers reported that somnolence was distressing or very distressing when it occurred 
often or very often.  
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Delirium at Discharge and at Home 
Almost 40% of the hospitalized older cancer patients had persistent delirium at 
discharge; 24% had severe delirium and 16% had mild delirium. Similarly, studies of 
delirium in hospitalized elderly medical patients have found that a significant number of 
patients with delirium during hospitalization have delirium or delirium symptoms at 
discharge and beyond. Levkoff et al. (1992) found that 96% of patients with delirium during 
hospitalization had symptoms of delirium at discharge. O’Keefe and Lavan (1997) monitored 
patients with delirium throughout hospitalization and found that 32% had delirium symptoms 
at discharge. Persistent delirium also has been noted in nursing facility residents with 
delirium during hospitalization; 72% who survived hospitalization had delirium at discharge 
(Kelly et al., 2001).   
The large number of older cancer patients with delirium or delirium symptoms at 
discharge has significant implications for post-hospital care and recovery. Naylor, Stephens, 
Bowles, & Bixby (2005) found that patients with cognitive impairment (delirium, dementia 
or both) during hospitalization and their family caregivers had multiple unmet needs in the 
weeks following hospital discharge. In addition, since most oncology treatment is provided in 
the outpatient setting, the fact that five of the older adults with advanced cancer had at least 
one episode of delirium at home has implications for their care and their caregivers. Delirium 
distresses family caregivers (Brajtman, 2003; Breitbart et al., 2002; Morita et al., 2004), in 
part, because patients with delirium need more assistance with self-care and require close 
monitoring to prevent injury. 
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Delirium Vulnerability 
Severity of Illness and Comorbidity 
Severity of illness and comorbidity are well recognized delirium risk factors. In this 
study, the hospitalized older cancer patients had a significant level of illness severity. Their 
mean APACHE II score (14.9) was similar to the APACHE II scores reported in samples of 
critically ill cancer patients (Sculier, Paesmans, Markiewicz, & Berghmans, 2000; Soares et 
al., 2004) and general MICU patients (Bo et al., 2003). In the hospitalized older cancer 
patients, those with delirium were more severely ill than those without delirium (mean 
APACHE II. score; 16.0 vs 13.5; p = 0.032).  
The adapted Charlson Comorbidity Index scores among the older adults with 
advanced cancer ranged from 1 to 3.  These scores are similar to the scores found in other 
samples of older cancer patients. Typically, in older cancer patients, scores on the adapted 
Charlson are skewed and range mostly from 0 to 3 (Extermann, 2000). In a sample of 203 
older cancer patients, only 36% demonstrated comorbidity when rated by the Charlson 
(Extermann, Overcash, Lyman, Parr, & Balducci, 1998). The median Charlson score was 0, 
and the range was 0-6, out of a total possible score of 25. Although widely used, the Charlson 
appears to be a restrictive measure of comorbidity and, therefore, may not account for some 
conditions or diseases that may affect treatment tolerance and response in older cancer 
patients. For example, renal impairment is considered a comorbidity only if the serum 
creatinine level is > 3 mg/dl. In older adults, serum creatinine level and estimations of 
creatinine clearance do not accurately reflect age-associated reductions in glomerular 
filtration rate (Wasil & Lichtman, 2005). An older adult with cancer may have a normal 
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serum creatinine level, but still have renal impairment that is significant enough to require 
chemotherapy dose adjustments.     
 
Physical Functioning  
In the older adults with advanced cancer, physical functioning declined prior to 
delirium episodes. The decline was most notable in ability to perform IADLs, but in many 
cases ability to complete PADLs also declined. Mr. G and Mrs. C continued to have 
progressive declines in functioning after their first delirium episodes. As their functioning 
decreased, they had additional delirium episodes. Prior to his death, Mr. G had multiple 
episodes that occurred more frequently, were longer in duration, and were more severe. Mrs. 
C’s second delirium episode preceding death occurred after a steady decline in her physical 
functioning. At the time of her second delirium episode, her IADL and PADL scores were 0, 
and her PPS score was 20.  
Mercadante et al. (2000) reported similar patterns of increasing delirium symptoms 
with decreasing function among a sample of 370 patients in a home palliative care program. 
Symptoms such as drowsiness, weakness, and confusion increased as the cancer progressed 
and peaked when performance status, as measured by the Karnofsky Performance Scale 
(KPS), dropped to lower levels. Drowsiness and weakness increased in frequency and 
severity from KPS 70 to KPS 10. Drowsiness increased significantly at KPS 40, and 
weakness at KPS 50. Confusion was rare early on but became progressively more frequent 
and more severe as performance status dropped from KPS 40 to KPS 10—80% of patients at 
KPS 10 were severely confused.  
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In the hospitalized older cancer patients, patients with delirium had more functional 
impairment in IADLs than those without delirium. Patients with delirium resolution were less 
functionally impaired than those with persistent delirium.  
 
Symptom Prevalence and Symptom Distress 
Overall, symptom prevalence and distress fluctuated in the older adults with advanced 
cancer. While no distinct pattern was observed, in some cases, it appeared as though there 
may have been interrelationships between physical symptoms—such as fatigue, nausea, 
vomiting, shortness of breath, and pain—and altered cognitive functioning, and between 
psychological symptoms and altered cognitive functioning. Cleeland et al (2000) used 
hierarchical cluster analysis to identify clustering of symptom items from the symptom 
responses of 527 outpatients receiving cancer treatment. They found a close relationship 
between clusters of cognitive symptoms and affective symptoms. They also found that a 
fatigue-related symptom cluster was more closely associated with cognitive and affective 
symptoms than with other physical symptoms clusters.  
As noted above, symptoms like decreased appetite, taste changes, nausea, vomiting, 
and dry mouth increase metabolic-nutritional risk. In addition, symptoms associated with 
either decreased fluid intake or increased fluid loss also contribute to orthostatic-dehydration 
risk. Additional research is needed to more closely examine the complex interrelationships 
between physical and psychological symptoms, and cognitive symptoms and delirium. As 
suggested in the study by Cleeland et al., specific-symptom clusters may exist. If so, effective 
management of the physical and psychological symptoms in the clusters may help to prevent 
or minimize cognitive symptoms and delirium.    
 198 
Etiologic Patterns and Risk Markers 
 Metabolic-Nutritional Pattern 
Findings from this research indicate that nutritional risk is a significant problem in 
older cancer patients. Ninety percent of the hospitalized older cancer patients had metabolic-
nutritional risk markers. All ten patients in the subsample who were near the end of life had 
metabolic-nutritional markers. Six of the seven older adults with advanced cancer had risk 
markers at baseline, and all had metabolic-nutritional markers prior to their first delirium 
episodes.  
Serum albumin levels and lymphocyte counts were indicative of nutritional risk, but 
weight loss was the primary risk marker. All but one of the older adults with advanced cancer 
had significant weight loss—greater than 10% of body weight or 5 kg—either prior to the 
study or over the course of the study. Five had experienced weight loss prior to enrollment in 
the study. During the study, two patients, who lost weight initially, gained because of fluid 
retention—ascites and pedal edema.     
Nutritional impairment and weight loss in cancer patients with advanced disease are 
complex and multifactorial. Typically, in the cancer treatment setting, nutritional intervention 
and other supportive measures are subsidiary to the cancer treatment itself. The findings from 
this research indicate that there is a critical need for early intervention to prevent or correct 
nutritional impairment.  
Although limited by small sample size, several studies have shown the effectiveness 
of nutritional interventions—nutritional assessment, dietary counseling, and nutritional 
supplements—in patients receiving cancer treatments. Odelli et al (2005) implemented a 
nutrition pathway in patients with esophageal cancer receiving chemoradiation. Patients were 
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provided appropriate intervention based on assessed nutritional risk: preventive counseling 
(low risk), oral nutrition supplements (moderate risk), and enteral feeding (high risk). 
Outcomes in 24 patients treated before using the nutrition pathway were compared to 
outcomes in 24 patients treated with the pathway. Patients treated with the nutrition pathway 
had decreased weight loss, greater radiation therapy completion rates, fewer unplanned 
hospital admissions, and, when hospitalized, a shorter length of stay. In a randomized trial, 
Isenring, Capra, and Bauer (2004) evaluated the impact of an early nutritional intervention in 
GI and head and neck cancer patients receiving radiation therapy. The nutritional 
intervention involved individualized, intensive nutrition counseling by a dietician and oral 
supplements, if indicated. Sixty patients were randomized to receive either the nutrition 
intervention or usual care. Patients who received the nutritional intervention experienced less 
declines in weight, nutritional status, global quality of life, and physical function. In a pilot 
study, Bauer and Capra (2005) found that an 8-week nutritional intervention comprised of 
weekly dietary counseling and consumption of a protein- and energy-rich nutritional 
supplement with eicosapentaenoic acid (EPA) improved dietary intake, lean body mass, 
functional capacity, and quality of life in seven patients with advanced pancreatic and non-
small cell lung cancer.  
The older adults with advanced cancer frequently reported the presence of and 
distress associated with symptoms that negatively affect nutritional status: lack of appetite, 
taste changes, nausea and vomiting, and diarrhea (Grant & Kravits, 2000). The timely and 
effective management of symptoms associated with nutritional risk is paramount in 
preventing and minimizing nutritional impairment.   
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Hypoxic Pattern 
 Hypoxic risk factors also were common in both groups of patients—the hospitalized 
older cancer patients and the older adults with advanced cancer. In the hospitalized patients, 
having hypoxic markers significantly increased the risk of developing delirium when 
compared to those without hypoxic markers. Other studies of delirium in hospitalized cancer 
patients (Tuma & DeAngelis, 2000) and in patients with advanced cancer (de Stoutz, Tapper, 
& Fainsinger, 1995; Lawlor et al., 2000; Morita et al., 2001) identified hypoxia as a cause of 
delirium, which is important because hypoxia is potentially treatable. Neelon, Ng’andu et al. 
(1996) found that delirium resolved within 24 hours in a significant number of hypoxic 
patients treated to improve oxygenation. Aakerlund and Rosenberg (1994) found that 
hypoxemia was the sole cause of post-operative delirium in 5 thoracic surgery patients, and 
that delirium resolved in all after treatment with supplemental oxygen. de Stoutz et al. (1995) 
reported that delirium resolved in four terminally ill cancer patients in whom hypoxia was 
treated.  
  
 Metabolic-Toxic Pattern 
Metabolic-toxic markers were present at admission in 40% of the hospitalized older 
cancer patients. Four of the 8 hospitalized patients near the end of life who had delirium 
exhibited metabolic-toxic pattern markers. In the older adults with advanced cancer, at 
baseline, two patients had pattern markers; three more acquired markers prior to developing 
delirium. Four patients had markers indicative of impaired liver or renal function, and three 
had a serum albumin level < 3.0 g/dl. Mr. G did not have a recent albumin level documented 
in his medical record, but it is likely that his albumin level dropped over the course of the 
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study as his cancer progressed and as he experienced significant weight loss and nutritional 
impairment.  
The metabolic-toxic pattern is important in older cancer patients because it has 
significant implications for drug distribution, metabolism, and elimination. At enrollment 
into the study, the older adults with advanced cancer were taking a large number of 
medications including those for cancer treatment, for symptom management, and for 
comorbid diseases and medical conditions. In many cases, multiple medications were added 
throughout the study.    
 
Orthostatic-Dehydration Pattern 
Common in older adults, dehydration is a well known risk factor for delirium 
(Mentes, 2006; Mentes, Culp, Maas, & Rantz, 1999; Sheehy, Perry, Cromwell, 1999). Older 
cancer patients are at risk for dehydration due to age-related physiological changes, the 
effects of cancer and its treatment, comorbid medical conditions, medications, and symptoms 
associated with decreased fluid intake and increased fluid loss such as nausea, vomiting, 
diarrhea, decreased appetite, and taste changes.  
Orthostatic-dehydration markers were common in the older cancer patients, 
particularly in those near the end of life and those with advanced cancer. Thirty six percent of 
the hospitalized older cancer patients had orthostatic-dehydration markers at admission. Six 
of the 8 hospitalized patients near the end of life who had delirium exhibited pattern markers, 
and all of the older adults with advanced cancer had orthostatic-dehydration pattern markers 
prior to developing delirium. These findings suggest that the orthostatic-dehydration pattern 
is particularly important in patients with advanced disease.  
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An abundance of clinical literature addresses concerns about providing artificial 
hydration at the end of life. The discussion tends to focus on ethical issues related to 
withholding and withdrawing treatment and other issues such as thirst, quality of life, and 
prolonging survival. The focus on preventing and managing delirium has been limited.   
Studies suggest that hydration in patients with advanced cancer may play an 
important role in maintaining cognitive functioning and minimizing delirium, particularly in 
those receiving high doses of opioids, but results have been mixed. Bruera, Franco, Maltoni, 
Watanabe, and Suarez-Almazor (1995) retrospectively compared the prevalence of agitated 
delirium in an inpatient palliative care unit before and after the implementation of routine 
cognitive assessment, and opioid rotation and hydration to manage delirium (cognitive 
failure). Prior to implementation, agitated delirium occurred in 26% of patients compared to 
its occurrence in 10% of patients after the implementation. They also found a reduction in the 
use of neuroleptics and benzodiazpines during the period following implementation.  In a 
similar comparison study, Morita et al. (2003) found that the occurrence of agitated delirium 
in the last week of life did not change significantly during a period with increased opioid 
rotation and hydration. In a more recent randomized study, Bruera et al. (2005) found that 
patients with clinical evidence of mild to moderate dehydration who received 1000 ml of 
fluid had improvement in myoclonus and sedation compared to patients who received a 
placebo with 100 ml, but there were no significant differences in improvement in 
hallucinations or fatigue.  
 In two studies of delirium in advanced cancer (Lawlor, Gagnon et al., 2000; Morita et 
al., 2001), treatments were targeted at delirium etiologies. Interventions included opioid 
rotation for opioid toxicity, rehydration, medication changes, antibiotics for infection, 
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bisphosphonates for hypercalcemia, and neuroleptics and, if needed to control agitation, 
benzodiazepines.  Lawlor, Gagnon, et al. reported using hydration in patients with clinical or 
laboratory evidence of deyhydration, where as Morita et al. reported using hydration in 
conjunction with opioid rotation for opioid toxicity. Reported delirium resolution rates in 
both studies were positive. In the study by Lawlor, Gagnon, et al., 49% of delirium episodes 
reversed. Delirium caused by psychoactive medications, including opioids, and dehydration 
was associated with reversibility. Morita et al. reported symptom improvement in 77% of 
episodes and complete reversal in 20%. Reversal was higher in delirium related to 
medications and hypercalcemia. Delirium reversal in episodes associated with other 
pathologies, including dehydration, was low. The contradictory findings related to delirium 
reversal and dehydration may result from differences in treatment protocols.       
   
 Chronic Cognitive Impairment Pattern 
Preexisting cognitive impairment is a widely recognized risk factor for delirium in 
medically-ill older adults (Duppils & Wikblad, 2000; Eden et al., 1998; Fisher & Flowerdew, 
1995; Francis et al., 1990; Galanakis et al., 2001; Inouye et al., 1993; Pompei et al., 1994; 
Rahkonen et al., 2001; Rockwood, 1989; Schor et al., 1992). The prevalence of delirium in 
hospitalized and community-dwelling older persons with dementia ranges from 22-89% 
(Fick, Agostini, & Inouye, 2002). Ljubisavljevic and Kelly (2003) found that impaired 
cognitive function was a risk factor for delirium in hospitalized cancer patients.  
In the current study, only a small number of the older cancer patients had chronic 
cognitive impairment. Five patients (6%) in the sample of hospitalized older cancer patients 
exhibited chronic cognitive impairment at admission. Based on their admission NEECHAM 
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scores, one patient was at risk for delirium (NEECHAM score > 25), one had mild delirium 
(NEECHAM score 20-24), and the other three had severe delirium (NEECHAM score < 20). 
At some point during hospitalization, all of the patients with chronic cognitive impairment 
had severe delirium. Importantly, at discharge, delirium had improved in three of the five 
patients, suggesting that even in patients with chronic cognitive impairment, delirium is 
potentially reversible. 
One of the older adults with advanced cancer had reported baseline cognitive 
impairment. During the study, he had one positive delirium assessment that occurred at a 
weekly scheduled visit the morning after he returned late the previous evening from an out-
of-state trip to visit with one of his children and grandchildren and to attend his sister’s 
funeral. According to his wife and CCC scores, he had additional signs of confusion and 
impaired cognitive functioning during the study but the investigator was not notified at the 
time.   
In summary, older cancer patients likely have an increased baseline vulnerability or 
risk for delirium at the time of cancer diagnosis due to age-related physiological changes in 
multiple organ systems and comorbid medical conditions. Findings from this study suggest 
that vulnerability increases over time with treatment or disease progression. For example, all 
of the older adults with advanced cancer exhibited an increase in number of pattern markers 
prior to their delirium episodes except in the participant with chronic cognitive impairment. 
In the hospitalized older cancer patients, patients with delirium had more etiologic patterns 
compared to those without delirium.  Therefore, the risk for delirium increases with a greater 
number of risk markers and patterns. Similarly, Inouye et al. (1993) found that delirium risk 
increased progressively as the number of risk factors multiplied: cumulative rate of delirium 
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in patients with no risk factors was 9%; with 1-2 risk factors, 23%; and with 3-4 factors, 
83%. Although not examined in these studies, the contribution of specific combinations or 
clusters of risk markers and patterns may play a key role in determining delirium risk. 
Multiple risk markers and etiologic patterns were common in the hospitalized older 
cancer patients and in the older adults with advanced cancer. Identification of clinical risk 
markers and etiologic patterns provide specific targets for interventions to prevent and 
manage delirium in older cancer patients.   
 
Methodological Issues 
Descriptive research and qualitative research is used to better understand a problem, 
to generate hypotheses, and to identify new and important questions about the problem 
(Grimes & Schulz, 2002; Malterud, 2001a; Malterud, 2001b). This research provides a 
necessary step to better understand delirium in older cancer patients.  It is among the first to 
examine delirium, specifically in a sample of hospitalized older cancer patients, and to look 
at delirium in older adults with advanced cancer cared for at home. Findings from the study 
highlight the magnitude of delirium and delirium vulnerability in older cancer patients, and 
provide directions for further research and intervention.  
Delirium research is methodologically complex and requires significant resources. 
The longitudinal, multiple case-study, descriptive design using quantitative and qualitative 
methods facilitated the intense examination of delirium and delirium vulnerability in a small 
number of older adults with advanced cancer near the end of life. 
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Recruitment  
Limited resources for recruitment and data collection and refusals to participate 
inhibited the ability to include more cases. Twenty seven patients were approached in the 
medical oncology clinic regarding participation in the study. Thirteen patients refused to 
participate either at the initial contact or at follow-up. Four patients were lost to follow-up. 
One patient’s condition declined before he could be enrolled, and two others expressed an 
interest in study participation but were deemed ineligible—one lacked contact with a regular 
caregiver and the other was found to have stable disease after further work-up. Patients and 
family caregivers reported the following reasons for refusal: feeling overwhelmed or too ill, 
the longitudinal nature of study and weekly commitment, and a lack of understanding about 
the nature of study.  Patients or family members often stated that they (or the patients) were 
“not having any problems with that right now.”  
No hospice patients were enrolled in the pilot study or the follow-up study. Others 
have described the challenges associated with recruiting and enrolling hospice patients and 
others into palliative care and end-of-life research (Ewing et al., 2004; Jordhoy et al., 1999; 
McMillan & Weitzner, 2003). In the current research, the investigator was not directly 
involved in recruiting hospice patients. The hospice team members (clinical supervisor, 
nurses, and social worker) agreed to introduce the study to patients and caregivers. In the 
pilot study they provided a recruitment flyer and stamped envelope, so that those who were 
interested in study participation could provide contact information to the investigator. This 
process was changed in the follow-up study. The hospice team members agreed to introduce 
the study to patients and caregivers, provide them with study brochure, and see if they were 
willing for the hospice team member to provide the investigator with contact information for 
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follow-up.  
Specific barriers to hospice patient recruitment were not determined. Because 
research is uncommon in the hospice setting, the hospice nurses may have been unfamiliar 
with conducting research and they may have felt uncomfortable approaching patients and 
families about research participation. Another potential barrier to hospice recruitment may be 
that the transition to hospice care is a crisis period for patients and their families, and that 
during this period, patients and their families are not able to entertain participating in 
research. The hospice program in the current study was small with an average daily census 
around 40 patients, so during the recruitment period, the number of eligible patients may 
have been limited.   
In another study, Kirsh et al. (2004) surveyed 225 hospice nurses to elicit their views 
on conducting end-of-life research with hospice patients and families. The nurses indicated 
an openess to research in the hospice setting, but they acknowledged protective attitudes 
(wanting to control access to patients) and concerns about time constraints. Education and 
hands-on participation in research in the hospice setting may help address these barriers and 
counter common beliefs against research with hospice patients and families.      
Recruitment in the medical oncology clinic provided benefits, but at times it was 
difficult to identify the most appropriate patients—those near the end of life. It allowed the 
investigator to capture the transition from active palliative treatment into the terminal phase. 
Earlier enrollment also may have prevented attrition at this transition, enabling the 
investigator to continue the research until death. When patients and families transitioned into 
the terminal phase, they were familiar with the research protocol and had established a 
relationship with the investigator. All of the patients and caregivers reported that 
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participation in the research was beneficial. The frequent assessments and visits from the 
investigator, who was also a nurse, provided reassurance and support.  
Recruitment during the period of active palliative treatment also allowed the 
investigator to identify whether patients experience cognitive changes and delirium earlier in 
the treatment course prior to the terminal period. The findings from this study suggest that 
they do. While the older adults with advanced cancer were at different points in their illness 
trajectories, all developed delirium. Delirium that occurred prior to the terminal period 
tended to be mild and transient, and associated with multiple factors. In most cases, it 
resolved spontaneously as the contributing factors were eliminated or as physiological 
mechanisms are corrected or restored.  
 
Measurement 
Routine screening and monitoring is the first step in the early identification of 
delirium. Earlier identification could lead to earlier intervention, and improved outcomes. 
The use of a validated delirium instrument with frequent direct observations is recommended 
for identifying and monitoring delirium. However, this approach may not always be feasible, 
especially in the outpatient setting. Today, many older cancer patients are being cared for 
primarily at home by family members. Therefore, there is a need to develop a methodology 
to detect and monitor delirium in the home setting. It is a key to advancing delirium research 
in older cancer patients and to improving their care.   
A baseline of cognitive and behavioral functioning is critical for recognizing subtle 
changes associated with subsyndromal or mild delirium. Therefore, family caregivers may 
play a key role in identifying early changes and signs of delirium before they progress to 
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more severe delirium. Fick and Foreman (2000) reported some evidence that family members 
recognized early changes in behavior in patients that developed delirium.  
In the current study, family caregivers were asked to monitor patients for signs of 
delirium and to complete the Caregiver Confusion Checklist (CCC) once or twice a day. 
Family caregivers were instructed to contact the investigator if two or more signs of delirium 
were noted. When notified, the investigator would conduct a more in-depth delirium 
assessment.  Caregivers demonstrated variability in completing the CCC. Some caregivers 
wrote additional comments that were helpful in understanding what was going on with the 
patients.   
 Additional research is needed to study and to establish the role of family caregivers in 
monitoring for and supporting patients with delirium at home. Educational interventions may 
help caregivers better understand delirium risk in patients with advanced cancer and increase 
their ability to identify early changes in cognitive and behavioral functioning associated with 
developing delirium. Gagnon et al. (2002) developed and provided a psycho-educational 
intervention to help family caregivers of patients with advanced cancer to better understand 
and cope with delirium. Caregivers who received the intervention demonstrated an 
understanding of what delirium is and reported increased confidence in their ability to react 
appropriately to delirium symptoms. The majority indicated that all family caregivers of 
patients with advanced cancer should be informed about delirium and delirium risk.      
 Other measurement concerns relate to the validity and reliability of self-report data in 
patients with advanced disease and variability in cognitive functioning. Self-reporting may be 
influenced by environmental, psychologic, physiologic, and pharmacologic factors. 
Steinhauser, Clipp, & Tulsky (2002) point out the problem of non-response bias in end-of-
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life research. In the current study, non-response was a problem at times because patients 
cancelled data collection visits, or they refused to respond to certain questions, or they were 
not able to respond, or the investigator eliminated instruments in order to decrease participant 
burden. The use of caregivers as proxy respondents and the use of multiple data sources and 
data collection techniques can help to address this problem. For example, in this study, the 
collection of qualitative data (observations and caregiver notes) helped to provide a better 
understanding of a patient’s condition and experience.   
This study used multiple instruments with different scaling. In some cases, it made 
comparison and interpretation of the data more difficult. However, the graphic techniques 
used in the analysis allowed for visual examination of trends in and among the data. 
Another problem encountered in data collection was the inability to obtain accurate, 
detailed, and specific information about medication use.  Most patients were self-
administering their medications until their condition or functioning declined. At the time of 
enrollment, Mr. G was managing a complex medication regimen that included multiple 
opioids for pain control. After his first delirium episode, the hospice nurses started filling a 
pill box, and his caregivers began to administer his regularly scheduled medications 
including long-acting opioids. Mr. G continued to self-administer his short-acting opioids for 
breakthrough pain. He was not able to accurately report when and how much medication he 
took over a period of time.  
The investigator did not implement pill counts due to intrusiveness. However, this 
strategy may be necessary in order to accurately monitor medication use. When family 
caregivers began to administer medications, the investigator provided them with a medication 
log that could be used to document when medications were given. It was intended not only to 
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help determine the frequency and dosage of medications administered but also to help 
caregivers keep track of medication administration.  
 
Maintaining Reserves in Older Cancer Patients 
One of the most striking observations among the older adults with advanced cancer 
was the prolonged and intensive nature of palliative cancer treatment and its impact on 
physiological, biochemical, and cognitive reserves. Most of the older adults with advanced 
cancer received multiple courses of cancer treatment over many years. Others who were 
more recently diagnosed underwent intensive first line treatment regimens. Findings from 
this study indicate that functional reserves and reserve capacity are depleted over time in the 
setting of prolonged and intensive cancer treatment. Diminished reserves lower the threshold 
of vulnerability in these patients, placing them at increased risk for cognitive and functional 
decline, delirium, and other poor outcomes.  
In older cancer patients, intense and effective supportive care must begin early—at 
the time of diagnosis—and focus on preventing reserve loss and treatment-related 
complications. Loss of reserves may be inevitable in older adults with advanced cancer as 
they approach the end of life. However, early supportive care that continues throughout the 
treatment course may help to maintain reserves for as long possible.  
The findings from this study suggest that the key components of supportive care 
should include monitoring for and addressing changes in behavior and cognitive and physical 
function, ongoing nutritional assessment and intervention, monitoring and maintaining 
adequate hydration, medication management, timely identification and effective management 
of physical and psychological symptoms, and management of other comorbid medical 
 212 
conditions. A comprehensive, multicomponent supportive care program would likely have a 
positive impact on treatment tolerance, cognitive and physical functioning, and overall 
quality of living and dying.  
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Appendix E 
 
Exemplar Case Study: Mrs. C 
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Mrs. C  
 
Background 
 Mrs. C was an 81 year old white female with adenocarcinoma of the colon. She was 
widowed and lived alone in a house next door to her daughter. She completed 11 years of 
school and worked for many years in a hosiery mill. She and her husband had also owned 
and operated a grill for 15 years. Mrs. C’s primary caregivers were her daughter who lived 
next door and her granddaughter-in-law who also lived nearby. Her daughter worked full-
time during the week, so her granddaughter-in-law who was unemployed checked in on Mrs. 
C throughout the day and took her shopping and to appointments. 
 In December 2002, Mrs. C began to experience abdominal pain. A computerized 
tomography (CT) scan revealed a pelvic mass. Around the same time, she had a colonoscopy 
that revealed a suspicious lesion that was biopsied and found to be malignant. Mrs. C’s 
cancer was diagnosed as Stage IV adenocarcinoma of the colon in February 2003 when she 
underwent a radical abdominal debulking with total abdominal hysterectomy and bilateral 
oopherectomy. At the time of diagnosis, the cancer had metastasized to the ovaries, 
omentum, and pelvis. 
   
 
Treatment and Disease Course:  
Table E3.1 outlines the course of Mrs. C’s treatment. Following surgery in February 
2003, Mrs. C underwent 3 six week cycles of 5-fluororuracil (5-FU) and leucovorin which 
were completed in late July 2003. In October 2003, a follow-up CT scan revealed a pelvic 
mass and fluid collection in the pelvic floor. An abcess was drained. Follow-up CT scans 
showed multiple small nodules but was otherwise unchanged. In January 2004 a scan showed 
interval progression in the size of the pelvic mass and an increase in number and size of the 
mesenteric soft tissue nodules. In February 2004, she was started on Xeloda at 2000mg per 
meter squared. A follow-up CT scan in April 2004 showed a mixed response to the Xeloda as 
well as slight progression with new mesenteric nodules and a slight increase in the size of 
another nodule. Oxaliplatin at a dose of 130 mg/m2 every 3 weeks was added to the 
treatment regimen. In May 2004, Mrs. C was hospitalized for 2 weeks with toxic 
enterocolitis associated with profound diarrhea, dehydration, hypokalemia, and diffuse lower 
abdominal pain. Following this episode, treatment was continued with a dose reduction of 
50%. In October 2004 scans showed evidence of slowly progressive disease. Avastin at 5 
mg/kg was added to the treatment regimen. In March 2005 a follow-up scan showed that the 
mesenteric nodules and pelvic mass had increased by 25%. In addition loops of bowel 
appeared adhered to one another. At that time, Mrs. C noted increased gas and slowing of 
bowel function with significant constipation. Her bowel function markedly improved with 
initiation of a bowel regimen and Flagyl. She was started on Irinotecan, a topoisomerase I 
inhibitor, at the end of March 2005. Mrs. C tested positive for expression of epidermal 
growth factor receptor (EGFR), so Cetuximab, a monoclonal antibody that targets EGFR, 
was added to the Irinotecan regimen. She was also consented for future participation in a 
Phase I vaccine trial so that she could be tested for Ras mutation.  
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Table E3.1. Course of Mrs C’s Treatment 
 
Dates  Treatment 
02/03  Radical abdominal debulking with total 
abdominal hysterectomy and bilateral 
oopherectomy 
03/03 – 07/03  3 six week cycles of 5-Flurouracil (5-FU) and 
leucovorin 
02/04 – 04/04  Xeloda 2000 mg/m2 
04/04 – 05/04  Oxaliplatin 120 mg/m2 every 3 weeks added 
05/04  50% dose reduction due to toxic enterocolitis 
10/04-03/05  Avastin 5mg/kg added  
03/05  Irinotecan started 
05/05*  Cetuximab added 
06/05 – 07/05  Phase I vaccine trial 
08/12/05  Enrolled in hospice 
08/26/05  Death 
*Enrolled in Delirium and Cancer Study on May 25, 2005 
 
Enrollment 
 
 I first met and introduced the Delirium and Cancer Study to Mrs. C and her daughter 
in the medical oncology clinic. Mrs. C did not have a lot to say except that she had already 
agreed to participate in the study, thinking that I was talking about the vaccine trial that she 
had already consented to participate in. Mrs. C’s daughter was interested in the study. I 
suggested that Mrs. C and her daughter discuss participation in the study and told them that I 
would follow-up with them when they came back to the clinic the next week. When I saw 
Mrs. C during her next clinic visit, she agreed to participate and her granddaughter-in-law 
who was with her concurred, so I set up an appointment to obtain consent and to collect 
baseline data. 
 I met with Mrs. C, her daughter, and granddaughter-in-law at her home in the late 
afternoon on May 25, 2005. I sat next to Mrs. C who was in a recliner. Her daughter and 
granddaughter-in-law sat across the room on a sofa and lounge chair, respectively. Mrs. C 
was attentive as I reviewed the patient consent form. I then provided Mrs. C and her daughter 
copies of the consent so that they could review it. Neither Mrs. C nor her daughter had 
additional questions before Mrs. C signed the consent. I then reviewed the caregiver consent 
and provided a copy of the caregiver consent to Mrs. C’s granddaughter-in-law who agreed 
to be Mrs. C’s family caregiver for the study.  
 
Baseline Characteristics 
 
Cognitive Functioning 
 Mrs. C’s initial NEECHAM Confusion Scale (NEECHAM) score (Range 0-30) of 28 
was her highest during the course of the study. During the initial assessment, she exhibited 
minimal difficulty with information processing or cognitive functioning. However, she 
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exhibited slight slowing of her motor behavior. She also had an irregular heart rate associated 
with atrial fibrillation.  
Mrs. C’s initial mini-mental status examination (MMSE) score (Range 0-30) was 27. 
Although she knew the month and year, she did not know the exact date. She recalled 2 of 3 
objects that were previously presented, but she was unable to accurately draw the intersecting 
pentagons.  
At the initial visit, Mrs. C reported experiencing two cognitive symptoms on the 
Memorial Symptom Assessment Scale-Short Form (MSAS-SF)—feeling drowsy and 
difficulty remembering. Her cognitive symptom distress score was 0.75 (Range 0-4). She 
reported that feeling drowsy was somewhat distressing and that difficulty remembering 
caused her a little bit of distress. She reported no prior history of confusion. Her family also 
did not acknowledge any previous episode of confusion. Mrs. C had had a previous 
hospitalization for acute treatment complications in May 2004. Her medical record did not 
indicate that she had any change in mental status during that time.  
 
Physical Functioning 
 At the time of enrollment into the study, Mrs. C was living independently with 
occasional assistance from her daughter and grandchildren. She had stopped driving but went 
shopping with her family. Her family prepared most of her meals but she was able to warm 
up the meals and eat them as she wanted. She did her own laundry and household chores 
(dusting, vacuuming, and dishes). An avid gardener, she also tended several tomato plants 
and outdoor flower beds. Her instrumental activities of daily living (IADL) subscale score 
(Range 0-14) was 10. Mrs. C’s physical activities of daily living (PADL) subscale score 
(Range 0-14) was 13. She reported occasional incontinence, once or twice a week. 
Otherwise, she performed all other PADLs independently.  
Mrs. C’s baseline Palliative Performance Scale (PPS) score (Range 0-100) was 70. 
Overall, her ambulation was reduced due to her low energy level, but she was able to do 
housework and go out with her family. She maintained a full level of consciousness and she 
was independent in caring for her own physical needs. Her appetite was decreased; thus, her 
overall food intake was reduced.   
 
Symptom Prevalence and Distress 
 At the initial visit, Mrs. C reported a total of 14 symptoms. Those causing quite a bit 
or very much distress were pain, low energy, change in taste, constipation, difficulty 
sleeping, and diarrhea. Those that were somewhat distressing included feeling drowsy, 
cough, and worrying. Other symptoms that caused a little bit of distress were sweating, 
itching, lack of appetite, weight loss, and difficulty remembering. 
 
Depression 
Mrs. C reported no prior history of depression, but her initial Geriatric Depression 
Scale (GDS) score (Range 0-15) was 6 – indicating that she may be depressed. She reported 
that she had dropped many activities and interests and that she felt her life was empty. She 
also reported feeling helpless and pretty worthless. Additionally, Mrs. C noted that her 
energy level was low and that she preferred to stay at home rather than going out doing new 
things. 
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Nutritional Status and Risk 
 Mrs. C reported that her usual weight before her cancer was 164 pounds. Pre-
treatment weights, documented in her medical record, were 136 pounds in January 2003 prior 
to her initial abdominal surgery and 136.4 pounds in February 2003 prior to the initiation of 
chemotherapy. Her weight upon enrollment in the Delirium and Cancer Study was 104.5 
pounds. Mrs. C’s height was 62.2 inches. Her body mass index (BMI) was 19.0 kg/m2, and 
she appeared thin. On May 13, two weeks before enrollment in the study, Mrs. C’s albumin 
level was 3.5 g/dl (3.5-5.0 g/dl) and her lymphocyte count was 0.8 x109/L (1.5-5.0 x109/L). 
Therefore, Mrs. C entered the study with markers for the metabolic-nutritional risk pattern. 
Her initial phase angle was 4.26. 
 
Overall Health and Comorbidity 
 Mrs. C rated her overall health as fair at enrollment. She also reported that her health 
then was about the same as it was 6 months ago. Her adapted Charlson Comorbidity Index 
score was 2. Mrs. C’s comorbid medical conditions included hypertension, mitral 
regurgitation, aortic insufficiency, and atrial fibrillation. Having quit 30 years ago, Mrs. C 
had a remote smoking history. She had never used alcohol. Table E3.2 shows the 
medications Mrs. C was taking when she enrolled in the study.  
 
Table E3.2. Mrs. C’s medication list at enrollment 
Medication  Dosage 
Isosorbide  30 mg QD 
Lanoxin  125 mcg QD 
Lasix  40 mg as needed 
Norvasc  5 mg QD 
Metoclopramide  10 mg QID 
Procholorpromazine  10 mg as needed for nausea 
Sorbitol  30 ml QD 
Quinine sulfate   325 mg Q HS 
Ibuprofen  200 mg as needed for pain 
Tylenol   650 mg as needed for pain 
Caltrate plus  1 tablet QD 
Multivitamin  1 tablet QD 
 
 
Study Course 
  
Mrs. C was enrolled in the Delirium and Cancer Study for 93 days from May 25, 2005 until 
her death on August 26, 2005. Figure E3.1 provides a timeline of major events and data 
collection visits during the study period. During the study period I conducted a total of 19 
home visits for data collection, 12 were scheduled weekly visits and 7 were follow-up visits. 
Mrs. C cancelled the scheduled weekly visits on Day 79) and on Day 51 because she was 
“worn out” after frequent trips to the cancer center for tests, treatments, and follow-up clinic 
visits. In addition to the data collection visits, I often saw Mrs. C briefly when she came to 
the cancer clinic for treatments or follow-up appointments. Table E3.3 shows the medications 
that were added during the study. 
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Figure E3.1. Major events and data collection visits during Mrs. C’s enrollment in study 
 
 
Table E3.3. Mrs. C’s list of medications added during the study 
Medication Dosage 
Hydroxyzine 12.5 mg Q 6 hr prn for itching 
Magnesium oxide 400 mg BID 
Ciprofloxacin 500 mg BID x 7 days 
Amoxicillin 250 mg QID x 10 days 
Pyridium 200 mg TID x 5 days 
Percocet (5/325) 1-2 tablets Q 4-6 hr prn for pain 
Oxycodone (5 mg) 1-2 tablets Q 3-4 hr prn for pain 
Morphine solution (20mg/ml) 0.25-0.5 ml prn for pain 
Diazepam 2.5 mg Q 6 hr prn for restlessness 
Haloperidol 0.5-1 mg q 6 hr prn for  
Atropine solution 3 gtts SL prn for congestion 
Tylenol suppositories 650 mg PR Q 4-6 hr prn for temperature 
 
 
When Mrs. C entered the study, she was receiving Irinotecan and Cetuximab. Her last 
chemotherapy treatment was on Day 84. A scan on Day 79 following two courses of 
Irinotecan and one course of Cetuximab showed progressive disease in the liver, abdomen, 
and pelvis. Mrs. C tested positive for the Ras mutation so she was enrolled in the Phase I 
vaccine trial that involved the administration of five weekly vaccine injections in the General 
Clinical Research Unit (GCRC). The trial start date was delayed a week when Mrs. C was 
found to have a urinary tract infection (UTI). The UTI was treated initially with a 7-day 
course of Ciprofloxacin. Since she continued to have lower abdominal discomfort and 
microscopic evidence of UTI, this treatment was followed by a 10-day course of Amoxicillin 
and Pyridium. Mrs. C received her first vaccine injection on Day 60. Following each 
injection, she had to remain in the GCRC for a 6-hour period of observation. Overall, Mrs. 
C’s condition began to deteriorate during the vaccine trial. A CT scan at the end of the trial 
showed continued disease progression.  
 After the clinical trial, Mrs. C received supportive care. For example, on Day 28, she 
received IV fluids and electrolyte supplementation. During the ride home, after receiving IV 
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fluids in the clinic, Mrs. C had urinary incontinence in the car. Early in the morning on the 
following day (Day 27), Mrs. C fell as she went from the bedroom to the kitchen. She was 
taken to her local MD to evaluate and care for an abrasion on her left forearm. After that 
time, her daughter placed a “baby monitor” between Mrs. C’s bedroom and her home next 
door so that she could hear Mrs. C when she got up and down during the night.  
 Over the next week, Mrs. C’s overall condition improved minimally. She was 
referred to hospice care at that time—14 days before her death. A hospital bed was set up in 
Mrs. C’s bedroom. She remained ambulatory with increasing assistance until 10 days prior to 
her death. On that day she was unable to support her weight when transferring to the bedside 
commode. On the morning of August 17, 9 days before her death, Mrs. C experienced chest 
pain and shortness of breath. Her daughter contacted the hospice nurse who instructed her to 
give Mrs. C pain medication. The nurse also ordered oxygen and other medications 
(concentrated morphine solution, Diazepam, Haloperidol, Tylenol suppositories, Atropine 
solution) to have available, if needed, for symptom management. Mrs. C’s caregivers gave 
her the morphine solution when she was no longer able to swallow pills. Morphine 5-10 mg 
was given every 6 hours around the clock. On Day 4, the morphine scheduled was changed 
so that Mrs. C was given a dose every 4 hours. The other medications were used 
intermittently during the week prior to Mrs. C’s death. Diazepam was given for restlessness. 
Tylenol was used for fever.  
 
Tolerance of Study Protocol 
 
 Mrs. C agreed to complete all of the study questionnaires during the first five data 
collection visits. She refused to write a sentence and draw the diagram on the MMSE. At 
times she mentioned that she did not like having to answer all of the questions. To prevent 
her from potentially dropping out of the study, from the eighth assessment on, I agreed to 
limit the formal questions and focus on collecting observational and physiological data. Mrs. 
C’s granddaughter-in-law monitored Mrs. C for signs of confusion and completed the 
Caregiver Confusion Scale twice each day during the study. She also documented frequent 
comments about changes in Mrs. C’s condition. 
 
Delirium Episodes  
 
 Mrs. C had two delirium episodes determined by positive delirium assessments – 
NEECHAM score < 24 and positive CAM. Figure E3.2 shows the trajectory of Mrs. C’s total 
NEECHAM scores during the study with the delirium episodes noted. Mrs. C’s first delirium 
episode occurred on July 27, 30 days before her death. She scored positively for delirium at 
the time of the scheduled weekly assessment. Mrs. C had only one positive delirium 
assessment with this episode. She did not score positive for delirium at the follow-up 
assessment the following day or during assessments over the next three weeks. The second 
positive delirium assessment was on August 17, 9 days before her death. Over the next 3 
days, her NEECHAM scores demonstrated increasingly severe delirium until she became 
stuporous and essentially unresponsive 5 days before her death. During assessments over the 
last 5 days, Mrs. C’s NEECHAM scores were 1 and 0. She exhibited moderate to deep levels 
of sedation before becoming unarousable 2 days before her death. The CAM could not be 
scored    
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Figure E3.2. Mrs. C’s total NEECHAM score trajectory with delirium episodes 
 
 
 
Delirium Episode #1 
 
The first positive delirium assessment occurred during a regular weekly visit on Day 
30. Two days before this episode (Day 32), Mrs. C had her final vaccine injection. That 
afternoon she also had a CT scan to evaluate her disease status. I visited Mrs. C in the 
GCRC. Both her daughter and granddaughter-in-law were with her. She was drinking liquid 
contrast in preparation for the scan. When she stood to go to the bathroom, Mrs. C was 
unsteady and shaky. Her granddaughter-in-law provided assistance, holding her arm as she 
walked.    
During the previous week, her granddaughter-in-law documented in her daily notes 
that Mrs. C had been staying in bed more, sleeping a lot, and talking less. She “only talks 
when you talk to her.” Mrs. C also had persistent abdominal pain. She was given a 
prescription for Tylenol #3 tablets on Day 46. She reported increased drowsiness when she 
took the Tylenol #3. This was bothersome to her so she limited the amount taking one half of 
a tablet once or twice during the day and a full tablet prior to bed. As her abdominal pain 
increased, Mrs. C tended to spend more time in bed. She noted that she felt more comfortable 
when lying down.  
When I arrived for the weekly visit on Day 30, Mrs. C’s granddaughter-in-law 
reported that Mrs. C had been in bed all day and that she was sleeping a lot. She also noted 
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that Mrs. C had not eaten much over the past two days because “if she thinks of food it 
makes her nauseated.” She had also taken intermittent Compazine for nausea, but the exact 
amount and timing of doses was unknown. Mrs. C agreed for me to conduct my assessment 
in her bedroom. She had always been in the living room for assessments in the past. When I 
entered the bedroom I noted that Mrs. T was lying on her left side with her eyes closed. She 
responded briefly to my questions. Her voice was weak. At times I had to repeat questions or 
commands in order to get a response. Mrs. T did not initiate conversation and she kept her 
eyes closed throughout most of the assessment. 
The total NEECHAM score on the day of the positive assessment was 21 and the 
CAM was positive. Figure E3.3 shows the trajectories of Mrs. C’s NEECHAM subscale 
scores. At the time of the positive delirium assessment, her NEECHAM subscale scores 
were: Level 1: Processing, 11; Level 2: Behavior, 7; and Level 3: Physiologic Control, 3.Her 
level of alertness and attention were diminished as reflected in the NEECHAM Level 1 
subscale score. The Level 2 subscale score had dropped from 9 to 7 at the previous 
assessment. At that assessment, Mrs. C exhibited changes in her postural control and 
appearance, slowed motor movements, and more limited speech (verbal interaction). The 
Level 2 score at the time of the positive assessment was unchanged from the previous 
assessment. The Level 3 score, which had begun to worsen 2 weeks before, reflected Mrs. 
C’s physiologic instability. 
 
 
Figure E3.3. Trajectories of Mrs. C’s NEECHAM subscale scores  
 
 
Figure E3.4 shows the trajectory of Mrs. C’s vital functioning. At the time of the first 
delirium assessment, she exhibited changes in her physiological functioning. Mrs. C’s 
systolic and diastolic blood pressure were elevated (167/94). Her temperature also was 
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elevated at 37.6 OC. Her respiratory rate, while elevated at 24 breaths per minute, did not 
differ from her average respiratory rate.  
There was some question regarding whether Mrs. C had taken her cardiac 
medications that day. After that episode, Mrs. C’s family began to assist her with her 
medications, putting them in a daily medication organizer. This would allow them to better 
monitor whether Mrs. C had taken her medications as prescribed. 
At the follow-up assessment the next day (Day 29), Mrs. C exhibited increased 
alertness. She was in bed when I arrived but came into the living room for the assessment. 
Her NEECHAM score was 24 and the CAM was not positive. 
 
 
Figure E3.4. Trajectories of Mrs. C’s vital functioning 
 
 
Delirium Behaviors 
 
The delirium episode was characterized by a decrease in her level of consciousness 
and attention, as well as by slowed motor and verbal behavior. At the time of the positive 
delirium assessment, Mrs. C exhibited the following hypoactive delirium behaviors on the 
Delirium Behavior Checklist: diminished alertness, lethargy, slow speech, slow movements, 
unawareness, and apathy. No hyperactive behaviors were noted. Consistent with these 
observed delirium behaviors, Mrs. C’s score on the sedation subscale of the Richmond 
Agitation-Sedation Scale (RASS) was -1, indicating that she was drowsy, and her score on 
the motor retardation item from the Delirium Rating Scale-Revised-98 (DRS-R-98) was 1. 
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Delirium Episode #2: 
  
 Mrs. C’s second positive delirium assessment was on Day 9, 21 days after the first 
positive assessment and 9 days before her death. As previously noted, on the morning of the 
second positive assessment, Mrs. C experienced chest pain and shortness of breath. She was 
started on oxygen at 2 L/minute, so at the time of the assessment, Mrs. C was wearing 
oxygen.  
At the second positive delirium assessment, the total NEECHAM score was 16 and 
the CAM was positive. From that point on, Mrs. C’s NEECHAM score declined steadily 
until she became stuporous and essentially unresponsive, 5 days before her death.  
Mrs. C’s NEECHAM scores at the 4 assessments over the three weeks between the first and 
second positive delirium assessments ranged between 23 and 24. The CAM was negative at 
each of the 4 assessments – indicating that Mrs. C likely was experiencing subsyndromal 
delirium during this period.   
Mrs. C’s cognitive functioning had declined over the two weeks prior to the positive 
assessment. Her behavioral performance and physiological functioning had also declined. At 
the time of the positive assessment, the NEECHAM subscale scores were: Level 1 
(Processing), 8; Level 2 (Behavior), 6; and Level 3 (Physiologic Control) 2. 
At the time of the second delirium assessment, Mrs. C’s systolic and diastolic blood 
pressures were similar to her usual blood pressure readings. Her pulse was elevated and her 
respiratory rate was decreased. The decreased respiratory rate may have resulted from the 
initiation of oxygen at 2 L/minute. Her oxygen saturation on oxygen was similar to her 
baseline on room air. Her temperature was slightly elevated.  
After the positive assessment, Mrs. C began to exhibit physiologic instability. Her 
blood pressure and oxygen saturation fell during the last week, while her pulse increased. Her 
temperature and respiratory rate were highly variable. 
 
Delirium Behaviors  
 
At the second positive delirium assessment, Mrs. C exhibited diminished alertness as 
well as increased slowing of her motor behavior and speech. Her score on the RASS sedation 
scale was -1 and her score on the motor retardation item of the DRS was 3—severe motor 
retardation with few spontaneous movements. She exhibited the following hypoactive 
delirium behaviors on the Delirium Behavior Checklist: diminished alertness, slow speech, 
lethargy, slow movements, and stare. On Day 7 and on Day 6, Mrs. C exhibited intermittent 
agitation and restlessness in addition to a diminishing level of consciousness. On Day 7, her 
caregiver noted, “sleeping off and on…she’ll answer you sometimes—you might have to say 
it 2 or 3 times…talking to her self now. At this point she said she was burning something. Its 
hot don’t you get burned…an went back to sleep…” On Day 6, her caregiver wrote, 
“Sleeping most of the time now. May or may not answer you when you ask her a question,” 
and “Talking out loud to her self. Today she was fishing. She had caught some fish.”  Most 
often, she exhibited the hypoactive delirium behaviors noted above. Over the last week, her 
RASS sedation scores fluctuated, but, overall, showed a decline in her level of consciousness 
from lightly sedated to unarousable, two days before her death. 
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Trajectories of Delirium Vulnerability 
 
Cognitive Functioning 
 
NEECHAM Scores 
 Figure E3.5 shows the trajectory of Mrs. T’s NEECHAM scores. Her NEECHAM 
scores ranged from 28 at the initial assessment to 0 the day before her death (M 17.3; SD 
10.4). Mrs. T’s only NEECHAM score in the normal range (> 27) was at the initial 
assessment when her NEECHAM score was 28. Otherwise, from Day 86 to Day 44, her 
NEECHAM scores ranged between 25 and 26 – indicating that she was at risk for developing 
delirium. On Day 37, one week prior to her first positive delirium assessment, her 
NEECHAM score was 24. However, the Confusion Assessment Method (CAM) was not 
positive. Mrs. T was found to be positive for delirium at the weekly assessment on July 27, 
30 days prior to her death. Following the positive assessment, Mrs. T’s NEECHAM scores 
improved and ranged between 23 and 24 over the next 2 weeks (Days 29-16). The CAM was 
not positive during this time. Mrs. T’s second positive delirium assessment occurred on 
August 17, 9 days prior to her death. Her NEECHAM score was 16 and the CAM was 
positive. Her NEECHAM scores declined steadily and the CAM remained positive over the 
next four days until she became stuporous and essentially unresponsive. 
 
 
 
 
Figure E3.5. Trajectory of Mrs. C’s total NEECHAM scores 
 
  
Figure E3.6 shows the NEECHAM subscale score trajectories. The NEECHAM 
Level 1 score, representative of information processing and cognitive functioning, was 
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relatively stable except during delirium episodes. Even when Mrs. C demonstrated slowed 
cognitive processing and diminished alertness, she was almost always very attentive. For 
example, she would be sitting silently with a blank stare but would interject appropriately 
into ongoing conversations. The Level 1 score began to drop more steadily a week prior to 
the second positive delirium episode. The behavior subscale (Level 2) was initially stable but 
declined over the two weeks prior to the first positive delirium assessment. After the positive 
assessment, the Level 2 score remained decreased. The Level 3 subscale score was decreased 
initially indicating that Mrs. C’s delirium risk also was physiologic. Her heart rate was slow 
and irregularly irregular due to atrial fibrillation and her respiratory rate was often increased. 
The Level 3 subscale score declined even more two weeks before the first positive delirium 
assessment.  
 
 
Figure E3.6. Trajectories of Mrs. C’s NEECHAM subscale scores  
 
 
MMSE Scores 
  
 Table E3.4 summarizes Mrs. C’s scores on the MMSE. She agreed to complete the 
MMSE during the first 6 assessments. She refused to complete the drawing during the second 
and fifth assessments and she refused to write a sentence and to complete the drawing during 
the sixth assessment. She intermittently had difficulty keeping up with dates and with object 
recall on the MMSE.  
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Table E3.4. Mrs. C’s MMSE scores 
 
 
Assessment 
 
 
Total MMSE Score 
 
Possible Total 
 
Percentage Correct 
 
1 
 
27 
 
30 
 
90 
 
2 
 
25 
 
29 
 
86 
 
3 
 
27 
 
30 
 
90 
 
4 
 
30 
 
30 
 
100 
 
5 
 
27 
 
29 
 
93 
 
6 
 
 
26 
 
28 
 
93 
 
 
 
 
Depression 
 
 Mrs. C completed the Geriatric Depression Scale (GDS) during the first four 
assessments. Figure E3.7 shows the trajectory of Mrs. C’s GDS scores. Her average GDS 
score was 6.0 (SD .82), indicating that Mrs. C may have been depressed. Mrs. C did not 
report a history of depression, but at three of five assessments she reported feeling sad 
occasionally or frequently (See Table***). Following Mrs. C’s death, her daughter and 
granddaughter-in-law questioned whether her changes in behavior over her last weeks of life 
were related to depression. They noted that she used to enjoy watching television but that she 
got to where she did not even want the TV on and if it was on she did not watch it but rather 
just seemed to stare across the room. 
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Figure E3.7. Trajectory of Mrs. C’s GDS scores 
 
Physical Functioning 
 
 Figure E3.8 depicts the trajectory of Mrs. C’s physical functioning measured by the 
OARS from enrollment in the study until her death. During the last 6 assessments, when Mrs. 
C was no longer willing or able to complete the OARS, her granddaughter-in-law reported on 
her ability to perform IADLs and PADLs. 
 Mrs. C’s PADL scores ranged from a high of 14 between Days 86 and 58 to a low of 
0, 9 days before her death (M 9.9; SD 5.2). With the exception of occasional incontinence 
reported at the first assessment, Mrs. C was independent in all of her physical activities of 
daily living (PADLs). Her PADL subscale score on the OARS remained stable over the first 
5 assessments (Range 13-14). Her PADL score dropped to 12 at the 6th assessment, 44 days 
before her death. She reported an increasing frequency of incontinence, three times a week or 
more. Her PADL score remained at that level until her first positive delirium assessment at 
the 8th assessment on July 27, 30 days prior to her death. During the two weekly assessments 
following the first positive delirium assessment her PADL score was 7. Nine days before her 
death when she again scored positively for delirium, her PADL score was 0. Over the 
previous week, Mrs. C had become completely bedbound, and she began to require total 
assistance with her PADLs. She remained dependent in all PADLs until her death. 
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Figure E3.8. Trajectory of Mrs. C’s Physical Functioning 
 
 As previously noted, Mrs. C required more assistance with her instrumental activities 
of daily living (IADLs). Her IADL scores ranged from 10 out of 14 at the initial assessment 
to 0, 9 days before her death (M 5.8; SD 3.4). At the time of enrollment in the study, her 
daughter and grandchildren provided transportation. She was able to manage her money and 
day-to-day buying but her daughter and granddaughter-in-law paid her bills and managed her 
checkbook. Mrs. C’s IADL score began to decline steadily 44 days prior to her death. Her 
score dropped 4 points over the two weeks prior to the first positive delirium assessment. 
During this period, Mrs. C was unable to go shopping and do household chores. She also 
began to need more assistance with managing her money and with taking her medications. 
After the delirium episode, Mrs. C’s IADL scores continued to decline steadily until 9 days 
before her death when she required total assistance with IADLs and PADLs. 
Mrs. C’s physical functioning and activity had begun to decline prior to the first 
delirium episode. She reported increasing incontinence and the need for more assistance with 
instrumental activities of daily living – shopping and household chores. Her granddaughter-
in-law reported that she had been staying in bed more, sleeping a lot, and talking less.  
At the assessment the week prior to the delirium episode, the IADL subscale score and the 
behavior subscale of the NEECHAM declined. Mrs. C’s PADL score during that time 
remained stable. Although Mrs. C’s NEECHAM scores improved slightly during the two 
weeks after the first delirium episode, both her PADL and IADL scores continued to decline 
after the episode.  
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Mrs. C’s OARS scores changed over the 21 days between the first and second 
positive delirium assessments. Mrs. C’s IADL and PADL scores declined steadily between 
the first and second positive delirium assessments. At the time of the second positive 
delirium assessment, Mrs. C was completely bedbound and required total assistance with her 
IADLs and PADLs.  
 Mrs. C’s PPS scores presented in Figure E3.9 demonstrated changes in her overall 
functioning. Over the course of the study, the PPS score ranged from 70 to 10 (M 40; SD 
22.5). The PPS score initially dropped because she was unable to continue doing household 
chores and other IADLs.  It then dropped further because she was less ambulatory and 
because she needed increasing assistance with PADLs. Mrs. C’s PPS score declined steadily 
over the last three weeks of her life as she required more assistance with her care, became 
bedbound, and exhibited confusion and a decreased level of consciousness.  
 
 
 
Figure E3.9. Trajectory of Mrs. C’s Palliative Performance Scale scores 
 
 
Symptom Prevalence and Distress 
 At each of the first five assessments, Mrs. C completed the Memorial Symptom 
Assessment Scale—Short Form (MSAS-SF). During the sixth assessment (Day 44), she 
reported the presence or absence of symptoms but did not rate how bothersome the 
symptoms were. Figure E3.10 depicts the trajectory of Mrs. C’s total number of reported 
symptoms. She reported having, on average, 13 symptoms (SD 2.7; Range 10-17) at each 
assessment over the 6 assessments.  
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Figure E3.10. Mrs. C’s symptom total trajectory 
 
 
 Figure E3.11 shows the trajectory of Mrs. C’s symptom distress over the first five 
assessments. Overall, Mrs. C’s symptom distress increased during this period. Her cognitive 
symptom distress increased sharply between second and third assessments and remained 
elevated. Her global distress index, physical symptom distress, and psychological symptom 
distress scores were increased at the fifth assessment. This increase in Mrs. C’s overall 
symptom distress and, in particular, her cognitive symptom distress may have contributed to 
her request to discontinue the self-report measures during weekly assessments. 
Mrs. C’s most common physical symptoms, reported at each assessment, were pain, 
low energy, diarrhea, itching, decreased appetite, and change in taste. Among those, low 
energy and change in taste were the most distressing, followed by itching, pain, feeling 
drowsy, decreased appetite, and diarrhea. Table E3.5 shows the distress associated with Mrs. 
C’s most common physical symptoms. Dermatologic reactions, particularly on the trunk and 
face, are common with Cetuximab. Mrs. C developed a rash on her scalp that caused 
significant itching. Hydroxyzine was prescribed to relieve the itching. The hydroxyzine, 
however, caused her to be drowsy. Mrs. C also experienced intermittent diarrhea, a common 
side effect of Irinotecan. 
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Figure E3.11. Trajectory of Mrs. C’s symptom distress  
 
  
Table E3.5. Distress associated with Mrs. C’s most commonly reported physical symptoms. 
 
 
Symptom 
 
Frequency* 
 
Distress 
   
M 
 
SD 
 
Range 
 
Low energy 
 
5 
 
3.36 
 
0.36 
 
3.2 – 4.0 
 
Change in taste 
 
5 
 
3.36 
 
0.36 
 
3.2 – 4.0 
 
Itching 
 
5 
 
2.56 
 
1.04 
 
1.6 – 4.0 
 
Pain 
 
5 
 
2.40 
 
0.80 
 
1.6 – 3.2 
 
Lack of appetite 
 
5 
 
2.40 
 
0.56 
 
1.6 – 3.2 
 
Diarrhea 
 
5 
 
2.24 
 
0.88 
 
1.6 – 3.2 
* Includes first 5 assessments 
 
  
 281 
Throughout the study, Mrs. C identified pain as a troubling symptom. She reported 
that her pain was associated with arthritis and her cancer. Initially, her pain was controlled 
with intermittent Ibuprofen and Tylenol. Over the course of the study, Mrs. C had increasing 
abdominal pain. She was started on Percocet, 46 days prior to her death. Her pain control 
improved with the Percocet but she experienced increased drowsiness that she disliked. 
Therefore, she tended to minimize the use of Percocet especially during the day. On Day 14, 
Mrs. C was given a prescription for Oxycodone 5 mg tablets. The Oxycodone tablets are 
small and, therefore, easier to swallow than Percocet tablets. In addition, although Mrs. C 
tended to self-limit the amount of Percocet she took, the recommended daily dosage of 
Percocet is limited by the amount of Acetaminophen, whereas, the daily dosage of 
Oxycodone is not limited. About a week prior to her death, when Mrs. C was less responsive, 
her family started administering concentrated morphine solution. On Day 6, her family began 
to document the medications and dosages administered. On Day 6, Mrs. C received morphine 
20 mg for pain, diazepam 2.5 mg for restlessness, and 3 drops of Atropine solution for noisy 
lung congestion. Based on the hospice nurse’s recommendation and their desire for comfort, 
Mrs. C’s family began to administer morphine 10 mg every 6 hours on Day 5 and then 
increased the frequency to every 4 hours on Day 4.   
 Table E3.6 summarizes Mrs. C’s reported frequency and distress associated with 
psychological symptoms. Her most common and most distressing psychological symptom 
was feeling sad. She also reported worrying. Mrs. C never reported feeling irritable or feeling 
nervous. 
 
 
Table E3.6. Reported frequency and distress associated with psychological symptoms 
 
 
Distress 
 
Symptom 
 
Frequency* 
 
M 
 
SD 
 
Range 
 
Feeling sad 
 
3 
 
1.4 
 
1.34 
 
0 – 3.0 
 
Worrying 
 
2 
 
0.8 
 
1.09 
 
0 – 2.0 
 
Feeling irritable 
 
0 
 
- 
 
- 
 
- 
 
Feeling nervous 
 
0 
 
- 
 
- 
 
- 
* Includes first five assessments 
 
 
 
Table E3.7 shows the reported frequency and distress associated with cognitive 
symptoms. Mrs. C frequently reported cognitive symptoms. The most common and most 
distressing cognitive symptom was feeling drowsy, followed by difficulty remembering, 
difficulty concentrating, and feeling confused.  
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Table E3.7. Reported frequency and distress associated with cognitive symptoms 
 
 
Distress 
 
Symptom 
 
Frequency* 
 
M 
 
SD 
 
Range 
 
Feeling drowsy 
 
5 
 
2.40 
 
0.56 
 
1.6 – 3.2 
 
Difficulty remembering 
 
4 
 
1.92 
 
1.21 
 
0 – 3.2 
 
Difficulty concentrating 
 
3 
 
1.12 
 
1.07 
 
0 – 2.4 
 
Feeling confused 
 
3 
 
1.00 
 
1.00 
 
0 – 2.0 
* Includes first five assessments 
 
 
 
 
Weight and BMI 
 
 Figure E3.12 shows the trajectory of Mrs. C’s weight. Over the course of her 
treatment, Mrs. C had lost at least 30 pounds. Her documented weight prior to the initiation 
of her cancer treatment was 136 pounds. Upon enrollment in this study, her weight was 104.5 
pounds; her height was 62.2 inches; thus, her initial BMI was 19.0 kg/m2. During the study, 
her weight increased up to 116.6 pounds because she began to develop ascites and dependent 
edema. Mrs. C did not stand for her weight during assessments the week of the first positive 
delirium assessment. Her documented weight in the clinic (111.8 pounds) two days before 
the positive assessment is reported. The last documented weight on Day 16 was 111.4 
pounds.  After that assessment, Mrs. C was unable to stand for weight measurements.  
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Figure E3.12. Trajectory of Mrs. C’s weight 
 
 
Phase Angle 
  
 Phase angle determined by bioelectrical impedance analysis (BIA) was measured at 
16 of the 19 assessments (M 3.29; SD 0.43; Range 2.85-4.26). Figure E3.13 shows the phase 
angle trajectory. The BIA measures were obtained with Mrs. C sitting in her recliner except 
when she was in bed. The initial phase angle was 4.26. After the initial assessment the phase 
angle declined to its lowest point (2.85), 37 days prior to Mrs. C’s death and one week prior 
to the first positive delirium assessment. The phase angle then tended to stabilize except for 
the measurement done at the first positive delirium assessment. This value may be inaccurate 
because I was unable to get Mrs. C positioned appropriately. She was partially rotated onto 
her side and her feet were almost touching each other. When Mrs. C was unable to stand to 
be weighed, I used the last recorded weight to obtain BIA measures. 
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Figure E3.13. Mrs. C’s phase angle trajectory 
 
 
Etiologic Risk Patterns and Clinical Markers 
  
 As previously noted, at the time of enrollment in the study, Mrs. C exhibited clinical 
markers for the metabolic-nutritional risk pattern. She also had risk markers for the 
orthostatic-dehydration etiologic risk pattern. Two weeks before enrollment in the study, her 
BUN/creatinine ratio was 29. In addition, at times throughout the study, Mrs. C noted 
dizziness with standing or she appeared unsteady when standing. Mrs. C became positive for 
the metabolic-toxic risk pattern on Day 46, when her albumin level had dropped to 2.7 g/dl. 
Thus, before her first positive delirium assessment on Day 30, she exhibited clinical markers 
for three etiologic risk patterns: metabolic-nutritional, orthostatic-dehydration, and 
metabolic-toxic. At the time of the second positive delirium assessment (Day 9), Mrs. C was 
on oxygen, a marker for the hypoxic risk pattern. The oxygen had been started earlier that 
day after Mrs. C experienced chest pain and shortness of breath.  
 
Caregiver Confusion Checklist 
  
 Mrs. C’s granddaughter-in-law completed the Caregiver Confusion Checklist (CCC) 
daily in the morning and in the evening. Figure E3.14 shows the trajectory of the CCC scores 
over the course of the study. On Day 84, Mrs. C was started on Hydroxyzine to relieve the 
itching from the rash on her scalp. Two days later on Day 82, her CCC score was 1 in the 
morning and in the evening due to decreased alertness. Her granddaughter-in-law reported 
that Mrs. C stayed in bed and slept most of the day after taking 50mg of hydroxyzine during 
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the previous 24 hours. Mrs. C also had increased sleepiness the following day. However, on 
Day 80, her granddaughter-in-law noted that she was a “whole lot better.” 
 
 
 
Figure E3.14. Trajectory of CCC scores 
 
 
 After that period, Mrs. C’s CCC scores remained at 0 until 43 days prior to her death. 
However, on Day 48, her granddaughter-in-law noted that Mrs. C had increased abdominal 
pain and that she was talking less. The CCC scores did not reflect this change in 
communication. After I reviewed the CCC’s with Mrs. C’s granddaughter-in-law during my 
weekly visit on Day 44, she began to note Mrs. C’s silence as inappropriate communication. 
She did not see it as a change in behavior—being more withdrawn. Over the next 14 days, 
Mrs. C’s granddaughter-in-law continued to score the CCC at 1, noting that Mrs. C was not 
talking much. She also documented that Mrs. C was “sleepy”, that she “stayed in the bed off 
and on”, and that she was “still (having) pain in her stomach”. On many days, Mrs. C’s 
granddaughter-in-law also documented that Mrs. C was “not feeling good”. The CCC scores 
did not reflect these changes and Mrs. C’s family never called me to report these changes – 
potential signs of confusion. 
 On the day of the first positive delirium assessment (Day 30), the CCC score was 2. 
Mrs. C’s granddaughter-in-law noted that Mrs. C was silent and drowsy. She continued to 
score the CCC as 2 except on the following day. On Day 11, she increased the CCC score to 
3. On that day, Mrs. C’s granddaughter-in-law indicated that Mrs. C exhibited altered 
behavior. She noted that Mrs. C had slowed movements and that she was staring. She also 
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documented that Mrs. C was “very slow at walking”. Mrs. C’s caregivers did not notify me 
to report these changes. Mrs. C’s granddaughter-in-law continued to score the CCC at 3 
throughout the week. When I conducted my scheduled home visit on Day 9, Mrs. C scored 
positively for delirium. Seven days before her death, the CCC score was 5. Mrs. C’s 
granddaughter-in-law noted that Mrs. C was disoriented with hallucinations. She noted, 
“She’ll answer you sometimes. You might have to say it 2 or 3 times”. She also documented 
that Mrs. C was “talking to herself now”. Mrs. C’s daughter also reported that she had given 
Mrs. T diazepam for restlessness. On the following day (Day 6), Mrs. C’s granddaughter-in-
law noted that Mrs. C continued “talking out loud to herself”. She also noted, “Today she 
was fishing. She had caught some fish. At this point she is not able to tell you if (she) has to 
use the bathroom”. The CCC score was 4 for the 5 days prior to Mrs. C’s death. During that 
time, her granddaughter-in-law noted that Mrs. C was mostly unresponsive – “sleeping just 
about all the time”. She also noted that Mrs. C “mumbles” at times when you turn her.  
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